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ABSTRACT
Cystic fibrosis (CF) is the most common, and ultimately fatal, inherited disease of
Caucasian populations with an incidence of 1 in 2,500 live births and affecting over
50,000 children and adults world-wide. Progressive lung disease, resulting from
impaired mucociliary clearance and persistent bacterial infection of the bronchial
mucosa, is the main cause ofmorbidity and mortality and affects over 90% of
individuals with CF.
CF lung infections are caused by a surprisingly narrow spectrum ofpathogens and
include Staphylococcus aureus, non-capsulate Haemophilus influenzae,
Pseudomonas aeruginosa and Burkholderia cepacia. Stenotrophomonas maltophila
is recovered from respiratory secretions with increasing frequency, however, its
pathogenic role remains unclear. The primary aims of this thesis include the
development and use of genomic fingerprinting systems to assist epidemiological
investigations ofCF pathogens, including S.maltophilia.
Genomic fingerprinting is based on digestion of total bacterial chromosomal DNA
with rare cutting enzymes, chosen on the basis of the bacterium's GC content.
Separation of the DNA fragments is then achieved by pulsed-field gel electrophoresis
(PFGE) in an appropriate apparatus such as the Bio-Rad contour clamped
homogenous electric field (CHEF) system. Although a variety of other genomic
typing systems are available, the thesis focused on PFGE, potentially the most
discriminating system at present. Another major theme of the thesis concerned the
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epidemiology ofB. cepacia. This highly adaptable plant and human pathogen causes
great anxiety in the CF community on account of its inherent resistance,
transmissibility and association with cepacia syndrome, a rapidly fatal pneumonia
affecting approximately 30% of colonised patients. PFGE is technically demanding,
time consuming and relatively expensive, thus attempts were made to assess the
reliability and potential of other systems, in particular, PCR-ribotyping as a simple
and rapid screening system for clonal analyses.
The project provided a limited opportunity for fingerprinting and other
microbiological studies of the commensal and pathogenic respiratory flora in CF
patients participating in the first human trials of CF gene therapy. Specimens were
examined before, during and after local nasal administration of a DNA/Iiposome
complex. Although only a Phase I study was achieved during the duration of the
thesis, microbiological analyses provided interesting results, in particular an
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Cystic fibrosis (CF), otherwise known as mucoviscidosis or fibrocystic disease of the
pancreas, was first recognised as a fatal disease of infants in the late 1930's
(Andersen, 1938). Today, it is recognised as the most common, fatal autosomal
recessive disease among Caucasian populations, although it is not found exclusively
in Caucasians. With an incidence of approximately 1 in 2,500 live births, CF affects
around 6,000 individuals in the UK and about 600 in Scotland. The incidence,
however, varies considerably on a geographical basis from 1 in 1,700 in N. Ireland,
1 in 7,700 in Sweden to 1 in 17,000 in African-Americans (Bye et al, 1994) and
reaches the highest level (1 in 313) in the closely-knit populations such as the
Hutterites ofNorth America (Mickle & Cutting, 1998).
One in 25 of normal individuals are heterozygous CF carriers. Carrier status is
asymptomatic but when both parents are carriers there is a 1 in 4 chance in every
pregnancy of a CF infant.
1.1 CLINICAL FEATURES
CF is a multisystem disorder of the exocrine glands including the lung,
gastrointestinal tract, pancreas, liver, vas deferans and the sweat glands. The major
pathophysiological aspects of the disease were described by Andersen (1938) as
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pancreatic insufficiency with malnutrition, hepatic disease and infection of the
airways. CF patients produce extremely viscous secretions which leads to
autodigestion of the pancreas through blockage of the pancreatic ducts and inability
to secrete digestive enzymes. Pancreatic insufficiency, occuring in 85 - 90% of CF
patients, leads to malabsorption of fat and proteins but this is largely corrected by the
use of oral pancreatic enzyme supplements (Kopelman, 1991). An additional
complication of CF, generally restricted to patients with pancreatic insufficiency, is
diabetes mellitis which occurs in 10-12% of patients with a tendancy to increase with
increasing age (Shwachman & Holsclaw, 1969).
Hepatic disease was described in the initial pathologic descriptions of CF (Andersen,
1938). The most common finding is focal biliary cirrhosis (Webster & Williams,
1953) found in less than 25% of CF patients while the more serious multilobulated
biliary cirrhosis occurs in 2-5% (di Sant' Agnese & Blanc, 1956) and may result in
progressive clinical liver failure. Symptomatic liver disease has been successfully
treated with implanted shunts or transplantation.
Meconium ileus is one of the earliest clinical manifestation of CF and occurs in 10-
20% of patients. Historically, it was a common cause of infant mortality but is now a
rare cause of death due to early diagnosis of CF, improved paediatric surgery and
neonatal intensive care (Dodge et al, 1988)
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Genitourinary abnormalities are found in both sexes although more common in
males. Male sterility is due to obstruction of the vas deferens and occurs in 95% of
male CF patients. Decreased fertility in females occurs due to increased amount of
mucus in the cervical canal resulting in blockages by mucus plugs (Bye et al, 1994).
Increased viscous secretions in CF patients also cause airway obstruction resulting in
impaired mucociliary clearance and recurrent pulmonary infections. Lung infection
and consequent bronchial and alveolar damage are the main causes ofmorbidity and
mortality in CF patients and are responsible for about 90% of deaths (Hoiby, 1982;
Fick, 1989). Progressive decline in pulmonary function is due to a viscous cycle of
airway obstruction, infection and inflammation. Airway inflammation is
demonstrated by raised levels of neutrophil and bacteria DNA, interleukin-8, free
neutrophil elastase and neutrophils in bronchoalveolar lavage fluid (Khan et al,
1995). These inflammatory markers may be present before the onset of clinically
apparent pulmonary disease.
1.2 CF MICROBIOLOGY
Surprisingly, only a small spectrum ofmicrobial pathogens, mostly bacteria, are
responsible for causing pulmonary infection in individuals with CF. Typically,
initial infection is caused by Staphylococcus aureus and Haemophilus influenzae
with Pseudomonas aeruginosa appearing at a later stage. Burkholderia cepacia is a
more recent pathogen in CF; colonisation with this inherently resistant environmental
bacterium is a cause of great concern among the CF community as certain strains are
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readily transmissible from patient-to-patient and approximately 30% of colonised
patients succumb to rapidly fatal pneumonia. In recent years, another potential
pathogen Stenotrophomonas maltophilia has emerged with increasing incidence
although its clinical role is unclear. Each of these major CF pathogens will be
discussed individually in later chapters of this thesis.
Other microorganisms are occasionally isolated from the respiratory secretions ofCF
patients but they do not appear to persist for extended periods of time. These include
Streptococcus pneumoniae, enteric bacilli and Gram-negative glucose-nonfermenting
bacilli other than P. aeruginosa and B. cepacia. Another two uncommon respiratory
organisms, Alcaligenes xylosoxidans (Vu Thien et al, 1996; Karpati, et al, 1994) and
Burkholderia gladioli (Wilsher et al, 1997) are increasingly isolated from sputum
specimens from CF patients.
Mycobacterium tuberculosis is rarely a cause of infection in CF patients and when it
does occur it can be treated successfully with anti-mycobacterium antibiotics
(Gilligan, 1991). Rapid growing Mycobacterium species such as M. avium and M.
fortuitum have been recovered from respiratory secretions of CF patients and
although they play a minor role in lung disease they may contribute to lung
deterioration (Boxerbaum, 1980; Gilligan, 1991).
Aspergillus fumigatus is the major fungal agent associated with pulmonary infection
in CF patients, causing allergic bronchopulmonary aspergillosis (ABA). The
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prevalence ofABA ranges from 0.5 - 11% and is thought to be more prevalent in
older children and young adults (Brueton et al, 1980; Paul et al, 1996). In CF
patients, clinical symptoms must be considered carefully in the diagnosis ofABA;
the prevalence of clinical disease is low despite the frequent presence of
immunologic responses to A. fumigatus colonisation (Becker et al, 1996). The yeast,
Candida albicans is frequently recovered from the respiratory tract of CF patients,
especially those receiving antibiotics or steroids, and usually disappears after
treatment is completed.
The role of viruses in CF lung disease is still unclear. Respiratory syncytial virus
(RSV) may act as a predisposing factor to bacterial colonisation with P. aeruginosa
(Petersen et al, 1981). RSV may also be responsible for deterioration in lung
function in young CF children (Abman et al, 1988). The role of other viruses,
including influenza and parainfluenza, in lower respiratory tract infection is similar
in CF as to that in non-CF individuals. Infection with Chlamydia pneumoniae has
been associated with acute pulmonary exacerbations in some CF patients (Emre et al,
1996).
The life expectancy of children with CF has increased dramatically in recent years.
In the early 1930's, a CF child rarely lived beyond infancy and even in 1969 the
mean survival age was only 14 years (FitzSimmons, 1993). In contrast, CF patients
born in the 1990's, have a projected mean survival age of 40 years (Collins, 1992). A
number of factors are thought to be associated with increased life expectancy. Early
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diagnosis of the disease has been associated with improved nutritional status,
decreased morbidity and less deterioration in lung function. However, there is no
evidence that early detection of CF through neonatal screening has led to an
improvement in survival (Rosenstein & Zeitlin, 1998). However, the establishment
of large CF centres throughout the UK has provided multidisciplinary management
of pulmonary and nutritional status of the patient. Despite the promise of gene
therapy, at present antimicrobial therapy is the major therapeutic intervention to
reduce pulmonary infection and hence increase life expectancy. Other factors
include lung or heart/lung transplantation with long term survival rates of 5 years and
over in 60 - 65% of patients. Recently, bilateral lobar transplantation, from related
donors, has been attempted successfully (Moss, 1995). As with all transplants, there
are problems of rejection and organ availability. In CF patients, however,
colonisation with Mycobacterium species or B. cepacia may also result in exclusion
from transplantation lists at some units.
Recent therapeutic strategies in CF include the use of recombinant
deoxyribonuclease to reduce the viscoelasticity of CF sputum. This relatively new
treatment appears to benefit some patients in conjunction with conventional
treatment by reducing the frequency of pulmonary exacerbations and delaying the
decline in pulmonary function (Fuchs et al, 1994). Expanding knowledge of
naturally-occuring antimicrobial peptides (defensins) in pulmonary secretions and
their relevance to CF lung infection may provide another potential treatment against
bacterial infections. These antimicrobial peptides are produced in human or animal
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airways; of particular relevance some defensins are 'salt-sensitive'. It has been
proposed that inactivation of defensins by high concentrations of salt explains why
CF patients become chronically colonised with bacterial pathogens such as
P. aeruginosa (Goldman et al, 1997).
1.3 DIAGNOSIS OF CF
One of the characteristic features of CF, affecting over 95% of patients, is elevated
levels of sweat electrolytes. This sweat abnormality led to the development of the
sweat test, which relies on detection of higher than normal concentrations of sodium
and chlorine in sweat (McPherson & Dormer, 1987). Although reasonably reliable
screening methods for sweat testing are available, results should be confirmed by
quantitative pilocarpine iontophoresis Gibson & Cooke, 1959).
Neonatal screening procedures may detect CF but as yet these are not carried out
routinely in all newborn babies. Immunoreactive trypsin is first measured in dried
blood spots; if the trypsin level is high, the sample is tested for the most common
CFTR mutation, AF508, or a panel of common mutations (Wilcken et al, 1995). CF
can also be diagnosed in utero by detection of two CF mutations in the foetus by
chorionic villus sampling or amniocentesis; in general, such testing is only done
when there is a history of CF in the family. The discovery of the CF gene in 1989
has made prenatal diagnosis of CF more accurate and accessible. It has also led to
improved accuracy in the diagnosis of CF, especially in patients with unusual CF
phenotypes (Strong et al, 1991).
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1.4 DISCOVERY OF CF GENE
In 1985, following location of the CF gene on the long arm of chromosome 7 at
position 7q31-32 (Tsui et al, 1985), the race to sequence the gene and identify the
encoded protein accelerated. This achievement one of the most outstanding in
modern biomedical science, occured in 1989 when the CF gene was cloned and
sequenced using genetic linkage analysis and techniques of chromosome walking and
jumping (Rommens et al, 1989; Riordan et al, 1989; Kerem et al, 1989). The 250kb
gene encodes a transmembrane protein, the cystic fibrosis transmembrane
conductance regulator (CFTR) comprising 1,480 amino acids. CF results from
mutations in the development or functions of CFTR and to date over 700 mutations
have been described. AF508 is the most common and is found in approximately 70%
ofCF patients; this mutation results in a three base pair deletion resulting in loss of
phenylalanine at position 508 in the amino acid sequence.
1.5 ROLE OF CFTR
CFTR functions as a cAMP-regulated chloride (CI) channel in the apical membrane
of epithelial cells (Welsh, 1990). In non-CF lungs, increases in intracellular cAMP
result in increased CI" transport followed by the movement ofwater by osmosis and
maintenance of adequately hydrated mucociliary clearance. In CF, CFTR is
mislocated or dysfunctional resulting in an alteration in the regulation of ion
transport across the apical membranes of the epithelial cells in the airways, gut,
pancreas, biliary and sperm ducts. In 1982, Quinton, a pharmacologist who himself
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has CF, was the first to note that the CF epithelium is relatively impermeable to CI",
suggesting a primary defect in anion transport (Quinton, 1983).
In the sweat glands ofnormal individuals , the CI" transport by epithelial cells of the
secretory coil, is accomplished by two channels, CFTR and a calcium-activated CI
channel: acting together to produce isotonic fluid. As this fluid flows the epithelial
cells lining the duct lumen absorb sodium (Na) and CI ions producing hypotonic
sweat. Both mechanisms are dependant on CFTR. In CF, these CI channels fail to
open resulting in high residual CI" and Na+ concentrations in the sweat. The opposite
occurs in the respiratory tract; CI" transport from within the cells towards the lumen
of the bronchus is impaired. The transport ofNa+ is also abnormal in respiratory
epithelia as there is an increase absorption ofNa from the lumen into the cells and
diffusion ofwater from interstitial fluid into the lumen is reduced (Knowles et al,
1981). These abnormalities in ion transport and hydration are thought to result in an
increase in viscosity of respiratory mucus which leads to impaired mucociliary
clearance predisposing to recurrent repiratory infections. Despite major advances in
the genetics and molecular basis ofCF, the pathogenesis of lung disease remains
unclear and highly controversial.
Studies of cultured human airway epithelial cells from CF and non-CF patients have
shown that airway surface liquid (ASL) covering CF epithelia have Na+ and CI"
concentrations that were approximately double the value ofnon-CF epithelia (Zabner
et al, 1998). In contrast, two other groups found no difference in the ASL NaCl
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concentrations between CF and non-CF patients (Knowles et al, 1997; Hull et
al, 1998)
A recent study by Matsui et al (1998) using planar and cylindrical culture models
also showed that there was little difference in the NaCl concentration ofASL of CF
and non-CF patients. However, the rate ofASL adsorption in CF respiratory
epithelia was abnormally high compared to normal respiratory epithelia. This
accelerated adsorption ofASL in CF resulted in depletion of the periciliary liquid
layer and concentration of the mucus on airway surfaces. The authors speculated that
failure of the thickened mucus to be removed from the airway surfaces allows
bacteria to colonise resulting in pulmonary infection. If this hypothesis is correct, a
logical therapeutic strategy treatment would be to add isotonic fluid to respiratory
surfaces to restore the fluid volume in the periciliary layer.
1.6 PROTEIN-REPAIR THERAPY
The different mutations of CFTR, responsible for causing CF, have been
characterised into four classes I - IV, based on biochemical disfunction (Welsh &
Smith, 1993) and a fifth group identified by Gan et al in 1995 was designated class V
by Rosenstein & Zeitlin (1998). An improved understanding of these different
mutations found in CFTR has led to new therapeutic approaches, termed protein-
repair therapy.
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Class I mutations cause defective CFTR protein production with little or no full-
length protein being produced and result in a loss of CFTR chloride ion channel
function in affected epithelia. Such mutations may involve frameshifts due to
insertions and deletions, splice site abnormalities and nonsense mutations (Tsui,
1992) and in some cases mRNAs are unstable (Hamosh et al, 1991). However,
certain aminoglycosides, such as gentamicin, can suppress these mutations and
restore full-length CFTR mRNA protein to the cell.
Class II mutations result in defective protein processing. AF508 is the most common
mutation in this class. The defect causes structural assembly in the endoplasmic
reticulum to be inefficiently glycosylated or transported to the correct cellular
location resulting in degradation of the CFTR protein (Cheng et al, 1990). Other
mutations, in this group, may be processed through the Golgi complex but fail to be
transported to the apical membrane.
Class III mutations are completely defective with respect to regulation and activation
of chloride channel activity. Although some mutant proteins do reach the plasma
membrane they have mutations in the nucleotide-binding domains. These mutations
can alter channel function as intracellular ATP regulates the opening of CFTR
chloride channels through direct interactions with the nucleotide-binding domains.
Some nucleotide-binding domain mutants have very little function, in others ATP is
less potent at stimulating activity (Anderson & Welsh, 1992; Drumm et al, 1991).
CFTR is also regulated by phosphorylation of the regulatory domain and although
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mutants have been reported in the regulatory domain they are less common than in
other parts of the protein (Welsh & Smith, 1993).
Class IV mutations demonstrate normal regulation but altered conduction. Channel
regulation appears intact but mutations in the membrane-spanning domain reduce the
rate ofCI" flow through the open channel (Welsh & Smith, 1993).
Mutations in classes III or IV are unresponsive to direct stimulation and protein-
repair would be of little use, however, gene therapy may be a potential treatment.
Class V mutations show reduced synthesis ofCFTR and are found in patients who
tend to have milder lung disease, borderline or normal sweat electrolyte values and
residual chloride secretion in the intestine.
Patients with defective CFTR in classes I - III generally exhibit pancreatic
insufficiency while those with class IV and V defects are pancreatic sufficient. At
present, there does not appear to be a correlation between the classification of CFTR
mutations and the pulmonary phenotype with the exception of AF508 and increased
Pseudomonas aeruginosa colonisation.
1.7 GENE THERAPY
Since the development of recombinant DNA technology in the 1970's, the prospect
that genetic diseases could be treated by introducing normal genes into affected
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individuals has been a possibility. Gene therapy for CF will require direct in vivo
delivery of vectors, containing the normal CFTR gene, into somatic cells of the host
which should then express the gene as messenger RNA (mRNA) and manufacture
normal CFTR. It is hoped that this will lead to normal ion channel functioning and
thus correction of the fundamental defect causing the disease. As with any new
therapy, thorough testing in cell culture and animal models is essential to monitor the
safety and efficacy of the vectors prior to the application of gene therapy to the
patient.
Several in vitro studies, using different cell lines, have shown interesting results.
Correction of the CF CI" permeability defect has been demonstrated in CF pancreatic
cells (Rosenfeld et al, 1992) and in CF epithelial cells using retrovirus and vaccinia
virus vectors (Drumm et al, 1990; Rich et al, 1990).
Extensive in vivo studies in animals have been undertaken using both the principal
gene delivery systems ofmodified adenovirus and cationic liposomes. The first
successful in vivo experiments involved transfer of the human CFTR gene, by means
of a modified adenovirus, into the respiratory tract of cotton rats (Rosenfeld et al,
1992); this resulted in detection of mRNA and CFTR protein within a week and was
sustained for up to four weeks. The development of a genetically modified mouse
model of CF, which is genotypically and phenotypically similar to human CF, should
also help answer some of the problems of gene therapy. Experiments using this
murine model showed that when the gene expressing CFTR is completely removed
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(Snouwaert et al, 1992) or even when low levels ofwild type CFTR mRNA are
produced (Davidson et al, 1995), CF mice demonstrate gut and pulmonary disease
abnormalities similar to CF patients. In the Edinburgh CF mutant mouse model the
abnormal tracheal potential difference associated with CF was partially or wholly
corrected by instillation (Hyde et al, 1993) or aerosolisation (McLachlan et al, 1996;
Alton et al, 1993) of human cDNA complexed with cationic liposomes. Grubb and
colleagues have also demonstrated a partial correction of the CI" transport defect in
the nasal epithelium of the CF mice following in vivo adeno-mediated gene transfer
to the nasal epithelium. However, no correction ofNa+ transport was observed. An
in vivo study using adenovirus-mediated gene transfer to the airway epithelium of
primates showed low efficiency (Rich et al, 1993). These animal experiments into
CF gene therapy were swiftly followed by a number of Phasel clinical trials in
humans.
1.7.1 Human gene therapy for CF
Which cells to target ?
Although the mutation in CFTR affects a number of different cell types in the body
the most important gene therapy target is considered to be the respiratory tract as this
is the main organ system associated with CF disease and mortality. The highest
levels ofCFTR are expressed in the submucosal glands while much reduced levels
are found in the surface epithelium. Furthermore, there are about 40 different cell
types within the respiratory tract and it is still not clear which cells offer the best
target. As the overall expression of CFTR in the lungs is low, it may be that clinical
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benefit can be achieved by correcting a small percentage of the target cells in order to
normalise the CI conductance (Johnson et al, 1992). This is encouraging as in vivo
studies have shown relatively low delivery using present vectors.
What vectors to use?
Currently, two main delivery systems are under investigation for transfer of the CF
gene into target cells; these are modified adenovirus and cationic liposomes.
Recombinant adenovirus vectors were originally favoured for gene delivery to the CF
lung because of their natural airway tropism, capacity to transduce the human CFTR
gene and because of encouraging results achieved with these viral vectors both in
vitro and in vivo. The adenovirus is modified for gene therapy by deleting and
inactivating the gene responsible for replication. Currently adenoviruses of serotype
2 and 5 are employed as vectors; in each case the modification involves the deletion
of the early region one (El) and a further deletion in the early region three (E3) in
serotype 5 (Engelhardt et al, 1993). Deletions of the El region results in a non-
replicating virus and the E3 region creates adequate space to insert the CFTR gene
with a suitable promoter to drive transcription. The recombinant 4.5kb human CFTR
cDNA, is then incorporated into the viral genome and delivered to the target cell
where it enters by a process of receptor-mediated endocytosis (Fitzgerald et al,
1983). Adenoviruses have an innate ability to escape the endolysosomal pathway
and exist primarily as an episome and seldom integrate into the host cell genome.
Unfortunately, gene therapy trials involving the use of adenovirus as a vector have
been associated with an inflammatory response (Crystal et al, 1994).
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The second delivery system for gene therapy, employed mainly in the UK, involves
the use of cationic liposomes. Liposomes are an attractive vector for gene delivery
because they are chemically defined, readily manufactured to pharmaceutical
standards and biodegradable. As used in the Brompton trial, cationic liposomes are
composed of cationic lipids such as 3(3[N-N',N'-dimethylamino ethane-carbamoyl]
cholesterol (DC-cholesterol) mixed in varying molar ratios with the neutral
phospholipid, dioleoylphosphatidylethanolamine (DOPE) ( Caplen et al, 1995).
Detergents and cholesterol, as in DC-cholesterol may be added to increase stability.
DC-cholesterol has two disadvantages; it is unstable with a short shelf life of only
five weeks and it is not readily available in bulk.
The negatively charged DNA component from a bacterial plasmid containing the
CFTR cDNA with a strong heterologous promotor combines to the cationic liposome
forming a liposome/gene complex. The mechanism by which the complexes mediate
gene transfer is unknown but they may enter the cell by either fusing to the cell
membrane or via endocytosis. The latter system is thought to be the most likely.
Once inside the cell the plasmid DNA most likely remains episomal (Sorscher et al,
1994).
Cationic liposomes are associated with low toxicity which makes them very
attractive as a gene therapy vector. They have the ability to transfect a variety of cell
types, are easy to prepare and can accomodate and deliver genes of almost unlimited
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size. However, cationic liposomes appear to be a less effective delivery system than
adenoviruses but the latter vector has been associated with an inflammatory response
in CF patients.
Another potential vector are adeno-associated viruses (AAV). These are small
single-stranded DNA parvoviruses that are nonpathogenic. They are generally
unable to replicate autonomously and require a helper virus such as adenovirus or
Herpes simplex. When an AAV infects a cell in the absence of a helper virus it
integrates into the host cell genome and becomes latent. The AAV genome is only
4.7kb and therefore most of the genome has to be removed to accomodate the CFTR
cDNA which may lead to inefficient packaging and difficulties in virus production.
However, in vitro studies have shown that AAV vectors are capable of correcting the
CF CI" permeability defect (Flotte et al, 1993) and a clinical trial is ongoing
(Rosenfeld & Collins, 1996). Although AAV vectors have shown promise a number
of disadvantages have become apparent; those include difficulty in obtaining large
quantities of the virus in high enough titres. Furthermore, in vivo studies, in
monkeys, have shown that the AAV vector may not always remain at the site of
administration following airway delivery (Flotte et al, 1995).
1.7.2 Gene therapy trials
A number of gene therapy trials in CF adults have been completed or are currently
underway in the USA, UK and France. The majority of these are Phase I ('proof of
principle') trials which involve local application of the adenovirus-mediated gene or
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the liposome/gene complex to the nasal mucosa. The principal objective of the Phase
I trials is to establish the efficacy of the delivery system and to determine whether
there are any adverse reactions to the vectors used to deliver the gene.
The vector of choice, in the USA, is the modified adenovirus and the first Phase I
clinical trial showed encouraging results with regard to functional correction
although only three patients were involved (Zabner et al, 1993). The first application
of gene therapy to the upper and lower airways of four CF patients, again using
adenovirus-mediated gene delivery, demonstrated that gene transfer was only
successful in one of the patients. Furthermore, a severe inflammatory reaction
occured in another patient emphasing the potential problems associated with
adenovirus vectors (Crystal et al, 1994). A further study, in 12 patients, using
escalating doses of the adenovirus-mediated gene complex to the nasal mucosa
showed no evidence of gene transfer at the lower doses but CFTR was expressed in
about 1% of the cells, at higher doses. Evidence ofmucosal inflammation was
demonstrated at the highest dose of vector and no functional correction was observed
(Knowles et al, 1995).
The first clinical trial ofDNA-liposome gene therapy for CF, using DC-cholesterol
(DOPE) administration to the nasal epithelium demonstrated transgene delivery and
expression by biopsy and showed around 20% correction of the electrophysiological
deficit 3 days after therapy; this affect disappeared by day 7 (Caplen et al, 1995).
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Unfortunately, false positive results in the placebo group limited the interpretation of
evidence of gene transfer in this trial.
The Edinburgh Phase I gene therapy trial, used an alternative cationic liposome,
DOTAP (N,N,N-trimethyl-2-3-bis ((l-oxo-9-octa-decenyl)oxy)-(Z,Z)-l-
propanaminium methyl sulphate) which was produced by Boehringer Mannheim,
Germany (Porteous et al, 1997). This liposome was chosen for the human trial as
repeat administrations of the liposome to the Edinburgh transgenic CF mutant mouse
were tolerated well (McLachlan et al, 1995) and when complexed with CFTR using
cytomegalovirus (CMV) as a promotor resulted in approximately 80% correction of
tracheal electrophysiological deficit in these animals (McLachlan et al, 1996). The
CMV promotor was chosen as studies in mice showed that it sustained expression for
at least 17 days in comparison to simian virus 40 (SM40) which was attenuated
rapidly (Caplen et al, 1995; McLachlan et al, 1995).
The first Edinburgh gene therapy trial recruited 23 patients but only 16 of these
individuals completed the trial. Eight patients were treated with the pCMV-CFTR-
DOTAP while the other eight patients received a placebo of buffer only. Evidence of
gene transfer was detected in seven of the eight treated patients at days three and
seven, post therapy, but in only two of the seven patients at 28 days. A partial
correction of the chloride abnormality averaging 20 % was detected, which is similar
to a previous study by Caplen et al (1995); in the Edinburgh trial no false positive
results were observed.
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For ethical reasons all CF human gene therapy trials to date have been carried out in
adult CF patients. However, this group ofpatients are unlikely to benefit
significantly as their lungs are already badly scarred due to recurrent pulmonary
infections and inflammatory damage. Ideally, CF patients should receive gene
therapy prior to the acquisition of P. aeruginosa as gene therapy only stops rather
than repairs progressive lung damage and the inflammatory obstructions and
microbial alginate produced by P. aeruginosa hinder the nebulised gene therapy from
reaching the target cells in the respiratory tract.
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CHAPTER 2
EPIDEMIOLOGY OF CF PULMONARY INFECTIONS
"In clinical practice, bacterial typing systems are applied primarily to address one
fundamental issue: are two isolates the 'same' or 'different' ?" (Maslow et al, 1993).
Epidemiological studies can provide insight into the spread and persistance of
pathogens, determine clonally related isolates of a species or provide evidence when
reinfection occurs as to whether this is due to the original isolate or acquisition of a
new strain. Epidemiological investigations have utilised a wide variety of bacterial
typing systems which can be conveniently classified into two categories: phenotypic
systems are based on detection of characteristics expressed by microorganisms;
genomic systems involve direct DNA-based analyses of chromosomal or extra-
chromosomal genetic elements. A list of phenotypic and genomic typing systems
together with their advantages and disadvantages are shown in Table 2.1.
An ideal typing system should possess the properties of reproducibility, stability,
discrimination and typeability (i.e. be able to assign a type to a high percentage of
isolates). Additional advantages would include rapid, inexpensive and technically
simple procedures with application to a wide range of different species.
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2.1 PHENOTYPIC TYPING SYSTEMS
Phenotypic typing systems (biotyping, serotyping, phage typing etc.) include classic
techniques for differentiating strains and are still commonly used in clinical
laboratories, although they are increasingly being superceded by genomic methods.
One of the main disadvantages of phenotypic typing systems is that organisms are
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prone to phenotypic variation resulting in the possibility of clonal isolates being
classified as different types. None of the phenotypic typing systems offer an ideal
approach to subdividing a microbial species as there are problems related to
typeability, reproduciblity or discriminatory powers. Furthermore, phenotypic typing
systems are not generally applicable. Instead, they have to be developed for a
particular organism and are not easily applied to fastidious organisms.
Unlike the other simple phenotypic typing systems, typing by protein analysis and
multilocus enzyme electrophoresis (MLEE) involve more complex techniques. They
are also time consuming and require specialised equipment.
2.1.1 Biotyping
Biotyping is based on the discriminatory results of a range ofbiochemical tests to
provide a biochemical profile from which different biotypes can be identified. In
most clinical laboratories conventional biochemical tests for identification of
organisms have largely been replaced by automated systems, such as API and Vitek
systems. Biotyping is not a reliable typing technique as variation in gene expression
may alter biochemical reactions leading to the production of different biotyping
patterns in otherwise clonally-related strains. In general, the discriminatory powers
ofbiotyping are poor which is probably not surprising considering that biotyping
systems for some organisms only involves a few biochemical tests. Biotyping has




Although this technique is performed routinely in clinical laboratories it is of limited
use in epidemiological studies because ofphenotypic variation and the emergence of
antibiotic resistance by selective pressure. Resistance can rapidly evolve within a
strain through various genetic mechanisms or by means of resistance plasmids; both
mechanisms are potentially unstable resulting in altered antibiogram patterns.
Consequently, two isolates of the same strain may exhibit different antibiogram
patterns and conversely, different strains may demonstrate similar antibiogram
patterns.
2.1.3 Serotyping
Serotyping is one of the oldest typing systems and is largely used for epidemiological
studies ofGram negative bacteria such as Escherichia coli, H. influenzae,
P. aeruginosa, Neisseria meningitidis and some Gram positive bacteria such as
Streptococcus pneumoniae (Maslow et al, 1993). This immunological technique
detects expression of distinct antigenic determinants on the cell surface. Specific
typing reagents are required such as polyclonal sera and monoclonal antibodies
which are often difficult and expensive to develop, and in some cases are not readily
available. Serotyping can be applied to many different bacterial pathogens but in
most cases a given set of antisera can only be applied to a single species. This
technique is relatively stable and reliable but often demonstrates poor discriminatory
powers. In CF patients, loss of LPS side chains in P. aeruginosa also results in an
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unacceptable number of untypeable or polyagglutinating isolates (Hancock et al,
1983).
2.1.4 Bacteriophage typing
A number of lytic bacteriophages or viruses capable of infecting bacterial cells, have
been identified. Isolates are characterised according to their susceptibility or
resistance to lysis by a panel of bacteriophages for a particular species. Phage typing
schemes have been developed for numerous bacterial genera but is notably the major
typing method for Staph, aureus (Blair & Williams, 1961). This technique is
generally restricted to reference laboratories due to the maintenance of stocks of
active typing phages. Bacteriophage typing is highly sensitive and is subject to
considerable experimental and environmental variability. Genetic mechanisms such
as lysogenic conversion, loss of prophages, LPS variation and the acquisition or loss
ofplasmids can affect the phage type.
2.1.5 Bacteriocin typing
The technique for typing isolates ofP. aeruginosa was developed in this laboratory
in 1966 by Gillies & Govan and was later modified by Fyfe et al in 1984. A similar
technique was developed for B. cepacia in 1986 by Govan & Harris. Many bacterial
species produce bacteriocins, a heterogeneous group of antimicrobial peptides and
defective phage particles are active against different strains of the same species with
the producing strain generally being resistant or immune. Bacteriocin typing is based
on the pattern of inhibition exhibited by the production of bacteriocins by the test
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strain against a set of indicator strains, or alternatively, susceptibility of a test strain
to bacteriocins produced by standard producer strains. The inhibition patterns
determine the bacteriocin type of the organism. This technique requires considerable
developmental work but has been applied successfully to P. aeruginosa, B. cepacia
and Enterobacteriacae. It is a relatively discriminating typing system but like other
phenotypic systems, lacks reproducibility. Although production of bacteriocins or
the susceptibility to them are relatively stable properties, the presence of transferrable
R plasmids may lead to a change in bacteriocin type.
2.1.6 Protein analysis
Variations in the structure ofbacterial proteins can be detected by a variety of
methods. The solubilised material isolated from whole-cell or cell-surface proteins is
separated by electrophoresis and detected by staining techniques to generate a
characteristic protein profde. One of the most widely used techniques is SDS-PAGE
(sodium dodecylsulphate polyacrylamide gel electrophoresis). Proteins are denatured
by heat, detergent and reducing agents to produce polypeptide subunits which are
separated by electrophoresis on the basis ofmolecular size. Alternatively, proteins
can be radiolabeled during isolation and the pattern detected by autoradiography. It
is important to standardise growth conditions such as media, inoculum size,
incubation conditions (time, temperature, gaseous atmosphere) for harvesting and
washing cells as the protein content ofmicrobial cells may be influenced by
environmental factors. Virtually all bacteria are typeable by this method. However,
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interpretation of results may prove difficult due to the large number of bands
produced in the electrophoretic patterns.
2.1.7 Multilocus enzyme electrophoresis (MLEE)
In MLEE, microorganisms are differentiated by analysis of electrophoretic mobility
of a range of soluble basic metabolic enzymes extracted from the organism. The
cellular proteins of the microorganism are separated by starch gel electrophoresis and
individual soluble metabolic enzymes are detected using specific subtrates and
chromogens. MLEE is technically demanding and is generally only moderately
discriminatory for clinical isolates. Consequently, this typing method has had
relatively limited application to epidemiological studies. However, the
discrimination of isolates and typeability by this technique may be enhanced by
analysis ofmultiple enzymes and a panel of 10 - 15 is commonly used. Combined
data for the range of enzymes tested is then used to assign an electrophoretotype to a
particular isolate which allows comparison with other isolates. Single amino acid
changes in enzymatic proteins encoded by different alleles or genes are sufficient to
change the electrophoretotype. As with protein analysis, the amount of enzyme
produced may be affected by cultural and environmental conditions.
2.2 GENOMIC TYPING SYSTEMS
The limitations inherent to traditional methods of typing microorganisms by
phenotypic characteristics stimulated the development of techniques relying on the
detection of polymorphisms at the level of nucleic acids (genotyping). Recent
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advances in nucleic acid technology have resulted in the emergence of a number of
genotypic typing methods. Initially, these methods were only used in research
laboratories due to the complexity of the techniques, complex interpretation of results
and the expensive equipment required. However, many of the techniques are now
being used in clinical laboratories. A particular genotyping system can be applied to
a wide range ofbacteria in comparison to phenotypic methods which generally have
to be developed for each species of organism. However, genotyping systems are not
without their own particular drawbacks such as being time consuming and requiring
considerable technical expertise both in performing and the interpretation of results.
2.2.1 Plasmid profile analysis
Plasmid analysis was one of the first DNA-based techniques to be applied to
epidemiological studies of bacterial pathogens (Meyers et al, 1976). Basically,
plasmid DNA is extracted from an isolate and separated by electrophoresis in an
agarose gel to determine the molecular size and number of plasmids present.
Additional information can be obtained by digestion of the plasmid DNA, with
restriction enzymes, prior to separation by electrophoresis. The agarose gels are then
stained with ethidium bromide and the plasmid profiles then observed by exposure to
UV light. Plasmid analysis is technically the simplest of the DNA-based methods
and requires only basic electrophoresis equipment. A major drawback of this typing
system is that plasmids are not always present. Even when they are present, stability
can prove a problem with plasmids being spontaneously lost or acquired.
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2.2.2 Restriction endonuclease analysis of chromosomal DNA (REA)
DNA is enzymatically cut or digested with restriction endonucleases or enzymes at a
particular 'restricted' nucleotide recognition sequence (Maslow et al, 1993; Kerr,
1994). The number and size of the restriction fragments generated by digestion of
the particular piece ofDNA reflect the frequency and distribution of such restriction
sites. Restriction enzymes with relatively frequent restriction sites are used to digest
bacterial DNA, resulting in hundreds of fragments, ranging from ~ 0.5kb to 50kb in
length, which are subsequently separated by agarose gel electrophoresis. The
agarose gels are stained with ethidium bromide and the banding patterns examined
under UV light.
REA has been successfully applied to many species ofbacteria (Towner &
Cockayne, 1993) and the majority of isolates found to be typeable. Different strains
of the same species have different REA profiles because of variations in their DNA
sequences. The major limitation of this method is the difficulty in interpretation of
the DNA fragment profiles due to the large number of closely spaced bands produced
(Maslow et al, 1993). The presence of plasmids may also alter REA profiles
resulting in isolates that differ only in their plasmid content to be designated as
different strains. Variation in the number and size of fragments, due to sequence re-
arrangments, insertions and deletions ofDNA within a particular restriction site,




Southern blotting, named after the investigator who first descibed this procedure
(Southern, 1975), reduces the number of observed DNA fragments produced by
REA. In Southern blotting, the separated restriction fragments are transferred to a
nitrocellulose or nylon membrane and a labeled fragment ofDNA as a probe can
detect the restriction ffagment(s) which hybridise with sequences homologous to the
probe. All strains carrying sequences homologous to the probe are typeable and
results are highly reproducible. The procedure requires technical expertise and
originally utilised radioisotopes to label the probe. Nonradioactive detective systems
for Southern blotting are now available. The discriminatory power of this technique
is related to the number and variability of the fragments detected.
2.2.4 Ribotyping
Ribotyping, first described by Grimont & Grimont (1986), is the analysis ofDNA
polymorphisms in the chromosomal regions containing highly conserved rRNA
genes. The rRNA genes are organised into operons, within which the individual
genes coding for 16S, 23S and 5S RNA are often separated by non-coding DNA
spacer regions. Ribotyping involves Southern blotting analysis using a rRNA probe
for typing purposes. In many bacteria, considerable variation occurs within the 16S-
23S spacer region, both in length and sequence. These variations are detected,
following hybridisation with a probe specific to this region, by the resulting pattern
of DNA fragments produced. Isolates are typed according to the different banding
patterns produced which are refered to as ribotypes.
30
Various probes can be used for ribotyping including labelled mixtures of 16S and
23 S RNA resulting in hybridisation only with the fragments of the chromosomal
DNA which contain parts of the corresponding gene. Commercially available rRNA
probes, derived from E. coli ribosomal operons, can be used as 'universal' probes to
ribotype a wide range of bacteria. However, specialised probes may give better
specificity and discrimination within a species.
Many organisms carry multiple (5 - 7) ribosomal operons including E. coli, Staph,
aureus and //. influenzae. Thus the ribotype patterns produced comprising 10-15
bands provide moderate to good discrimination. In contrast ribotyping is of limited
use in mycobacteria which have only a single operon and produce only 1-2 ribotype
bands (Maslow et al, 1993). Ribosomal genes are relatively stable because they are
located on the chromosome, however, epidemiologically unrelated isolates
sometimes demonstrate the same ribotype pattern limiting the discriminatory power
and reliability of this typing system. Other factors affecting the level of ribotype
discrimination include the precision of the probe and restriction enzyme(s) used.
Ribotyping is reproducible but is time-consuming and relatively complex to perform.
An advantage is that interpretation of the results is relatively simple. Ribotyping has
the disadvantages that are associated with the use of radioactive material including
exposure hazards, short half-lives and disposal ofwaste material. However, non-
isotopic methods are available such as biotinylated probes (Pitcher et al, 1987) and
chemiluminescence (Gustaferro & Persing, 1992) to examine rRNA restriction
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patterns. The main discriminatory disadvantage of ribotyping is that it only
examines the specific region of the genome which hybridises with the particular
probe used. This contrasts with other genomic typing systems whose discriminatory
potential benefits from examination of the entire bacterial chromosome.
2.2.5 Polymerase chain reaction (PCR)
PCR is an enzymic method for exponentially amplifying specific nucleic acid
sequences ofDNA and was introduced by Saiki et al in 1985. This technique has a
wide variety of applications including detection, identification and epidemiological
typing ofmiroorganisms. Amplification of specific sequences is achieved with a
DNA template, oligonucleotide primers, deoxynucleotide triphosphates (dNTP's) and
a thermostable DNA polmerase in a suitable buffer. Each PCR amplification is sub¬
divided into three steps comprising denaturation, primer annealing and primer
extension, which are repeated in cycles. The double stranded DNA is denatured by
heating to over 90°C, resulting in separation of the strands. The sample is then
cooled to around 50°C to allow the primer(s) to hybridise to their complementary
sequences and thereby initiate copying of the single stranded template. The final
process involves an extension of the annealed primers by polymerase-mediated
nucleotide additions to produce two copies of the original sequence. This is achieved
by heating to 70 - 75°C, which is the optimum temperature for heat-stable DNA
polymerases. Once this cycle is completed, the sample is heated again to enable a
further round of DNA amplification to take place.
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The original method for PCR used DNA polymerase I (Klenow fragment) from
E. coli (Saiki et al, 1988). However, the high temperatures necessary for
denaturation ofDNA inactivated this enzyme resulting in the need to replenish the
enzyme before every cycle after restoration of the sample temperature to 37°C. This
enzyme was subsequently replaced by a thermostable DNA polymerase (Tag)
isolated from Thermus aquaticus (Saiki et al, 1988) which can withstand repeated
exposure to the high temperatures of 94 - 95 °C. T. aquaticus is a thermophilic
eubacterium found in hot springs and water heaters. Another benefit achieved by
using Taq DNA polymerase is that it can withstand the rapid 37° to 96°C
temperature changes necessary for PCR amplication.
A number of factors are important for a successful PCR reaction to occur, the most
important being the selection ofprimer. The primer should have a GC content
similar to the fragment being amplified. In addition, the concentration ofMgCl2 in
the buffer can have a profound effect on the specificity and yield of an amplification.
Generally, excess Mg++ will result in accumulation of non-specific amplification
products and insufficient Mg++ will reduce the yield. dNTP's appear to
quantitatively bind Mg++ therefore the amount of dNTP's present in a reaction will
determine the amount of free Mg++ available. Temperature, Mg++ concentration and
Taq polymerase concentration are all known to exert a strong effect on the specificity
of a PCR reaction. Annealing temperatures depend on the length and GC content of
the primers. PCR is an extremely powerful technique and a common problem is
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cross-contamination: PCR is so sensitive that it has been said that it is capable of
detecting a single molecule in a swimming pool.
A number of PCR-based typing techniques have been developed including PCR-
ribotyping, arbitrarily-primed PCR (AP-PCR) or random amplification of
polymorphic DNA (RAPD-PCR), and enterobacterial repetitive intergenic consensus
(ERIC-PCR).
2.2.6 PCR-ribotyping
This technique is an alternative approach to traditional ribotyping, uses PCR to
amplify the 16S-23S intergenic spacer region of the bacterial rRNA operon for the
specific purpose of detecting heterogeneity between and within species (Kostman et
al, 1992). The choice of primers is critical for successful detection of spacer
variation. PCR- ribotyping detects variation in length polymorphism and sequence
heterogeneity within the intergenic spacer regions by PCR amplification using
specific oligonucleotide primers (Kostman et al, 1992). These primers are
complementary to the highly conserved regions flanking the intergenic spacers of the
ribosomal RNA genes. The resultant PCR product is then separated by agarose gel
electrophoreisis. The epidemiological relatedness ofmicroorganisms can be
determined by comparison of the amplification patterns produced by PCR-
ribotyping. As only a small number of bands are produced, greater discrimination
can be achieved by further digestion of the PCR product, using restriction
endonucleases, prior to separation by electrophoresis. Primer specificity and high
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annealing temperatures make random amplification of the bacterial genome unlikely
in PCR-ribotyping. PCR-ribotyping is a rapid, reproducible, stable and an adaptable
method for molecular epidemiologic analysis. As most bacteria contain multiple
copies of ribosomal RNA genes, this technique can be applied to type many different
genera and species of bacteria. However, as mentioned in the introduction to
conventional ribotyping, certain bacterial species have only one or two rRNA
operons per genome and subsequently the spacer length and variation among such
species is limited.
2.2.7 AP-PCR or RAPD
Conventional PCR techniques amplify DNA sequences that are characteristic of a
particular species ofbacteria, using specific oligonucleotide primers. A prior
knowledge of the DNA sequence of the organism under investigation is therefore a
prerequisite. This requirement does not apply to RAPD as amplification of template
DNA is achieved by a single arbitrary primer which is not complementary to any
designated target but instead relies on the primer binding at multiple sites on the
bacterial chromosome. RAPD is carried out under conditions of low stringency (low
annealing temperatures), in the early cycles, followed by numerous cycles at high
stringency resulting in the primers annealing sufficiently close together in the correct
orientation with subsequent amplification of the intervening sequences. RAPD
typing is based on polymorphic variations in the intensity, number and length of the
multiple amplification products. RAPD analysis is rapid and cost effective but its
reproducibility is a subject of debate. Factors which affect reproducibility are the
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extraction methods employed for DNA (Gomez-Lus et al, 1992), concentration of
template DNA (Davin-Repli et al, 1995) and selection of primers, polymerase and
cycling conditions (Kerr, 1994). Identifying a suitable primer that provides
consistent, reproducible results may be difficult.
2.2.8 ERIC-PCR
Repetitive DNA sequences have been identified in bacterial genomes and are widely
distributed throughout the chromosome. ERIC sequences are ~126bp and occur
singly at each location on the chromosome. Primers based on ERIC sequences are
used for PCR amplification of genomic DNA and the resulting PCR product is
separated by agarose gel electrophoresis. The banding patterns produced by ERIC-
PCR represent amplification of DNA between adjacant repetitive elements within the
limits of polymerase extension and can be used to fingerprint bacteria. Differences
in band sizes probably result from polymorphisms in the distance between ERIC
sequences in different genomes. An advantage of ERIC-PCR typing is that DNA
does not have to be extracted as whole bacterial cells can be used.
2.3 PULSED FIELD GEL ELECTROPHORESIS
"It is unquestionable that PFGE is the 'golden standard' for typing most bacterial
species" (Liu et al, 1995).
For the purposes of genomic fingerprinting, the problem of complex REA banding
patterns resolved to some extent by the use of rare cutting restriction enzymes which
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digest chromosomal DNA at infrequent occuring restriction sites yielding 5-30
fragments of much larger sizes ranging from ~10kb to 800kb in length. In terms of
DNA analysis, conventional gel electrophoresis is dependant on the migration of
DNA molecules through a solid matrix, usually agarose, under a static electric field.
This is a disadvantage as it can only separate molecules less than 50kb. In contrast,
PFGE can separate much larger DNA fragments up to 7Mb. During conventional gel
electrophoresis, the DNA molecules elongate, align with the electric field and
migrate towards the anode. Attempts were made to extend the range of separation by
reducing the concentration of agarose and the use of very low voltage gradients but
this resulted in gels which were difficult to handle and run times of several days or
weeks only to achieve separation of at the most a few hundred kilobase pairs.
Klotz and Zimm (1972) demonstrated that DNA molecules elongate in the direction
of the electric field. When this field is withdrawn the DNA molecules relax back to
their original state, with the rate of relaxation dependant on the length ofDNA.
Schwartz, a student of Zimm, focused on this size-dependant relaxation and
succeeded in separating large DNA molecules. He found that changing the
orientation of the electric field forced the DNA molecules in the gel to relax on
removal of the first electric field, then elongate and align with the new field.
Schwartz et al (1982) introduced pulsed-field gel electophoresis (PFGE) as a method
of separating DNA molecules larger than 50kb by using two alternating electric
fields, one homogeneous and the other non-homogeneous. Their first study was
applied to yeast chromosomes to demonstrate the effectiveness of field switching or
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pulsing to separate high molecular weight DNA molecules in the range of 200-
3000kb. PFGE works on the principle that DNA molecules, in the agarose gel,
elongate in the direction of the electric field and begin to migrate through the gel.
When the first electric field is removed, and a second field at an angle to the first is
activated, the DNA molecules change conformation and reorientate before they can
migrate in the direction of the second electric field. The time required for
reorientation is dependant on the length of the DNA molecule, with larger molecules
taking longer to realign than smaller ones due to the physical barrier of the agarose
matrix. Provided the alternating electric fields are equal in length and voltage, the
DNA will migrate in a straight path through the gel.
A number of different 'commercial' PFGE systems are now available. Each has the
ability to separate the same range ofDNA sizes but differs in the speed of separation
and the resolution obtained in any specific size range. In a variation to PFGE, Chu et
al (1986) applied the principles of electrostatics to generate homogeneous electric
fields using multiple electrodes arranged around a closed contour, known as contour
clamped homogeneous electric field electrophoresis (CHEF). The 24 electrodes are
arranged in a hexagonal configuration with the voltage divided between these
electrodes so that the voltage gradient produced is constant across the gel. The
CHEF DRII system has a fixed angle between the direction of the pulsed fields
(reorientation angle) of 120°C but the newer model CHEF DRIII has a variable
reorientation angle of 90 - 120°, which can speed up the separation of the very large
molecules. The major advantage of the CHEF system is its ability to separate a large
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number ofDNA samples in straight lanes due to the use of homogeneous electric
fields. Chu et al (1986) also used yeast chromosomes to demonstrate that
homogeneous electric fields are necessary to separate large DNA molecules in
straight lanes in pulsed-field gels.
2.3.1 Preparation ofDNA for PFGE
Bacteria are embedded in low melting agarose plugs prior to the lysing process. The
agarose allows free flow of solutions necessary for lysing the bacteria and subsequent
digestion of the chromosomal DNA. Materials released during the lysis and
digestion procedures diffuse out of the agarose during washing, while the DNA
remains intact. The agarose protects the long strands ofDNA from mechanical
breakdown and nucleolytic degradation. DNA can remain intact, without
degeneration, when stored in an appropriate buffer for several years.
The optimisation of a number of variable parameters is necessary to obtain good
separation ofDNA fragments by PFGE. These variables include: pulse times,
voltage gradient, type and concentration of agarose, buffer composition, temperature,
and run time.
2.3.2 Pulse times
This is the most crucial factor in obtaining good separation of chromosomal DNA.
The size range of fragments resolved is directly proportional to the pulse time, which
can vary from a fraction of a second, which will separate molecules of a few
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kilobases to over an hour for molecules >5Mb. Ramping procedures are generally
used to separate a range of different sized DNA fragments starting with a short initial
pulse time which gradually increases during the run time until the longer final pulse
time is reached. The initial and final pulse times are dependant on the size range of
the fragments to be resolved.
2.3.3 Voltage gradient
This is the difference between the electrical potential of the electrodes in the gel tank,
and represents the force that drives the DNA molecules through the gel. Different
voltage gradients are used for separating different sizes ofDNA, fragments with
larger DNA molecules requiring lower voltage.
2.3.4 Type and concentration of agarose
Low melting agarose has reduced gel strength and smaller pore size than regular
agarose gels and is used for the preparation of agarose plugs, as already mentioned.
Pulsed-field gel agarose has to have a high degree ofpurity. It also has a precise
level of charged constituents present. Since the DNA migrates faster as the level of
charge is reduced.
Unlike conventional electrophoresis, where different concentrations of agarose are
used to separate different size ranges ofDNA fragments, changing the concentration
of agarose ofPF gels affects the speed at which the DNA migrates through the gel.
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As the agarose concentration decreases the DNA migrates faster but the bands appear
less sharp.
2.3.5 Composition of running buffer
The composition of the buffer affects the mobility and resolution of DNA through
the gel. DNA migrates quicker in buffers of low ionic strength. The two main
buffers used for PFGE are Tris-borate-EDTA (TBE) and Tris-acetate-EDTA (TAE).
DNA fragments run faster in TAE buffer and this is generally used for the separation
of larger fragments but the buffer has to be changed frequently to maintain its
buffering capacity. TBE buffer is used to separate fragments <2Mb and has a greater
buffering capacity than TAE buffer.
2.3.6 Temperature of running buffer
As the temperature of the buffer increases, the DNA fragments migrate more quickly;
however, the resolution diminishes. The migration of DNA fragments is sensitive to
change in temperature therefore it is important to maintain the running buffer at a
constant temperature to ensure equal migration in each of the lanes.
2.3.7 Run time
In PFGE, the run time of the gel depends on the range of sizes ofDNA fragments to
be resolved and the pulse times used. The temperature of the running buffer also
affects the run time as the cooler the temperature the longer the run time. Larger gels
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require longer run times but the further the bands migrate down the gel the less sharp
they become.
PFGE has been described as being nearly the optimal typing method, certainly for
isolates ofE. coli and Mycobacterium avium (Maslow et al, 1993). This technique
provides a highly reproducible restriction profile that typically shows distinct well-
resolved fragments representing the entire bacterial chromosome in a single gel.
Several studies have documented the superiority ofPFGE in comparison to a variety
of phenotypic and other molecular epidemiological typing methods (Goering et al,
1990; Saulnier et al, 1993). PFGE also has been referred to as the gold standard for
epidemiological analysis of nosocomial infection (Goering, 1993). PFGE
demonstrates excellent reproducibility and discrimination (Anderson et al, 1991;
Bingen et al, 1993; Steinbach et al, 1994) and can be applied to virtually any
organism from which the DNA can be extracted. Within the past few years, PFGE
technology has been applied to the epidemiological analysis of a large number of
microorganisms, as shown in Table 2.2. As with all typing systems, there are a
number of disadvantages; these include the understood fact that PFGE is time
consuming, technically demanding and requires the use of expensive equipment.
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Table 2.2. Examples ofmicroorganisms investigated by PFGE of chromosomal
DNA fragments
Organism Restriction enzyme Reference
Acinetobacter baumannii Apal Gouby et al (1992)
Bacillus cereus Xbal Liu et al (1997)
Bordetella pertusis Xbal Syedabubakaret al (1995)
Burkholderia cepacia Spel Anderson et al (1991)
Burkholderia picketti SpeI Chetoui et al (1997)
Campylobacter jejuni Smal Yan et al (1991)
Campylobacterfetus Smal Fujita et al (1995)
Clostridium difficle Smal Kristjansson et al (1994)
Corynebacterium diphtheriae Sfil Dezoysa et al (1995)
Enterobacter cloacae NotVXbal Haertl & Bandlow (1993)
Enterobacterfaecium Smal Miranda et al (1991)
Enterococcus faecalis Smal Tomayko & Murray (1995)
Escherichia coli Xbal Bohm & Karch (1992)
Klebsiella pneumoniae Xbal Gori et al (1996)
Legionella pneumophilia BssUll/SaWSpel Johnson et al (1994)
Listeria monocytogenes Apal/Smal Brosch et al (1991)
Mycobacterium avium Sspl Coffin et al (1992)
Mycobacterium fortuitum Xbal Hector et al (1992)
Mycobacteria tuberculosis Xbal/Spel Zhang et al (1992)
Neisseria gonorrhoeae Xbal/Nhel Xia et al. (1995)
Neisseria meningitidis Sfil/Spel/Nhel Bygraves & Maiden (1992)
Pseudomonas aeruginosa Xbal/Dral Bennekov et al (1996)
Shigella sonnei Xbal Litwin et al (1997)
Staphylococcus aureus Smal Bannerman et al (1995)
Staphylococcus epidermidis Smal Hu et al. (1995)
Streptococcus thermophilus SmallApal/Sfil Boutrou et al. (1995)
Salmonella typhi Xbal/Spel Nair et al. (1994)
Salmonella enteritidis Xbal/Spel/Avrll Thong et al. (1995)
Vibrio cholera Notl / Sfil Mahalingam et al. (1994)
Yersinia enterocolitica Notl Najdenski et al. (1994)
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2.3.8 Interpretation of banding patterns
The interpretation of the banding patterns produced by PFGE can prove difficult,
especially in determining the relatedness of a number of isolates. Alterations may
occur in both the number and position of the bands due to the presence of plasmids or
bacteriophage DNA (Towner & Cockayne, 1993). A single band difference may be
due to genetic variation. Point mutations resulting in gain or loss of a restriction site
will result in a three band difference. Insertion or deletion ofDNA into or from a
fragment will result in a two band difference. It is now generally accepted that
isolates demonstrating up to a three band difference in their PFGE profiles are
regarded as being closely related (Tenover et al, 1995) or subtypes of the same strain
(Goering, 1993). A 4 - 6 band difference demonstrates strains which are possibly
related (Tenover et al, 1995), as two genetic events could result in up to a six band
difference.
PFGE banding variations have been observed among isolates collected over long
periods of time. However, isolates that have no epidemiological link are likely to be
different if they demonstrate more than a three band difference. Isolates producing
more than a six band difference are classified as different strains.
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The Dice coefficient (Dice, 1945) can be used to determine the degree of similarity in
the banding patterns of two isolates using the following formula (Steinbach et al,
1994):
Dice coefficient of similarity (D)
D = 2nxy / n, + n2 where n, = total number ofDNA fragments from strain x
n2 = total number ofDNA fragments from strain y
nxy = number of identical fragments
A D value of> 0.9 represents closely related strains
< 0.6 unrelated strains
As PFGE is considered to be the 'gold standard' typing method for fingerprinting
isolates ofmicroorganisms, it was proposed to investigate the use of this system for




The general aims of this thesis focus on the major bacterial pathogens responsible for
pulmonary infection in CF patients. As mentioned previously, the spectrum of
pathogens is limited and primarily comprises; Staphylococcus aureus, Haemophilus
influenzae, Pseudomonas aeruginosa and Burkholderia cepacia.
Stenotrophomonas maltophilia has also been investigated although the pathogenic
role of this organism in CF patients remains unclear. The thesis investigates the
major epidemiological issues of each pathogen focusing, in particular, on the
application of the genomic typing system, pulsed-field gel electrophoresis. More
precise aims will be addressed in the chapter covering the individual pathogen.
3.1 STAPHYLOCOCCUS AUREUS
Staph, aureus is a common commensal of the anterior nares in many healthy
individuals with a higher incidence in infants and young children than in adults
(Gould & McKillop, 1954). As this organism is generally the first pathogen to cause
pulmonary infections in CF patients, particularly in babies and young children, it has
been speculated that nasal Staph, aureus acts as a reservoir which subsequently leads
to colonisation of the lower respiratory tract and pulmonary infection. Nasal flora
has been shown to be responsible for endogenous infections in other groups of
patients (White, 1963). The aim of this section of the thesis is to examine isolates of
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Staph, aureus cultured from nasal and sputum specimens from the same CF patient
by PFGE to confirm or reject the hypothesis that nasal carriage ofStaph, aureus is
responsible for subsequent pulmonary infection in CF patients.
Pulmonary infection due to Staph, aureus is less common in adult CF patients than in
paediatric CF patients. Could this be attributed to a lower nasal carriage rate of
Staph, aureus, assuming that the carriage rate in CF patients is the same as for
healthy individuals? To investigate this hypothesis, nasal swabs from paediatric and
adult CF patients were investigated to determine the incidence of nasal carriage of
Staph, aureus in paediatric and adult CF patients and in healthy individuals.
Sixteen CF patients were involved in a Phase I gene therapy trial at the Western
General Hospital, Edinburgh. This was basically a safety trial to show that a single
local application of the liposome/gene complex to the nasal epithelial cells had no
adverse affects on the patient. The liposome/gene complex was administered to eight
patients and the remaining eight patients received a placebo. Sputum and swabs of
the anterior nares were taken at various intervals throughout the trial to monitor the
effect of treatment on the bacterial flora, with particular interest in Staph, aureus.
Subsequently, nasal swabs were obtained from this group of patients to investigate




H. influenzae is present in the majority of healthy individuals as an upper respiratory
tract commensal. However, H. influenzae is a common cause ofpulmonary infection
in CF patients, especially in infants and young children. Consequently, the
significance ofH. influenzae recovered from respiratory secretion ofCF patients
poses a problem i.e. in determining whether the organism is merely a contaminant
from the upper respiratory tract or the cause of an exacerbation. During the thesis,
isolates ofH. influenzae were recovered from CF patients and examined by the
classical phenotypic typing system ofbiotyping, and by genomic analysis (PFGE) to
determine if certain strains are associated with pulmonary infection whilst others act
as commensals.
Prior to commencing this study, it was necessary to develop a suitable method for
extracting chromosomal DNA from isolates ofH. influenzae and to select an
appropriate restriction enzyme for DNA digestion prior to electrophoretic separation
by PFGE.
Isolates ofH. influenzae causing chronic lung disease and respiratory infection in
non-CF adult patients are predominantly biotypes II and III (Brabender, 1984).
Previous studies on biotyping ofH. influenzae isolated from CF patients have
produced conflicting results regarding the prevalence of these biotypes. Thus, it was
decided to investigate the biotypes of isolates ofH. influenzae from both non-CF and
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CF patients to allow comparison between the distribution ofbiotypes within the two
groups ofpatients.
3.3 PSEUDOMONAS AERUGINOSA
In the CF lung, P. aeruginosa generally supercedes Staph, aureus and H. influenzae
and is responsible for exacerbations in the older child or adult patient. Early
aggressive antipseudomonal treatment, when the organism is first cultured, may
result in eradication. Unfortunately, this strategy only delays the onset of
colonisation as the organism tends to return at a later date. The time interval between
eradication and the re-emergence ofP. aeruginosa varies depending on the patient.
It may become increasingly difficult to eradicate the organism with each subsequent
colonisation and a stage is reached when antimicrobial therapy fails to eradicate the
organism although the load ofP. aeruginosa may be reduced. Studies using
phenotypic typing systems have shown that once a patient becomes chronically
colonised with P. aeruginosa the same strain generally remains for the life of the
patient. One of the aims of this section of the thesis was to perform a longitudinal
study to compare the phenotypic and genomic fingerprints of the original isolate of
P. aeruginosa with subsequent isolates from the same patient.
P. aeruginosa undergoes a striking transformation in the majority of CF patients who
have been colonised for some time, with the classical non-mucoid colonial phenotype
converting to a highly gelatinous mucoid variant. The time taken for this conversion
differs from patient-to-patient and varies from as short as a few weeks to several
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years. Although phenotypic fingerprinting, and CF 'tradition' has suggested that the
mucoid organism is a clonal variant of the non-mucoid form, the transition has not
been investigated to any great extent using more discriminating molecular typing
techniques. Thus, PFGE was used to compare the DNA fingerprint of the original
non-mucoid isolate ofP. aeruginosa and the emerging mucoid phenotype.
In contrast to the notorious spread ofB. cepacia, there is little evidence that
P. aeruginosa is associated with cross-infection in CF patients, except in siblings and
small clusters ofpatients within individual CF centres. Recently, however, a large
number of CF patients attending a Liverpool clinic were found to be colonised with a
ceftazidime resistant strain ofP. aeruginosa. These isolates were investigated by
bacteriocin typing and PFGE to determine if the outbreak is due to a common strain
of P. aeruginosa.
3.4 BURKHOLDER1A CEPACIA
B. cepacia is a relatively recent pathogen to be isolated from respiratory secretions of
CF patients, and only emerged as a problem in the UK in the late 1980s. However,
in addition to innate multiresistance and virulence, B. cepacia is now a cause of great
concern within the CF community, due to the ability of certain strains to be readily
transmitted from patient-to-patient. For example, by the mid 1990s, the 'epidemic' or
ET12 strain ofB. cepacia was detected in 50% of CF patients in the UK (Pitt et al,
1996). Another B. cepacia issue is the association of certain strains with the life-
threatening fulminant pneumonia known as 'cepacia syndrome'. Hence,
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epidemiological studies form an essential part of surveillance to monitor the spread
ofB. cepacia among CF patients and to identify the individual strain ofB. cepacia
responsible for colonising an individual patient. An aim of this thesis was to
investigate the efficacy of PFGE as a typing system for B. cepacia.
The first isolate of the 'epidemic' strain ofB. cepacia from an Edinburgh CF patient
was recovered in 1989. This patient remains colonised with B. cepacia ten years
later. Using stored isolates from the Edinburgh strain repository, a longitudinal study
was carried out on the isolates recovered over the period of colonisation to identify
any change in the PFGE profiles produced during this time. Furthermore, a number
ofEdinburgh CF patients have acquired this 'epidemic' strain ofB. cepacia over the
last nine years and it is proposed to investigate isolates from each of these patients
for any variation in the strain as it transfered from one patient to another.
In North America, there is an increasing interest in the agricultural use ofB. cepacia
for soil bioremediation and as a biological control agent against major fungal
infections in commercial crops. Several studies have claimed that environmental and
biopesticide isolates ofB. cepacia differ from those causing infection in humans
(Butler et al, 1995; Honicky et al, 1993). However, this issue is the subject ofmuch
debate. One of the aims of this section is to use PFGE to investigate the relationship
between environmental and clinical B. cepacia and in particular to address the




In recent years, S. maltophilia is recovered with increasing frequency from CF
respiratory secretions. However, the reasons for this increase and the pathogenic
significance of S. maltophilia remain unclear. The aims of this thesis were to
investigate if cross-infection could explain the increased prevalence. For this
purpose, isolates of S. maltophilia from paediatric and adult CF patients were
examined by PFGE and their clonality determined. A second aim was to test the
hypothesis that the increased incidence of this inherently resistant organism might





Bacterial isolates used in this thesis were obtained from the Edinburgh CF
Microbiology Laboratory culture collection, the Clinical Microbiology Department,
Western General Hospital, Edinburgh or the Clinical Microbiology Department,
Royal Infirmary ofEdinburgh. Specimens of sputum and nasal swabs were obtained
from CF patients attending the CF clinics at Royal Hospital for Sick Children and
Western General Hospital, Edinburgh. Nasal swabs were also obtained from
members of staff in Medical Microbiology Department, Edinburgh University
Medical School.
4.2 CHEMICALS AND MEDIA
Unless otherwise stated, all chemicals were obtained from Sigma (Sigma-Aldrich
Coy. Ltd., Poole, Dorset) and all media from Oxoid (Oxoid, Basingstoke, Hants).
Nutrient agar (NA): Columbia blood agar base 39 g/L.
Blood agar (BA): Columbia blood agar base, 39 g/L, with 5% defibrinated horse
blood (Oxoid).
Chocolate agar (CBA): Columbia blood agar base, 39 g/L, with 5% defibrinated
horse blood, heated in boiling water until the blood turns brown.
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Chocolate agar plus bacitracin (CBA+): chocolate blood agar plus bacitracin
(lOU/ml).
Tryptone soya agar (TSA): Tryptone soya agar 40 g/L.
Sensitivity test agar (STA): Diagnostic sensitivity test agar 40 g/L.
Pseudomonas isolation agar (PIA): Pseudomonas isolation agar (Difco
Laboratories, Michigan, USA) 45 g/L with 2% (v/v) glyerol (BDH, Merck Ltd.,
Dorset) added prior to autoclaving.
Cepacia agar (CEP): Cepacia agar (Mast Diagnostics Ltd., Bootle) 32.5 g/L. Add
one Selectatab (Mast) per 100 ml agar, after autoclaving and when agar has cooled to
50°C. This gives a final concentration of 300 U/ml polymyxin and 100 pg/ml
ticarcillin.
Nutrient broth (NB): Oxoid nutrient broth No 2, 25 g/L.
Nutrient broth yeast extract (NBYE): Oxoid nutrient broth No 2, 25 g/L, plus 0.5%
yeast extract (Difco) added prior to autoclaving.
Brain heart infusion broth (BHI): brain heart infusion powder (Difco) 37g/L.
Skim milk: Skim milk powder, 10% (w/v). Sterilised by autoclaving at 121°C for
5 min.
Saline: 0.85% sodium chloride in distilled water
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Malka medium (Robert-Gero et al, 1970)
Stock solutions:
A Na2HP04 (7.34 g/lOOml), KH2P04 (3.24 g/lOOml). pH adjusted to 7.2.
Stored over 5 ml chloroform.
B MgS04.7H20 (2.05 g/lOOml). Stored over 5ml chloroform.
C 50% (w/v) glucose. Filter sterilised
D FeS04.7H20 (0.183 g/lOOml). Add 1 drop of concentrated H2S04 or HC1.
Sterilised by autoclaving for 15 min.
E (NH4) 2S04 (5 g/lOOml). Stored over 5 ml chloroform.
Add 20 ml A, 20 ml B, 5 ml C, 1ml D and 20 ml E to 934 ml sterile distilled water.






Brain heart infusion broth (Difco) was made according to the manufacturers
recommendations. BHI was boiled vigorously, 10% defibrinated horse blood
(Oxoid) was added. The mixture was filtered through Whatman No 1 filter paper and
sterilised by membrane filtration (Gelman Sciences, Northampton).
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Equal volumes of the Levinthal stock and autoclaved peptone solution; 1% bacto-
peptone (Difco) and 0.5% proteose peptone (Oxoid) were mixed and dispensed into
sterile bijoux, prior to inoculation. The bijoux were incubated at 37°C overnight.
The culture was mixed and 0.5 ml of Kovac's indole reagent was added. A pink
reaction indicated a positive result.





This solution was adjusted to pH 7.0 prior to autoclaving.
A stock solution of urea (20%) was sterilised by filtration and 1ml added to 20ml
medium. The urea solution was dispensed into 1ml amounts in WR tubes prior to
inoculation. The tubes were incubated at 37°C in a waterbath and results read after
2hr and overnight incubation. A read colouration was indicative of a positive result.
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Ornithine decarboxylase test (Moller, 1955)
proteose peptone (Oxoid) 5g




bromothymol blue, 0.2% soln. 5ml
cresol red, 0.2% soln. 2.5ml
The solution was adjusted to pH 6.0 prior to the addition of the indicators and then
sterilised by autoclaving at 115°C for 20min. A filter sterilised solution of
L-ornithine hydrochloride was added to the medium to a final concentration of 1%.
lml of the ornithine decaboxylase medium was dispensed into WR tubes and sterile
liquid paraffin was added until a thick layer was formed on top of the medium. The
medium was inoculated through the paraffin layer and incubated at 37°C for up to
five days, although examined daily. If decarboxylation occurs the medium turns a
violet colour.
All media was steriled by autoclaving at 121°C/15psi for 15 min, unless otherwise
stated.
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4.3 GENERAL BACTERIOLOGICAL METHODS
4.3.1 Storage, recovery and growth of bacteria
Bacterial colonies were suspended in skimmed milk and stored at -70°C and were
recovered by streaking out onto the appropriate media. Staph, aureus was inoculated
onto BA, H. influenzae onto CBA, P. aeruginosa onto PIA or NA, B. cepacia onto
CEP or NA and S. maltophilia onto NA. All plates were incubated at 37°C
overnight or for 48 h in the case of some isolates ofB. cepacia. Isolates of
H. influenzae were incubated under microaerophilic conditions (in the presence of
10%CO2).
4.3.2 Recovery of Staph, aureus from nasal swabs and sputum specimens.
Nasal swabs
Swabs of the anterior nares, in transport medium, were inoculated by rotating the
swab onto the surface of a BA plate to form a well. The inoculum was then streaked
out and the plate incubated at 37°C overnight. Colonies suspected as being Staph,
aureus were confirmed by Staphaurex Plus reagent (Murex Biotech Ltd., Dartford,
Kent) according to the manufacturers instructions.
Processing of sputum
An equal volume of Sputolysin (Calbiochem Novabiochem (UK) Ltd., Nottingham)
was added to the sample of sputum and vortexed.
Sputum was then diluted in sterile saline from 10"1 to 10"4.
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100(j.l of each dilution: neat, 10"2 and 10"4 was pipetted onto the following culture
media: BA, CBA+, PIA and CEP
The inoculum was spread across the surface of the plate using a sterile glass
spreader.
The plates were then incubated at 37°C overnight aerobically, except CBA+ which
was incubated in 10 % C02.
4.3.3 Making an isolate of S. maltophilia resistant to imipenem
Isolates CI931 and CI941 had a minimum inhibitory concentration (MIC) to
imipenem of 2 pg/ml. STA plates containing imipenem at varying concentrations
from 2 pg/ml to 40 pg/ml, in increments of 2 pg/ml, were made. Each isolate was
inoculated into 10 ml NBYE and incubated overnight at 37°C in shaking incubator.
The broth was diluted to 106 orgs/ml in saline, then 0.1 ml was spread across the
surface of several STA plates containing different concentrations of imipenem. The
same procedure was carried out with the isolates which grew at the highest
concentration of imipenem until a final MIC was reached.
4.3.4 Test for DNase production in isolates of S. maltophilia
A suspension of each isolate was made in 1 ml saline and inoculated onto DNA
medium (Mast Diagnostics, Bootle) using the multipoint inoculator (A400
Multipoint Inoculator, Denley, Billingshurst, Surrey). The plates were incubated at
37°C overnight. The plates were then flooded with N HC1 and left for a few
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minutes. DNase production is observed as an area of clearing, in the agar, around the
inoculated site.
4.3.5 Maceration of onions by B. cepacia
The outer skin of the onion was removed and then the onion was cut into slices using
a sterile scalpel. A medical wipe saturated in sterile distilled water was placed in a
sterile petri dish, to create a moist environment, and a slice of onion placed on top. A
few drops of an overnight NBYE culture of the test organism, grown at 37°C
shaking, was pipetted onto the surface of the onion. An uninoculated onion slice in a
petri dish was also incubated, as a negative control. The onion slices were incubated
at 30°C for 7 - 10 days. The onions were examined on a regular basis for any signs
ofmaceration.
4.3.6 Minimum inhibitory concentrations of antibiotics
Minimum inhibitory concentrations were determined by agar dilution method as
described in the Journal ofAntimicrobial Chemotherapy Volume 27, Suppl. D, 1991
page 28.
4.3.7 Inhibition of isolates ofH. influenzae by P. aeruginosa
An isolate ofP. aeruginosa was streaked down the centre of a CBA plate and
incubated at 37°C overnight. The growth was removed using a slide dipped in
chloroform. The plate was then exposed to chloroform for 15 min and exposed to the
air for a further 15 min to allow any residual chloroform to evaporate. This
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procedure was carried out in a Class I safety cabinet. The strains ofH. influenzae,
under investigation, were inoculated across the diameter of the plate, at right angles
to the area in which the P. aeruginosa growth had been removed. The plate was
again incubated at 37°C overnight and then examined for any sign of inhibition of
growth of the H. influenzae across the area in which the P. aeruginosa had grown.
4.4 PHENOTYPIC TYPING SYSTEMS
4.4.1 Bacteriocin typing
Bacteriocin or pyocin typing of P. aeruginosa was performed by the method of Fyfe
et al (1984) using eight main and five sub-indicator strains.
Bacteriocin typing ofB. cepacia was performed by the method ofGovan & Harris
(1986).
4.4.2 Biotyping
The work in this thesis used conventional biochemical testing methods for indole,
urea and ornithine decarboxylase to biotype isolates ofH. influenzae.
4.5 GENOMIC TYPING SYSTEMS
4.5.1 Pulsed-field gel electrophoresis (PFGE)
Buffers
SE buffer: 75mM NaCl, 25mM EDTA; pH 7.5.
Lysis buffer: 1% (w/v) N-lauroylsarcosine, 0.5M EDTA; pH 9.5.
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TE buffer: lOmM Tris, lOmM EDTA; pH 7.5.
EC buffer: 6mM Tris-HCl, 1M NaCl, 0.1M EDTA, 0.5% Brij 58, 0.2%
deoxycholate, 0.5% sarkosyl.
TEN buffer: 0.1M Tris-HCl, 0.15M NaCl, 0.1M EDTA.
Tris borate EDTA X5 concentrate (Sigma T-6400)
Preparation of chromosomal DNA
Method for the preparation of chromosomal DNA from B. cepacia, P. aeruginosa,
and S. maltophilia was modified from that described by Vasil et al (1990). Cultures
were grown in 10 ml NBYE overnight at 37°C with orbital incubation at 100 rpm.
After centrifugation at 2500 x g for 10 min, bacteria were resuspended in SE buffer
and standardised spectrophotometrically to an OD590 of 1.5. 0.5 ml of 1% low melt
agarose (Bio-Rad Laboratories Ltd., Hemel Hempstead, Herts.), in SE buffer, was
added to 0.5 ml of the suspension and pippeted into the plug mold. The mold was
placed at 4°C for 15 min. to allow the plugs to solidify. The plug was placed in a
bijoux containing 2 ml lysis buffer plus proteinase K, 0.5mg/ml (Sigma) and
incubated at 55°C overnight. After the lysis step the buffer was replaced by washing
three times in TE buffer and stored at 4°C until required.
Digestion ofDNA involved cutting a portion of the plug and placing it in an
Eppendorf tube together with 100 pi diluted restriction buffer; 2 pi bovine serum
albumen (BSA), 10 mg/ml; 2 pi dithiothreitol (DTT), 1.5 mg/ml; 2 pi restriction
enzyme Xbal (TCTAGA) or SpeI (ACTAGT) (Gibco BRL, Life Technologies Ltd.,
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Paisley, Renfrewshire). After overnight incubation at 37°C, the plug was loaded
into the well of a 1% pulsed-field agarose (Bio-Rad), prepared in 0.5 x TBE buffer.
Electrophoresis was performed with the CHEF-DRII (Bio-Rad). The pulse times
varied according to the organism involved but in each case electrophoresis was run
for 20 h. The gel was then stained with ethidium bromide (0.5 jig/ml) (Bio-Rad) for
15 min. followed by 30 min. destaining in distilled water prior to examination by UV
transillumination (UV Products, Cambridge). The photograph was taken using a
Polaroid camera with a setting of F11 B for 2.5 min. using black and white fdm type
665 (Polaroid) and allowed to develop for 50 sec.
Further modifications were involved for each organism and those will be outlined in
the relevant chapters.
Chromosomal DNA was prepared from H. influenzae by a modification of the
method used by Vasil et al (1990). A suspension of the growth from an overnight
culture ofH. influenzae on CBA was made in 1 ml NB. After centrifugation (MSE
Microcentaur) at 6,500 rpm for 2 min, the pellet was washed in 1 ml SE buffer and
resuspended in 0.5 ml SE buffer. An equal volume of 1% low melt agarose, in SE
buffer, was added and the suspension was pippeted into the plug mold. The plugs
were placed in a bijoux containing 2 ml lysis buffer plus proteinase K, 0.5 mg/ml and
incubated at 55°C overnight. After the lysis step the buffer was replaced by washing
three times in TE buffer and stored at 4°C until required.
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The method for the preparation of chromosomal DNA for Staph, aureus was
modified slightly from that described by Bannerman et al (1995). Cultures were
grown in 5 ml BHI broth (Oxoid) for 3hr and 0.7 ml of this culture was centrifuged
(MSE Microcentaur) at 6,500 rpm for 2 min. Cells were washed once in 1 ml TEN
buffer and resuspended in 0.3 ml EC buffer. 2 pi lysostaphin (1 mg/ml solution)
dissolved in 20 mM sodium acetate was added to the cell suspension and vortexed.
0.3 ml of 2% low melt agarose, in EC buffer, was added to the cell suspension,
mixed and pippeted into the plug mold. The plugs were allowed to solidify at room
temperature for 15 min. and then placed into a bijoux, containing 3 ml EC buffer, and
lysed at 37°C for lh. The EC buffer was removed and 3 ml TE buffer added and
incubated at 55°C for lh. This buffer was then replaced with 3 ml TE buffer and
stored at 4°C until required.
For electrophoresis, a portion of the plug was placed in an eppendorf tube to which
100 pi diluted restriction buffer, 2 pi BSA, 2 pi DTT and 2 pi Smal (CCCGGG) was
added. After 5 h incubation at 25°C the digested plug was loaded into the gel, as
above. The running parameters were as follows: initial pulse time 5 s; final pulse




50 mM Tris-HCl (pH 8.0) - 20 mM EDTA
50 mM Tris-HCl (pH 8.0) - 2 mM EDTA
10 mM Tris-HCl (pH 7.5) - 1 mM EDTA
DNA preparation. Whole chromosomal DNA was purified by a modification of the
method of Stull et al (1988). Cultures were grown overnight in 10 ml NBYE in
orbital shaking incubator at 37°C. 0.7 ml of culture was centrifuged at 13,000 rpm
for 2 min, washed in 1 ml 50 mM Tris-HCl - 20mM EDTA, and resuspended in
0.5 ml 50 mM Tris-HCl - 2 mM EDTA containing lysozyme (100 pg/ml) and
incubated at 4°C for 15 min. Proteinase K and sodium dodecyl sulfate were added to
a final concentration of 100 pg/ml and 0.5%, respectively. The mixture was
incubated at 37°C for 2 h. The bacterial lysate was extracted with phenol:chloroform
(1:1). Sodium acetate was added to a final concentration of 0.3 M, and two volumes
of 95% ethanol were added. After a 2 h or overnight incubation at -70°C the
precipitated DNA was recovered by centrifugation at 13, 000 rpm for 30 min and
resuspended in 10 mM Tris - ImM EDTA to give a final concentration of~ 1 pg/ml.
PCR-ribotyping was performed by the procedure ofKostman et al (1992). The
sequence of the primers used were: 16S, 5'-TTGTACACACCGCCCGTCA-3' and
23S, 5'-GGTACCTTAGATGTTTCAGTTC-3' (Crauchem, Glasgow). Amplification
was performed in a mixture of 10 mM Tris-HCl (pH 8.8), 50 mM potassium
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chloride, 1.5 mM magnesium chloride, 0.1% Triton X-100, 200 pM deoxynucleoside
triphosphates, 100 pmol of each primer and 1 pi DNA template. 0.2 pi PrimeZyme
DNA polymerase (Biometra Ltd., Maidstone, Kent) was added. The DNA was
amplified during 30 cycles ofPCR consisting of denaturation at 94°C for 1 min,
annealing at 55°C for 1 min, and extension at 72°C for 1 min, except for the last
cycle, during which the extension step lasted 4 min using Gene E thermocycler
(Techne (Cambridge) Ltd., Duxford, Cambridge). Twelve microlitres ofPCR
product was analysed by electrophoresis at 150V for 1 h in a 1% molecular biology
agarose (Bio-Rad). The gel was then stained by ethidium bromide and examined by
UV transillumination.
4.6 STATISTICAL ANALYSIS
Statistical analysis was carried out using the chi-squared (x2) test with the following
formula: the sum of (O - E)2 /E, where O is the observed number and E the expected
number. Having obtained a value for x2, and using the table of x2 distribution




5.1 TAXONOMY AND NOMENCLATURE
Over a hundred years ago, cocci were first observed in diseased tissues and in pus
obtained from human abscesses. These organisms were classified by Billroth (1874)
on the basis of their cell arrangements as monococcos, diplococcos, streptococcos
and gliacoccos. In 1880, a Scottish surgeon, Sir Alexander Ogston, showed
conclusively that a cluster-forming coccus was the cause of certain pyogenic
abscesses in man. At the same time, similar observations were made in France by
Louis Pasteur. This pyogenic organism was named Staphylococcus by Ogston
(1882); the name being derived from the Greek noun staphlye (a bunch of grapes)
and coccus (a grain or berry). Ogston proposed this name for the cluster-forming
cocci to distinguish them from the chain-forming streptococci classified by Billroth.
Rosenbach (1884) was probably the first to isolate and grow Staphylococcus in pure
culture and to study its characteristics. This organism was isolated from pus and was
considered identical to those observed and described by Ogston; Rosenbach adopted
the name Staphylococcus for the genus. Two colonial types were observed,
distinguished only by their colour: one being cream or yellow and named
Staphylococcus pyogenes aureus {Staph, aureus) and the other white, named
Staphylococcus pyogenes albus {Staph, albus or Staph, epidermidis). There are now
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nearly thirty defined species ofStaphylococci ofwhich the three species, Staph,
aureus, Staph, epidermidis and Staph, saprophyticus account for the majority of
infections in man.
5.2 GENERAL CHARACTERISTICS
Staphylococci are non-motile, non-spore forming, catalase-positive Gram-positive
spherical cocci which divide in more than one plane to form clumps. Their cell walls
comprise two main components, peptidoglycan and teichoic acid, which are
important cell-adherence factors. Staph, aureus contains an additional third
component, protein A, an antiphagocytic factor, not present in other species of
staphylococci, which is covalently incorporated into the cell wall. The peptidoglycan
chains, within the cell walls, are linked by pentaglycine bridges which break under
attack by lysostaphin causing lysis of the bacteria.
Staphylococci are facultative anaerobes but grow best under aerobic conditions
requiring as many as 12 amino acids and growth factors for growth (Fildes et al,
1936). They are also able to grow under anaerobic conditions where they require
uracil and a fermentable carbon source (Richardson 1936).
Staph, aureus is readily distinguished from Staph, intermedius by production of
coagulase (Chapman, 1934, Cruickshank, 1937). The majority of strains possess
"bound" coagulase on their outer surface which binds to fibrinogen causing
organisms to aggregate in the presence of rabbit plasma. However, in some strains
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only "free" coagulase is produced and this can only be detected by the clotting of
plasma in a test tube. Staph, aureus ferment a wide range of carbohydrates; these
include mannitol which can be incorporated into medium as a selective agent to
assist in the isolation ofStaph, aureus (mannitol salt agar).
Staph, aureus gives positive results to acetoin production (Voges-Proskauer),
gelatinase, alkaline phosphatase and DNAse but does not produce indole. It can
survive in the environment under moist and dry conditions, has the ability to grow in
up to 15% sodium chloride, withstand heat at 60°C for 30 min but is killed by
phenolic and hypochlorite disinfectants.
Staph aureus produces a number of enzymes which may act as virulence factors;
these include catalase, coagulase, nucleases, hyaluronidase, proteinase, phosphatase
and flbrinolysin and several toxins including enterotoxins A-E, toxic shock syndrome
toxin, epidermolytic toxins A & B and haemolysins alpha, beta, gamma and delta
(Cohen, 1986). Almost all strains ofStaph aureus produce toxic alpha haemolysin
while beta haemolysin is more commonly associated with isolates cultured from
animals.
Some strains ofStaph, aureus have been shown to produce capsular polysaccharides
(CPs) which have been classified into eight types (1-8) using monoclonal
antibodies. The capsules cannot be detected by traditional methods such as India ink
preparation or by the specific capsule reaction because of their small size (Fournier et
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al, 1984). Encapsulated strains of Staph, aureus have been isolated from CF patients
with a random distribution of capsular types. Antibody response to CP types 5 and 8,
measured by ELISA, was not elevated in CF patients with chronic Staph, aureus lung
infection; interestingly, the levels of antibody to CP 8 were significantly lower in
comparison with healthy carriers (Albus et al, 1988)
5.3 PATHOGENESIS
Staph, aureus is the most important staphylococcal pathogen in humans. Human
skin is densely colonised with coagulase negative staphylococci and to a lesser extent
with Staph aureus; the latter is more commonly found in human anterior nares.
Staph aureus causes a wide variety of infections ranging from localised or superficial
to systemic infections and toxin-mediated illnesses. Localised or superficial
staphylococcal infections include skin infections, otitis-media, post-operative wound
infections, osteomyelitis, bronchopneumonia, lung abscess, endocarditis and
empyema. Systemic infections include septicaemia and "spontaneous" bacteraemia;
these may occur without an obvious septic focus, particulary in patients debilitated
by chronic hepatic or renal disease or by diabetes mellitus. Toxic shock syndrome
and food-poisoning due to Staph, aureus are toxin-mediated illnesses.
For bacteria to colonise mucosal surfaces, they must first be able to attach to
epithelial cells and once bound to evade immune clearance. Bacteria vary in their
ability to attach to epithelial cells but Staph aureus has a high binding capacity for
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such cells. Fibronectin, a glycoprotein found in biological fluids such as plasma, has
been shown to bind to teichoic acid, a major structural component of the Staph,
aureus cell wall, thus allowing the bacteria to adhere to epithelial cells (Aly & Levit,
1987). Teichoic acid together with staphylococcal slime, which is biochemically
distinct from the alginate-like exopolysaccharide produced by P. aeruginosa
(Campbell et al, 1986), play significant roles in the adherence of Staph, aureus to
respiratory epithelial cells in patients with CF. Once bound, Staph, aureus produces
a variety of virulence factors including protein A and leucocidins which lyse
phagocytic cells.
Staph aureus together with P. aeruginosa, Staph, epidermidis, Strep, pyogenes and
diphtheroids adhere to nasal mucosal cells where the staphylococci constitute the
major components of the bacterial flora of the anterior nares. P. aeruginosa also
demonstrates good attachment but is rarely found in the nares of healthy adults (Aly
& Levit, 1987). Why the anterior nares are colonised by Staph, aureus in some
individuals or carriers is not known; however, microorganisms from carriers appear
to adhere readily to nasal epithelial cells in vitro. Another possible reason for nasal
colonisation by Staph, aureus may be minor deformities of the nasal cavity (Jacobs et
al, 1961).
There appears to be three groups of individuals with respect to nasal carriage of
Staph, aureus: persistent carriers, persistent non-carriers and transient carriers (Hu et
al, 1995). Bacterial fingerprinting by PFGE demonstrated that carriers may harbour
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the same strain ofStaph, aureus in their nose for over a year while others may be
colonised intermittently. Carriage appears to vary according to age with the majority
of babies carrying Staph, aureus in their noses, within a few days ofbirth (Aly &
Levit, 1987). Carriage decreases with increasing age and usually reaches adult levels
by the age of five to six years (Williams, 1963). A study in the Netherlands showed
that carriage varied from 40% in individuals under 20 years, to 30% in those over 20
years, 0% in 60 year olds and 15% in those over 70's (Noble, 1967). A higher
carriage rate (approximately 58%) was observed in hospitalised patients or
individuals working in hospitals (Miles et al, 1944).
Methicillin-resistant Staph, aureus (MRSA) is one of the most frequent agents of
nosocomial infection. Although these organisms have not been shown to be more
virulent than other Staph, aureus, their multiresistance makes them responsible for
higher mortality rates in compromised patients (Locksley et al, 1982).
5.4 STAPH. AUREUS IN CF PATIENTS
Staph aureus is generally the initial bacterial pathogen detected in respiratory
secretions from CF patients, especially young children, and is usually followed by
P. aeruginosa. The precise reasons for this progression are not known although an
attempted explanation is the adhesion ofboth pathogens to asialoganglioside GM1
(aGMl) epithelial receptors and the increased population of aGMl in regenerating
epithelium (Prince, 1992; De Bentzmann et al, 1996). Before the antibiotic era, lung
infection due to Staph, aureus was the major cause ofmortality in CF patients
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(Anderson, 1938). For example, in 1946, di Sant 'Agnese reported Staph, aureus as
the main organism cultured from the respiratory tract in 11 out of 14 cases on post¬
mortem examination. Although antibiotic therapy is probably a major factor
contributing to the decline of staphylococcal infections, particularly in adult CF
patients, bacterial antagonism by P. aeruginosa may play an important role. Machan
et al (1991) have shown that some strains ofP. aeruginosa produced two substances
which inhibit the growth of Staph, aureus. One of the substances was pyocyanin, a
pigment produced by P. aeruginosa, and known to be an antibacterial agent
(Schoental, 1941) while the other was present in non-pigmented strains of
P. aeruginosa, was soluble in chloroform, heat stable and showed strong anti-
staphylococcal activity which included MRSA.
Staph, aureus has the ability to adhere to respiratory epithelial cells and once bound
to evade immune clearance. Together with P. aeruginosa, Staph, aureus also has an
affinity for CF mucin and this property together with abnormalities ofmucociliary
clearance in the CF lung may contribute to persistent infection and progressive
pulmonary damage. The two pathogens do not, however, share the same mucin
receptors (Ramphal, 1990).
Interestingly, Staph, aureus has been found to adhere better to a CF bronchial cell
line (genotype AF 508/wl282X) than to control cells (Imundo et al, 1995). CF
patients overproduce a particular ganglioside (aGMl) on the surface of epithelial
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cells and increased binding of Staph, aureus to the tetrasaccharide (Gaipi-
3GalNac|31-4Gaipi-4Glc) of aGMl has been found (Imundo et al, 1995).
Early aggressive anti-staphylococcal therapy is essential to prevent lung damage in
CF patients (Marks, 1990). Many CF centres use long term prophylatic
antistaphylococcal therapy from the first diagnosis ofCF but this strategy remains
controversial and may lead to two major problems. First, continuous anti¬
staphylococcal treatment results in a more rapid emergence ofP. aeruginosa
colonisation or infection (Bauernfeind et al, 1987, Geddes, 1988) and the emergence
ofmucoid variants (Kulczychi et al, 1978). Second, the emergence ofStaph, aureus
resistance, in patients receiving long-term cotrimoxazole arises due to the uptake of
thymidine from the environment resulting in thymine-dependant strains. These
organisms produce typical colonial morphology on mannitol salt agar but fail to
grow on normal isolation media. In a study by Gilligan et al (1987), 21% of the CF
patients were infected with thymidine-dependant Staph, aureus. These organisms
could be easily missed if the use ofmannitol salt agar was not used routinely. The
strategy ofprophylactic anti-staphylococcal therapy remains controversial. The use
of long-term anti-staphylococcal prophylatic treatment showed significantly higher
hospital admission rates in CF patients not receiving flucloxacillin than those treated
with flucloxacillin prophylatically (Weaver et al, 1994). However, in Edinburgh, the
policy of only treating patients presenting clinical evidence of exacerbations and
Staph, aureus greater than 106 cfu/ml in their sputum may explain the relatively low
incidence of P. aeruginosa (Govan et al, 1987).
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Methicillin resistant Staph, aureus are recovered infrequently from respiratory
secretions of CF patients (Bauernfeind et al, 1990). A study by Boxerbaun et al
(1988) showed no recovery ofMRSA in the years 1984 and 1985 but 14 cases in 212
CF patients occured in 1986. Recovery ofMRSA from individual patients was not
associated with any clinically significant outcomes and the patients did not receive
any specific antimicrobial treatment. Of the 14 MRSA positive patients, 10
spontaneously lost the organism while four remained colonised without any adverse
results.
5.5 EPIDEMIOLOGY AND TYPING SYSTEMS
Staph, aureus is a major cause ofnosocomial and community-acquired infections and
the second most persistent pathogen isolated from respiratory secretions of CF
patients. In the management of non-CF patients, it is important to determine the
relatedness of staphylococcal isolates when investigating an outbreak and to consider
the possibility of carriers acting as a source of nosocomial infection. In CF patients,
epidemiological studies of Staph, aureus could determine whether the same strain or
different strains are responsible for recurrent bronchopulmonary infections.
Numerous typing systems are available for epidemiological studies ofStaph, aureus.
Phenotypic typing systems, including phage typing, are easy to perform and interpret
while systems involving DNA probing, include ribotyping, restriction fragment
length polymorphism (RFLP) and insertion sequence (IS) typing are labour intensive
and time consuming. However, phenotypic markers are often unstable and evidence
suggests that genomic typing systems are more reliable.
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5.5.1 Bacteriophage typing
Traditionally, bacteriophage typing (Blair & Williams, 1961) has been the most
widely used fingerprinting system for epidemiological studies of Staph, aureus,
although its use has been mainly restricted to reference laboratories. Phage typing
has been used in the CDC (Communicable Disease Center, Atlanta) for over 30 years
and has several known weaknesses; these include poor reproducibility and the
problem that around 20% - 30% of strains are untypeable (Tenover et al, 1994;
Schlichting et al, 1993; Bannerman et al, 1995). Maintenance of the large number of
phage stocks and propagation strains is also laborious. However, phage typing
shows a high degree of discrimination; it has been observed that isolates with
identical genotypes, using PFGE, may produce different phage types (Branger et al,
1996). Similar findings were observed using field inversion gel electrophoresis
analysis ofRFLP where isolates with similar but not identical profiles, suggesting
relatedness of the strains, were shown to have different phage types (Goering et al,
1990).
In contrast, PFGE identified subgroups within a phage group and is thus more
discriminating than bacteriophage typing (Bannerman et al, 1995). This result
combined with the other weaknesses ofphage typing has led the CDC to convert
from phage typing to the use of PFGE for typing strains of Staph, aureus.
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5.5.2 Biotyping
Biotyping using the method ofHebert et al (1988) works well for coagulase-negative
staphylococci but produces too many subtypes when used for Staph, aureus and does
not produce good correlation with epidemiological data or other typing methods.
5.5.3 Capsular serotyping
Capsular serotyping (Arbeit et al, 1984) divides Staph, aureus into eight types 1 - 8
but has a very low power of discrimination and has a similar number of untypeable
strains to phage typing. However, good correlation was found between this method
and esterase electrophoretic typing in a study of Staph, aureus in CF patients
(Branger et al, 1994).
5.5.4 Esterase electrophoretic typing
Esterase electrophoretic typing (EET) or zymotyping (Branger & Goullet, 1987)
involves electrophoretic mobility patterns of esterases produced in lysostaphin-
treated staphylococcal cultures. Zymotyping is stable and reproducible.
Epidemiological studies ofStaph, aureus in CF patients showed that no specific
zymotype was associated with CF and the same zymotypes were found in both CF
and non-CF patients, however, slightly more diversity occured among the CF
patients (Branger et al, 1994). EET is less discriminating than PFGE as isolates of
Staph, aureus, previously characterised by EET, with identical PFGE profiles did not
differ in EET but isolates with identical esterase typing belonged to different
genotypes (Schlichting et al, 1993).
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5.5.5 Plasmid analysis
Plasmid restriction analysis (Archer & Mayhall, 1983) was the first DNA-based
method to be applied to Staph, aureus and is probably the easiest and most
inexpensive of the genomic systems. Although used extensively, it is dependant on
the presence and stability of staphylococcal plasmids. Specificity of the technique is
high but the reproducibility poor (Tenover at al, 1994). CF patients found to be
infected with Staph, aureus on only one occasion revealed no predominant plasmid
or lysotype whereas five patients, who were colonised for over 10 months, had
identical strains when examined by phage and plasmid profile typing techniques
(Goering et al, 1990).
5.5.6 Ribotyping
Ribotyping is less discriminating than PFGE for typing strains of Staph, aureus
(Prevost et al, 1992). Ribosome spacer DNA amplicon polymorphism or RS-PCR is
a more rapid method of ribotyping, is relatively inexpensive, highly reproducible and
almost as discriminating as PFGE (Kumari et al, 1997).
5.5.7 Insertion sequence typing
Insertion sequence typing (Barberis-Maino et al, 1987) was primarily designed to
type MRSA and is relatively effective. However, this system is fairly ineffective for
typing methicillin sensitive strains of Staph, aureus. Additional discrimination may




Immunoblotting (Tsang et al, 1983) is easy to perform and was successful at
distinguishing outbreaks from unrelated strains of Staph, aureus, as long as the
subtypes were ignored. Using a stricter interpretation of results produced a much
lower degree of sensitivity. Interpretation of the complex banding patterns are
difficult for inexperienced individuals. One of the disadvantages of this system is the
use ofhuman serum for Western blots.
5.5.9 PFGE
Isolates ofStaph, aureus from two epidemiologically unrelated groups (one in France
and the other in Germany) were genotyped by PFGE. Results showed that three
strains ofStaph, aureus with identical genotypes were present in both groups of
patients (Schlichting et al, 1993). As there was no contact between the two groups,
these findings demonstrate that the appearance of identical genotypes does not
necessarily indicate an epidemic situation. Similar findings were observed by
Branger et al (1996) in that isolates of Staph, aureus with identical genotypes were
found in CF patients attending the same or different hospitals but there was no
evidence of contact among those patients.
PFGE was used to provide evidence ofpossible transmission of a strain ofStaph,
aureus from a CF patient to four other CF patients, attending a four-week summer
camp (Schlichting et al, 1993).
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PFGE is the most discriminating method of typing isolates of Staph, aureus but there
remains the problem of determining the number ofband differences allowed before
judging isolates as clonally unrelated. Branger et al (1996) has shown that
consecutive isolates ofpersistent Staph, aureus, causing chronic or recurrent
infections in CF patients, may demonstrate variant PFGE patterns differing by more
than three bands due to several genetic random events, whereas other strains showed
identical patterns.
5.6 COMPARISON OF TYPING SYSTEMS
Isolates ofStaph, aureus from epidemiologically unrelated sources were investigated
using the genomic typing system ofPFGE compared with established and commonly
used phenotypic methods such as zymotyping, capsular serotyping and bacteriophage
typing (Schlichting et al, 1993). Comparison of the typing techniques revealed that
capsular typing showed the poorest discrimination followed by zymotyping or
esterase electrophoretic typing and phage typing with PFGE being the most
discriminating typing system.
Tenover et al (1994) described an epidemiological study of 59 isolates ofStaph,
aureus and one strain ofStaph, intermedius which determined the strengths and
weaknesses of 12 available typing systems ranging from simple phenotypic systems
to more technically demanding genomic methods. Each system was assessed
according to the five criteria set out by Maslow et al (1993): typeability,
reproducibility, disciminatory power, ease of interpretation and ease of use. The
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methods involved were antibiograms, biotyping, bacteriophage typing,
immunoblotting, insertion sequence typing (IS), multilocus enzme electrophoresis,
restriction analysis ofplasmid DNA, PFGE, field inversion gel elctrophoresis,
restriction analysis of PCR-amplified coagulase gene sequences, RFLP using four
staphylococcal genes as probes and ribotyping. Tenover et al (1994) found that no
single method was superior to the others but biotyping produced numerous subtypes
and was not effective at grouping outbreak-related strains ofStaph, aureus. It was
suggested that a combination of two methods may be most efficacious: one method
to screen isolates and the other for detailed strain differentiation.
5.7 AIMS
Staph aureus is a commensal of the anterior nares in many healthy individuals,
appearing at higher levels in infants and young children than in adults (Gould &
McKillop, 1954). Several studies have investigated the incidence of carrier status in
different groups ofpeople but CF patients do not appear to have been included. Thus
it was proposed to obtain nasal swabs from paediatric and adult CF patients and
determine the carriage rate of Staph, aureus within this group of individuals.
During a Phase 1 gene therapy trial undertaken at the Western General Hospital,
Edinburgh, eight patients received local application of the liposome/gene complex to
nasal epithelial cells and eight patients received a placebo. Specimens of sputum
were taken prior to treatment, on the day of treatment and at intervals of 3, 7, 21 and
28 days after treatment. Swabs of the anterior nares were taken 7 days before and 7
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days after treatment with the exception of three patients who also had swabs taken on
the day of treatment. The aim was to examine nose swabs to determine whether the
delivery of the gene/liposome complex to the nose had any affect on the nasal flora,
with particular interest in Staph, aureus. Further nasal swabs, from this group of
patients, were examined to determine whether the anterior nares remained colonised
with the same strain ofStaph, aureus for any length of time.
As Staph, aureus is commonly found in the nose and is a common pathogen in
respiratory secretions ofCF patients, the rather obvious hypothesis was addressed
that Staph, aureus from the nose was responsible for colonising the lower respiratory
tract and causing pulmonary infection in CF patients. To answer this hypothesis,
isolates ofStaph, aureus from the anterior nares and sputum from the same patient
were genotyped by PFGE to determine the relatedness, if any, between the isolates
from the two sources.
5.8 RESULTS
5.8.1 Nasal carriage
One hundred and twenty one swabs of the anterior nares were sampled from 87 CF
patients; 79 swabs from 49 (56%) paediatric patients and 42 swabs from 38 (48%)
adult patients. Identification of isolates of Staph, aureus recovered from nasal swab
cultures were confirmed by Staphaurex Plus. Staph, aureus was recovered from 16
of the 49 paediatrics and from 26 of the 38 adult CF patients, indicating a carriage
rate of 33% in paediatric and 68% in adult patients, respectively.
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A similar study was undertaken among members of staff in the Medical
Microbiology Department at Edinburgh University, to determine the carriage rate in
healthy individuals. Forty nasal swabs were collected and examined for the presence
ofStaph, aureus. The incidence of nasal carriage of Staph aureus in this group of
individuals was surprisingly low at 25 %.
5.8.2 Fingerprinting isolates ofStaph aureus by PFGE.
Isolates ofStaph, aureus were typed by PFGE using the method described by
Bannerman et al (1995). However, the density of the DNA fragments together with
smearing within the lanes indicated that the concentration ofDNA was too high.
This problem was rectified by reducing the incubation period of the broth culture
from overnight to 3h. The DNA digestion time using restriction enzyme Smal
(CCCGGG) was increased from 2h to 5h at 25°C, as this produced clearer banding
patterns. Once the optimum conditions for PFGE separation of chromosomal DNA
for Staph, aureus were achieved, numerous isolates from CF and non-CF patients
were examined to assess the discriminatory powers of this technique. Figure 5.1.
shows a range of PFGE profiles produced by Staph, aureus isolated from nine CF
patients. Smal digestion ofDNA from Staph, aureus produced 15-18 fragments with
a size range of < 48.5kb to 630.5kb.
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FIG. 5.1. Smal digestion of DNA from nine isolates of Staph, aureus (lanes 1 to 9)
showing heterogeneity of PFGE profiles. Lane 10, lambda concatemers (size range
48.5 kb to 630.5 kb, in increments of 48.5 kb).
J
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5.8.3 Affect of local application of the liposome/gene complex on nasal flora.
Of the 16 CF patients involved in the gene therapy trial, Staph, aureus was isolated
from nasal swabs in 15 patients on at least one occasion. Comparison of isolates of
Staph aureus taken before and after the nasal application of gene therapy was
possible in only nine of the 15 CF patients. Of the remaining six patients, only a
single isolate of Staph, aureus was obtained from three patients and no Staph, aureus
was present in the pre-treatment swabs from the other three patients. Subsequent,
PFGE fingerprinting of the 18 nasal isolates ofStaph aureus, from the nine CF
patients, revealed the same strain ofStaph, aureus was present before and after
treatment in four of the nine patients while the remaining five patients harboured
different strains ofStaph, aureus.
5.8.4 Is the same strain ofStaph, aureus present in both the nose and sputum?
As specimens of sputum were taken at the same time as the nasal swabs during the
gene therapy trial, it was decided to compare the isolates ofStaph, aureus from both
sources. Staph, aureus was cultured from sputum only in seven of the 16 CF
patients. Comparison of the PFGE profiles of the sputum isolates with those from
the corresponding nasal isolates proved interesting. In four of the seven patients,
isolates ofStaph, aureus from the nose and sputum were found to be different.
Patients 5 and 6 had two different strains ofStaph, aureus present in the nose and in
each case one of the nasal isolates was identical to the isolate present in the sputum.
Patient 7 produced a particularly interesting result (Fig. 5.2). In this patient, Staph,
aureus was detected from the anterior nares at day 7 (pre-treatment) and day 7 (post
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treatment) and both isolates produced identical PFGE profiles, indicating that they
were the same strain. This strain was not isolated in subsequent nasal swabs.
Surprisingly, the original sputum isolate ofStaph, aureus, taken prior to gene therapy
treatment, appeared to have been replaced by the nasal isolate on treatment day and
was still present three days later. However, the original sputum isolate returned at
day 7 (post treatment) and was still present 28 days after treatment together with an
additional strain. In fact, the original strain ofStaph, aureus was still present in the
sputum two years later. Meanwhile, the strain common to the nose and sputum was
not detected in any of the specimens taken seven days post-treatment or later.
These results suggest the unexpected fact that the majority of the isolates of Staph,
aureus found in the nose of the CF patient are different to those present in the
sputum. Could nasal application of the liposome/gene complex be responsible for
this phenomenon? To answer this question it was necessary to obtain isolates of
Staph, aureus from other CF patients, not involved in the gene therapy program.
Isolates ofStaph, aureus were obtained from nasal swabs and sputum from 17 CF
patients. Both specimens were taken on the same day, where possible, but otherwise
within a few days of each other. Once again, PFGE revealed that different strains of
Staph, aureus were present in the nose and sputum of individual patients, in this case
in 13 of the 17 CF patients. Figure 5.3. shows four such CF patients, demonstrating
the difference between isolates ofStaph, aureus recovered from the nose and sputum.
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FIG. 5.2. Smal digestion ofDNA from Staph, aureus isolated from sputum and nasal
swabs in a CF patient undergoing gene therapy. Lanes: 1,3,4, 5,7, are sputum isolates
taken at -14 days, TD, +3 days, +7 days, and +21 days, respectively. Lanes: 2, 6, and 8
are nasal isolates taken at -7 days, +7 days, and a year later, respectively. Lane 9.
lambda concatemers (size range 48.5kb to 630.5kb, in increments of 48.5kb).
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FIG. 5.3. Smal digestion ofDNA from Staph, aureus isolated from the nose and sputum
in four different CF patients. Lanes: 1 to 8, P-A n/s, sputum; P-B n/s, sputum; P-C n/s,
sputum; P-D n/s, sputum, respectively.
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5.8.5 Does the same strain ofStaph, aureus remain in the nose for any length of
time?
It was decided to investigate the 15 CF patients involved in the gene therapy trial to
determine whether the same strain ofStaph, aureus remains in the nose for any
length of time. Unfortunately, six of the CF patients were recruited from Glasgow
and no further specimens were available. Staph, aureus was recovered from nasal
swabs in only five of the nine remaining CF patients. Based on PFGE analysis, the
results obtained from the 5 patients showed that the same strain of Staph, aureus was
present in the nose of 2 patients more than a year later and eight months later in a
third patient. The remaining two patients had two different strains of Staph, aureus
during the gene therapy trial and in both cases the isolates recovered a year later were
different to any previous isolate.
5.9 DISCUSSION
The primary reservoir of Staph, aureus is thought to be the anterior nares, which is
the most consistent area from which this organism can be isolated (Williams, 1963)
A recent review correlated the results ofmany studies on the incidence of nasal
carriage undertaken over several decades and calculated that the mean rate of
carriage ofStaph, aureus in healthy individuals is 37.2 % (Kluytmans et al, 1997).
Surprisingly at 25%, the rate of nasal carriage in members of staff in the Medical
Microbiology Department at Edinburgh University is relatively low considering a
significant proportion of individuals are exposed to Staph, aureus in their working
environment. However, comparison of carriage rates between healthy individuals
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and CF patients showed a marked difference; with a significantly (p<0.001,
yj test) higher carriage in adult CF patients (68%) compared to 33% in CF patients
under 16-years old. Interestingly, carriage in the latter group is virtually the same as
in the healthy non-CF population.
A possible explanation for the high nasal carriage rate in CF adults, could be the
increased affinity of Staph, aureus for adherence to CF epithelial cells. However,
this hypothesis does not explain the difference between paediatric and adult CF
patients.
The diversity in PFGE profiles produced by Staph, aureus is less than that produced
by other pathogens associated with pulmonary infection in CF patients. This general
lack of heterogeneity became apparent when examining PFGE profiles of isolates of
Staph, aureus from different patients. The same 'strain' was found among CF
patients, who had no possible contact with one another, and also common strains
were found among CF and non-CF patients. Similar findings were observed by
Schlichting et al (1993), who found common strains of Staph, aureus in two groups
of unrelated patients in France and Germany.
The nose has long been regarded as the major site ofStaph, aureus carriage and the
source from where the organisms can spread to other parts of the body (White, 1963).
This dogma has been supported by epidemiological studies (Kluytmans et al, 1997;
Nguyen et al, 1999). It was therefore assumed that the nose of a CF patient would
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act as a reservoir for Staph, aureus with the potential to spread to the respiratory tract
causing pulmonary infection. However, since PFGE data indicated that 76% of the
patients in this study had different strains in the nose and sputum it would appear that
pulmonary infection in the majority ofCF patients is caused by Staph, aureus
acquired from another source. Studies on an individual CF patient revealed that a
nasal isolate ofStaph, aureus appeared in the sputum and remained for a few days
but was then eradicated and the original isolate returned. Analysis of subsequent
specimens showed that the same strain of Staph, aureus can remain in the respiratory
tract for at least two years. These results suggest that infection with a particular
strain ofStaph, aureus prevents further acquisition of a different strain.
The application of the liposome/gene complex to the nasal epithelial cells appeared
to have little affect on the nasal flora in the CF patients. In some patients, the isolate
ofStaph, aureus in the nose before and after treatment was the same while in others
the isolates were different. As none of the isolates ofStaph, aureus in different
patients were the same strain, it would appear that the invasive treatment associated
with gene therapy was not responsible for the isolation of different strains of Staph,




6.1 TAXONOMY AND NOMENCLATURE
The genus Haemophilus is based on the 'influenzae bacillus' discovered by Pfeiffer in
1892. During a major outbreak of influenza, which took place between 1889-1892,
Pfeiffer examined sputa from affected patients and found a similar type of bacillus in
each case; the organism was absent in individuals who had not acquired influenza.
He concluded that the bacillus was the causative agent for influenza and named it
Haemophilus influenzae. In 1917, the organism was officially named H. influenzae
by the classification committee of the Society of American Bacteriologists (Winslow
et al, 1917). Subsequently, there was intermittent controversy as to whether
Pfeiffer's bacillus was the cause of influenza or a secondary invader; this doubt was
resolved in 1933 when Smith et al established that influenza was caused by a virus.
After this discovery, interest in the genus Haemophilus declined but was revived in
the 1970's when H. influenzae was confirmed as a pathogen causing a range of
infections in man and various animal species (Kilian, 1976).
6.2 GENERAL CHARACTERISTICS
H. influenzae is a small non-motile, non-sporing, Gram-negative bacillus and shows
marked pleomorphism varying from a cocco-bacillus to a long filamentous form.
Some strains are facultative anaerobes in that they require 5-10% carbon dioxide for
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growth but the majority of strains grow aerobically. H. influenzae ferments glucose,
deoxyribose and xylose, with gas production in some strains, but not sucrose, lactose
or mannitol. They reduce nitrates to nitrite and are catalase positive and oxidase
positive. Identification ofHaemophilus species is dependant on the requirement for
the growth factors X and V, with some species requiring only a single factor while
others, notably H. influenzae require both factors. X factor is heat-stable and is
found in haemin or other iron- containing porphyrins. X dependant strains are unable
to convert aminoalaevulinic acid to protoporphyrin. On the other hand, V factor is
destroyed by heating to 120°C but is released from red blood cells by gentle heating
or can be replaced by coenzyme I and II or by nicotinamide dinucleotide.
H. influenzae demonstrate the phenomenon of 'satellitism' when grown in the
presence of Staph, aureus on blood agar. Satellitism is recognised when colonies of
H. influenzae grow larger around Staph, aureus as the latter secrete V factor into the
medium to join X factor already present in the blood.
Immunoperoxidase staining for H. influenzae with monoclonal antibodies directed
against outer membrane proteins provides a higher detection rate than cultural
techniques (Moller et al, 1992); however, this procedure is not used routinely.
In general, infections due to H. influenzae are effectively treated with antibiotics,
however, the use of P-lactam antibiotics can result in spheroplastic forms of
H. influenzae which do not grow on standard culture media (Roberts et al, 1984).
These spheroplastic forms revert to normal forms ofH. influenzae if cultured on
media supplemented with N-acetyl-D-glucosamine (Roberts et al, 1984).
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6.3 PATHOGENICITY
In pathogenic terms, H. influenzae is the most important species of the genus
Haemophilus and only affects man. H. influenzae and other Haemophilus species
form part of the normal commensal flora of the mucous membranes of the throat, oral
cavity and to a lesser extent in the genital tract in normal healthy individuals.
However, following a viral infection, the organism can act as an opportunist
pathogen causing secondary infections in the respiratory tract.
In 1931, Pittman identified the presence of capsulate and non-capsulate forms of
H. influenzae and subdivided the former group into six capsular types, a - f,
distinguishable by serotyping based on the antigenic nature of the capsular
polysaccharide.
Capsulate strains, especially type b, are the most virulent form ofH. influenzae and
are responsible for invasive infections, and account for 95% of cases ofmeningitis,
epiglottitis and bacteraemia associated with this organism. The presence of the
capsule is a major virulence factor in H. influenzae serotype b although other
pathogenic factors may exist (Moxon, 1992).
Non-capsulate strains ofH. influenzae colonise the nasopharyngeal region in up to
80% of healthy people (Turk, 1984) but they can also play a pathogenic role. Non¬
capsulated H. influenzae is the cause of acute, recurrent and persistant infections of
the mucous membranes in humans including lower respiratory tract infections in
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patients with chronic obstructive pulmonary disease (Groeneveld, 1988). Non-
capsulate H. influenzae is also an important pathogen in both children and adults
with CF (Murphy et al, 1987) and a cause of otitis media, sinusitis, pneumonia and
various infections in immunoglobulin-deficient patients. Musher et al (1983)
reported serological evidence to suggest that non-capsulate strains ofH. influenzae
may be the causative agents ofpneumonia and chronic bronchitis by demonstrating a
host antibody response to the patient's infecting organism.
Non-capsulate H. influenzae, responsible for respiratory disease, was thought to be
merely a capsulate strain that had lost its capsule during bronchial invasion; however,
capsulate strains appear to play no role in bronchiectasis. Another explanation for
non-capsulate phenotypes was that the capsule was lost during passage in vitro.
Gyorkey et al (1984), however, showed that non-capsulate strains are present in vitro
and in vivo. In the early 1980's, several reports established clear distinctions between
non-capsulate and capsulate type b strains ofH. influenzae. These organisms affect
different patient populations, cause different infections, present different surface
antigens to the host and are genetically different. However, PCR has been used to
show and confirm that a non-serotypable strain ofH. influenzae may be derived from
a type b capsulate strain (Jordens et al, 1993).
Fimbriae are present on the surface ofmany Gram-negative bacteria including
H. influenzae. Their presence is not always associated with virulence but there is
clear evidence that fimbriae function as adherence factors in many bacteria, thereby
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enhancing bacterial colonisation ofmucosal surfaces (Beachey, 1981). The role of
fimbriae in the pathogenesis of infection caused by H. influenzae is unknown. They
are, however, found in both capsulate and non-capsulate strains of H. influenzae
recovered from the respiratory tract of adults (Apicella et al, 1984).
6.4 //. INFLUENZAE IN CF PATIENTS
Staph, aureus is generally held to be responsible for most of the initial chronic lung
infections in young CF patients and is subsequently followed by H. influenzae and
P. aeruginosa. It has been suggested that prophylatic treatment against Staph,
aureus increases the incidence ofH. influenzae and P. aeruginosa but this hypothesis
has not been verified (Bauernfeind et al, 1987a). Interestingly, however, there is
clear evidence that H. influenzae isolates responsible for colonisation of the lower
respiratory tract, and pulmonary exacerbations in CF patients, are invariably non-
capsulate. In some cases, it may be difficult to determine whether the strains isolated
from respiratory secretions are the cause of infection or merely normal commensal
flora of the upper respiratory tract. Respiratory exacerbations in CF patients caused
by non-capsulate strains ofH. influenzae are probably underdiagnosed and their
pathogenic significance under estimated. Rayner (1990) showed that non-capsulate
strains ofH. influenzae are significant pathogens in children with CF as a rise in the
number of organisms in sputum preceded the developement of acute exacerbation
and clinical improvement coincided with a reduction in bacterial numbers after
antimicrobial treatment. Studies on the use ofC-reactive protein, as an indicator of
pulmonary inflammation, also provided evidence that very high levels of the
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inflammatory marker are associated with H. influenzae exacerbations in CF patients
(Glass et al, 1988). Sputum cultures from CF patients show that H. influenzae can be
isolated in similar numbers to those ofP. aeruginosa suggesting both organisms play
a significant role in the pathology of airway inflammation. Although H. influenzae is
associated with pulmonary exacerbations in CF patients, there is no evidence to
suggest it has a primary role in the chronic progressive pulmonary decline (Pressler
et al, 1984).
The prevalence ofH. influenzae in sputum culture from CF patients varies
considerably, from 11% in a survey carried out in the USA (Gilligan, 1991) to 30%
in Manchester (Bilton et al, 1995). This discrepancy in the rate of isolation may
derive from differences in the methods involved in processing sputum specimens and
on the age ofpatients investigated. Detection ofH. influenzae in sputum cultures
from CF patients can prove challenging especially when larger numbers ofmucoid
and non-mucoid P. aeruginosa are present in the specimen. Colonial morphology of
H. influenzae may be difficult to distinguish from that of atypical non-mucoid
colonial forms ofP. aeruginosa associated with long-term pulmonary colonisation.
The sheer mass ofbacterial growth associated with mucoid P. aeruginosa can also
suppress the growth (Moller et al, 1993) or even overgrow the smaller colonies of
H. influenzae.
A number ofmethods have been proposed to increase the recovery rate of
H. influenzae from CF sputum. The use of quantitative procedures in the processing
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of sputum cultures as well as selective medium (eg. chocolate blood agar
incorporating bacitracin) and incubation in an atmosphere of 5 to 10 % C02 may
assist in overcoming this problem and account for the difference in the isolation rate
between different studies. Roberts and Cole (1980) used a haemin-bacitracin
medium incubated under anaerobic conditions and described an increase from 5 to
80% in the isolation rate. Bauernfeind et al (1987b) used pyocins to inhibit the
growth ofP. aeruginosa in order to enhance the recovery ofH. influenzae. More
recently, Moller et al, (1993) reported that the use ofN-acetyl-D-glucosamine and
cefsulodin discs in an anaerobic atmosphere improved the recovery rate of
H. influenzae. Their rationale was that the lack of oxygen combined with the action
of the antibiotic was inhibitory to P. aeruginosa whilst the presence ofN-acetly-D-
glucosamine allowed recovery of spheroplast forms ofHaemophilus. The
significance ofH. influenzae in CF sputum culture, especially in small numbers, still
remains debatable as it may be difficult to determine whether the organism is the
cause of pulmonary infection or merely a contaminant from upper respiratory
secretions.
6.5 EPIDEMIOLOGY
Biotyping and outer membrane protein analysis are the two most commonly used
typing systems amongst many that are available for epidemiological studies of
non-capsulate H. influenzae. However, these phenotypic systems are now being
superceded by genomic methods. Biotyping ofH. influenzae is a classification
system based on enzymatic and biochemical properties of the organism. Initially,
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H. influenzae was divided into five biotypes (I - V) on the basis of three tests
involving ornithine decarboxylase, indole production and urea hydrolysis (Kilian
1976). Subsequently, an additional three biotypes, VI, VII and VIII were added
(Table 6.1), also based on the same three tests (Oberhofer & Back, 1979, Gratten,
1983, Sottnek & Albritton 1984).
TABLE 6.1. Biotypes ofH. influenzae
BIOTYPE INDOLE UREA ODC
I + + +
II + + -
III - + -
IV - + +
V + - +
VI - - +
VII + - -
VIII - - -
ODC - ornithine decarboxylase
+ = positive result
- = negative result
There is little evidence that any particular biotype ofH. influenzae is more
pathogenic than any other; the exception is biotype I which is associated with
enhanced virulence regardless of capsulation (Long et al, 1983) and is predominant
in meningitis, septicaemia and otitis media in children. Biotype I is also responsible
for 80% of infections in invasive disease with the majority of the strains being
serotype b and capsulate (Long, 1983). The other biotypes are generally
nonserotypeable. In a study of children with otitis media, 53% of the strains of
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H. influenzae were biotype II (De Maria et al, 1984). Biotype II & III are
predominant in respiratory infections in non-CF adults with chronic lung disease
(Brabender et al, 1984) but are also found in the respiratory tracts of individuals with
no evidence of respiratory infection (Watson et al, 1985). Biotype III has been
shown to be the cause of septicaemia in USA (Kamme, 1980) and is found in both
CF and non-CF adults with chronic lung disease (Bilton et al, 1995).
In patients with CF, H. influenzae has been found to be predominantly biotype I
(Watson et al, 1985) although a subsequent study carried out by Rayner et al (1990)
showed biotype V to be more common that biotype I. However, this study also
demonstrated that biotype I was isolated more frequently immediately prior to an
exacerbation. CF patients may harbour a particular biotype for several months but
some show a change in biotype after an exacerbation (Rayner et al, 1990). Some
patients may possess more than one strain ofH. influenzae, although one strain tends
to predominate, and up to four biotypes have been present simultaneously. This type
ofmixed infection differs from non-CF patients where there is rarely more than one
biotype present at any one time (Watson et al, 1988).
Isolates ofH. influenzae are commonly characterised by analysis ofMOMP with
SDS PAGE. This typing system is highly discriminatory with non-capsulate
H. influenzae showing greater strain to strain variation compared to capsulate type b
strains (Murphy et al, 1983). However, the MOMP patterns have been shown to
change during persistent infection in patients with chronic obstructive pulmonary
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disease (Groeneveld et al, 1988). Although SDS PAGE analysis of these
//. influenzae variants showed variation in MOMP composition, genomic typing
systems based on PCR and RFLP showed the isolates to be identical (Van Belkum et
al, 1994). In studies with other H. influenzae isolates both genomic systems
provided good strain discrimination with PCR having the advantage ofproducing
results which are easier to interpret.
The surface ofnon-capsulate H. influenzae contains OMP and lipooligosaccharide
(LOS), which exhibit antigenic heterogeneity and can be used to serotype isolates
(Murphy & Apicella, 1987). Serological reactivity ofOMP with specific antisera
divides H. influenzae into six serotypes (Murphy & Apicella 1985). The structure of
H. influenzae LOS, based on SDS-PAGE and silver staining, is fundamentaly
different from that of LPS of enteric Gram negative bacilli (Flesher & Insel, 1978).
Multilocus enzyme electrophoresis (MLEE) is a means of characterising strains of
H. influenzae based on the relative electrophoretic mobility of a number of different
water-soluble metabolic enzymes. A drawback of this phenotypic typing system is
that it analyses only a small fraction of the structural gene loci ofH. influenzae in
contrast to some of the genomic systems which examine the entire genome. MLEE
was initially employed to estimate diversity of capsulate serotype b isolates of
H. influenzae (Musser et al, 1985). A further study, again using MLEE,
demonstrated a greater degree of diversity among non-capsulate isolates than was
observed in capsulate serotype b isolates ofH. influenzae. Interestingly, there was no
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evidence of any sharing ofMLEE types between capsulated and non-capsulated
strains ofH. influenzae (Musser et al, 1986).
In recent years, a number of genomic fingerprinting systems for H. influenzae have
been developed. These include RNA gene restriction pattern analysis (Bruce &
Jordens, 1991) which provides low discrimination; DNA - RFLP (Loos et al, 1989)
which produces complex banding patterns and ERIC - PCR (Van Belkum, 1994)
which is as discriminating as DNA-RFLP but provides more interpretable banding
patterns. Jordens et al (1993) compared SDS-PAGE analysis ofOMP, ribotyping
and RAPD-PCR and showed concordance with all three methods.
6.6 AIMS
Biotyping has been frequently used for epidemiological investigations of
H. influenzae, however, this phenotypic technique is now being superseded by
genomic systems. PFGE, generally considered to be the gold standard of genomic
systems, has not been investigated as a means of typing H. influenzae nor has the
method been compared with the traditional phenotypic biotyping system.
Successful application of PFGE for bacterial fingerprinting relies to a great extent on
a suitable method for extracting chromosomal DNA and optimising each of the
running parameters: pulse times, run times and temperature of the running buffer.
Adequate DNA digestion relies on finding a suitable rare cutting restriction enzyme.
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This aim was addressed prior to the epidemiological aims outlined in the following
paragraph.
As H. influenzae is present as normal human commensal flora in the upper
respiratory tract, it can be difficult to determine whether organisms isolated from CF
respiratory secretions are associated with infection or merely contaminants from the
upper respiratory tract. Previous studies have also provided conflicting results as to
which H. influenzae biotypes might be responsible for pulmonary exacerbations.
One of the aims of this thesis was to examine II. influenzae isolates from both
paediatric and adult CF patients to determine whether particular biotypes were
present during pulmonary infection and whether there was a difference in the
distribution of biotypes between children and adults. It was also proposed to
examine H. influenzae isolates from non-CF patients to compare the biotypes found
in CF and non-CF patients.
6.7 RESULTS
6.7.1 Developement of PFGE for H. influenzae.
Chromosomal DNA was prepared from H. influenzae by a modification of the
method used by Vasil et al (1990), see Material and Methods. The next step was to
find an appropriate restriction enzyme which would cleave genomic DNA from
H. influenzae. Initially, Xbal was used as it successfully digested the genomes of the
other Gram-negative bacterial species investigated. Xbal appeared to be successful
in cutting H. influenzae DNA into 20 - 24 fragments. However, separation of the
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fragments by PFGE resulted in profiles with banding patterns close together in the
lower section of the agarose gel. In an attempt to rectify this problem, the effect of
different pulse times on banding patterns was investigated. Optimum results were
found with pulse times of 0.5s - 20s. Initially, agarose gel strength was 1% run at
200V in TBE buffer at 14° C for 20h, but reduced later to 16h. Although these
conditions slightly improved the PFGE profiles the bands were still confined to the
lower section of the gel. Consequently, other restriction enzymes SpeI, Smal and
Dral (TTTAAA) were investigated in the hope of achieving an enzyme capable of
cleaving the DNA into fragments with a greater range of size distribution. The
PFGE profiles produced using Spel showed slightly better variation in DNA
fragment sizes compared to those produced by Xbal\ Dral completely failed to digest
DNA from H. influenzae. The best results were obtained using restriction enzyme
Smal which generated 12-19 fragments ranging in size from < 48.5 - 388 kb
consequently, Smal was selected as the enzyme of choice for the purpose of
epidemiological studies. Figure 6.1 illustrates PFGE banding patterns of two isolates
ofH. influenzae using the restriction enzymes Xbal, Spel, and Smal.
In this thesis, the final conditions chosen for PFGE fingerprinting isolates of
H. influenzae involved digestion with restriction enzyme Smal and the following
running parameters: initial time of 0.5s; final pulse time of 20s for 16h at 200V using
TBE buffer at 14° C. The diversity in PFGE profiles produced by 9 CF isolates of
H. influenzae are shown in Figure 6.2.
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FIG. 6.1. PFGE profiles of two isolates ofH. influenzae C2337 and C2386 digested




FIG. 6.2. Smal digestion ofDNA from nine CF isolates ofH. influenzae showing the
diversity ofPFGE profiles. Lanes 1 to 9, C2491, C2481, C2827, C2830, C2831, C2849,
C2851, C2737, C2832, respecitvely; lane 10, lambda concatemers (size range 48.5kb
to 388kb, in increments of 48.5kb).
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6.7.2 Comparison of Biotyping and PFGE
Preliminary studies comparing biotyping and PFGE were carried out on ten isolates
ofH. influenzae recovered from three adult CF patients undergoing CF gene therapy
treatment. Biotyping showed that isolates from two of the patients were biotype II
with the isolates from the third patient belonging to biotype V. On fingerprinting
these isolates by PFGE, the biotype II isolates, from both patients, showed identical
PFGE profiles while the isolates in biotype V were identical to each other but
different from those produced by the biotype II strains.
Since these preliminary results suggested that there may be some correlation between
the two typing systems a further 58 isolates ofH. influenzae from 37 CF patients,
comprising of 32 paediatric and 5 adults, were obtained from the Clinical
Microbiology Department, Western General Hospital, Edinburgh. Thirty additional
isolates ofH. influenzae, recovered from sputum from non-CF hospitalised adults,
were obtained from the Clinical Microbiology Department, Royal Infirmary,
Edinburgh.
All 88 H. influenzae isolates were biotyped using conventional biochemical tests for
indole, urea and ornithine decarboxylase. The isolates within each biotype were also
genotyped by PFGE and the banding patterns examined to determine the relationship,
if any, between isolates within a biotype. The results revealed that at least two
isolates ofH. influenzae within each of the biotypes I, II, III, and V produced similar
or identical PFGE profiles; furthermore a strain common to both CF and non-CF
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patients was observed in biotype V. All isolates in biotype IV and VI produced
different PFGE patterns. There was no evidence of isolates from different biotypes
producing the same PFGE profiles.
Analysis ofbiotyping results indicated that two of the 16 CF isolates of II. influenzae
belonging to biotype I exhibited the same PFGE profile. Both isolates were obtained
from sputum but from two different paediatric CF patients. None of the CF isolates
in biotype II appeared to be related on the basis of PFGE, however, two non-CF
isolates showed PFGE profiles, differing by only a single band. Four of the 11 CF
isolates, in biotype III, produced similar PFGE profiles and these included two
siblings C 2732 and C2698, whose isolates produced a two band difference (Fig.
6.3). One of the three CF isolates in biotype V showed similar PFGE banding to
three of the non-CF isolates. No isolates, either from CF or non-CF patients, were
found to belong to biotypes VII or VIII.
When multiple isolates ofH. influenzae from 13 CF patients were typed by biotyping
and PFGE the results obtained were concordant. All isolates in six of the patients
appeared to be the same strain. However, biotyping and PFGE suggested that the
remaining seven patients harboured two or more strains ofH. influenzae. Figure 6.4.
shows PFGE profiles from 3 CF patients colonised with 2 or 3 different strains of
H. influenzae simultaneously.
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FIG. 6.3. Smal digestion ofDNA from isolates ofH. influenzae, classified as biotype
III. Lanes 1 to 7, CF isolates (C2688, C2699, C2732, C2698, C2547, 8399, 8328,
respectively); lanes 8 and 9, non-CF isolates (6160 and 9841, respectively); lane 10,
lambda concatemers (size range 48.5 kb to 388kb, in increments of 48.5kb).
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FIG. 6.4. Smal digestion of isolates ofH. influenzae from three CF patients, colonised
with strains ofdifferent biotypes. Lane 1 to 3, (patientA C2687, C2656, 8399 - biotypes
I, II and III, respectively); lanes 4 to 6, (patient B C2647, C2594, C2723 - biotypes I, II,
and III, respectively); lanes 7 and 8, (patient C C2734, C2599 biotypes I and II,
respectively).
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6.7.3 Distribution of Biotypes
In calculating the prevalence of each biotype, only 45 isolates ofH. influenzae from
the 37 CF patients were included; patients with multiple isolates of the same biotype
were only included once. The distribution ofbiotypes for both CF and non-CF
isolates are shown in Table 6.2.
TABLE 6.2. Distribution of biotypes in CF and non-CF patients
BIOTYPE CF (%) SPECIMEN NON - CF (%)
I 14(31) 5 sputum (38%) 2(7)
9 T/S (28%)
II 11(24) 3 sputum (23%) 18(60)
8 T/S (25%)
III 11 (24) 1 sputum (8%) 3(10)
10 T/S (31%)
IV 4(8) 1 sputum (8%) 2(7)
3 T/S (9%)
V 3(7) 1 sputum (8%) 5(17)
2 T/S (6%)
VI 2(4) 2 sputum (15%) 0
T/S, throat swab
Biotyping data demonstrated little difference in the incidence ofbiotype I, II, and III
in CF isolates, with a slightly larger number of isolates falling into the biotype I
group. Only a small number ofCF isolates were found to be biotype IV, V or VI and
no isolates were found in biotype VII or VIII. When the source of the isolate was
taken into account, a difference in distribution ofbiotypes was observed. Thirty
eight per cent of the isolates ofH. influenzae recovered from sputum were biotype I
compared with 23% biotype II, 15% biotype VI and only 8% in each ofbiotypes III,
IV, and V. In contrast, there was little difference in the distribution between biotypes
I, II, and III in isolates recovered from throat swabs and the incidence of the other
biotypes IV and V were similar to those found in the sputum isolates. No isolates of
H. influenzae recovered from nose swabs were found to belong to biotype VI.
These results suggest a difference in the distribution of biotypes between CF and
non-CF isolates (p<0.01, %2 test). The majority of isolates from non-CF patients
belonged to biotype II with only small numbers in biotypes I, III, IV, and V, and no
isolates in biotypes VI, VII, or VIII.
6.7.4 Can P. aeruginosa inhibit H. influenzae?
Problems in culturing H. influenzae from sputum culture are well documented,
especially in patients who have been colonised with P. aeruginosa for a considerable
time. Could this be an explanation as to why H. influenzae was only isolated from
five adult CF patients? All 37 CF patients, from whom H. influenzae was recovered,
were investigated to determine what other organisms were present in their sputum
and to determine whether these might influence the recovery ofH. influenzae.
P. aeruginosa was isolated from 14 of the 32 paediatric patients and one patient was
colonised with B. cepacia. Of the five adults, four were colonised with both
P. aeruginosa and B. cepacia and the fifth patient with B. cepacia alone. Isolates of
H. influenzae, P. aeruginosa and/or B. cepacia, from the same patient, were tested
against one another to see if they showed any signs of an inhibitory affect.
Interestingly, in all cases P. aeruginosa inhibited the growth ofH. influenzae,
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regardless ofwhether the strain was mucoid or non-mucoid whereas B. cepacia was
not inhibitory to any of the isolates ofH. influenzae. An additional six strains of
P. aeruginosa, isolated from other CF patients, were checked for inhibition against a
selection of 12 different strains of H. influenzae. In all cases, P. aeruginosa
inhibited the growth ofH. influenzae in all cases.
6.8 DISCUSSION
RFLP analysis following whole DNA digestion and PFGE appears to be a valuable
and discriminatory technique for characterisation ofH. influenzae strains. Unlike
some other organisms, the PFGE profiles produced by H. influenzae were always
clear, sharp and easy to interpret. A frequent comment ofPFGE is that it is time-
consuming. In fact, it is no more time consuming than conventional, non¬
commercial, biochemical analysis. However, if commercially available kits are used
for biotyping H. influenzae, results are available within 24 h - 48 h; in contrast PFGE
takes at least three days.
Comparative analysis ofbiotyping and PFGE confirmed the preliminary findings and
indicated a degree of concordance between the two typing systems. Within biotypes
I, II, III, and V there were at least two isolates ofH. influenzae with the same PFGE
profile and no isolates with different biotypes were found to have the same PFGE
profile. However as expected, PFGE proved to be more discriminatory than
biotyping.
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An interesting difference was observed in the distribution of biotypes between CF
and non-CF patients with the majority of isolates ofH. influenzae in the non-CF
group belonging to biotype II. These results are similar to those observed by
Brabender et al (1984) who found that biotypes II and III were predominantly
responsible for respiratory infection in non-CF adults.
As mentioned previously, it can prove difficult to judge whether an isolate of
H. influenzae recovered from a CF patient is a pathogen or merely commensal flora
from the throat. However, the presence ofH. influenzae in sputum culture at levels
of >10 6 orgs/ml generally indicates that this organism should be considered to be
the cause of, or contributed to, pulmonary infection. In such cases, the predominant
biotype was biotype I. Further studies are required to determine whether isolates of
biotype I are associated with pulmonary infection. Two previous studies have shown
that biotype I was predominant in CF patients (Watson et al, 1985) although in one
study biotype I isolates were only predominant immediately prior to an exacerbation.
In most cases biotype V was the predominant biotype (Rayner et al, 1990). In
studies for this thesis, only three H. influenzae isolates were found to belong to
biotype V. Interestingly, all five isolates ofH. influenzae from adult CF patients
belonged to different biotypes.
H. influenzae is not a common cause of pulmonary exacerbation infection in adult CF
patients and subsequently only a small number of isolates were obtained from this
group ofpatients. This study also demonstrated that P. aeruginosa has the ability to
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inhibit the growth ofH. influenzae, certainly in vitro. As the majority ofCF adults
are colonised with P. aeruginosa, could this account for the low incidence of
H. influenzae recovered from sputum culture in this group ofpatients? However, this
explanation does not explain why 14 of the 32 paediatric CF patients were colonised




7.1 TAXONOMY AND NOMENCLATURE
Fordos (1860) described the pigment responsible for the blue-green appearance of
infected wound pus, named it pyocyanine, and reported it to be soluble in water,
alcohol, ether and chloroform. It was not until 1872, however, that Schroeter stated
that a motile microbe was responsible for the production of this pigment. Despite
neither chemical or microscopic observation for this theory, he proposed the name
Bacterium aeruginosum for this bacterium. Ten years later, Gessard (1882) isolated
and described the organism which produced pyocyanin but did not propose a
scientific name for the organism. However, the name Bacillus pyocyaneus was
attributed to Gessard by a number of authors. The generic name Pseudomonas
(Greek for 'false unit') was first used by Migula in 1894 and the species name
pyocyanea (Greek for 'blue pus'). Subsequently, Migula altered the species epithet in
1900 to P. aeruginosa (Latin,' full of copper rust or verdigris', hence green).
Controversy continued as to whether the species should be called pyocyanea or
aeruginosa until the Judical Commission of the International Committee on
Nomenclature ofBacteria (1952) stated that P. aeruginosa was the name of choice.
Finally, in 1994 the species epithet aeruginosa was accepted as the official
denomination of the bacterium in Bergey's Manual of Determinative Bacteriology
(Holt etal, 1994)
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7. 2 GENERAL CHARACTERISTICS
P. aeruginosa is a Gram-negative non-sporing bacillus, motile, usually with a single
polar flagellum and polar fimbriae. This organism is a strict aerobe although nitrate
can be used as an electron acceptor to permit growth under anaerobic conditions.
Growth occurs over a wide range of temperatures, 4 - 42°C, with an optimum of
37°C. Unlike most pseudomonads, P. aeruginosa will grow at 42°C but is killed by
exposure at 55°C for 1 hour.
P. aeruginosa can produce six distinct colonial morphotypes, designated 1-6 with
type 1 the classic, pigmented non-mucoid morphotype being most common (Phillips,
1969). Type 2 colonies are small, smooth and coliform-like; types 3 & 4 are small,
rough and rugose; type 5 describes the mucoid morphotype associated with
overexpression of alginate exopolysaccharide. Type 6 are dwarf colonies; these may
appear slightly mucoid as they are usually variants of the mucoid type. All six types
have been found in sputum specimens from CF patients.
Non-pigmented or atypical strains ofP. aeruginosa can prove difficult to identify
and in such cases identification relies on the use ofbiochemical tests, in particular
the characteristic cytochrome oxidase test with the majority of strains producing a
positive reaction. P. aeruginosa has the ability to oxidise a number of carbohydrates
with acid production only. Other biochemical tests include indole, hydrogen
sulphide, Voges Proskauer, methyl red, lysine decarboxylase and aesculin which
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produce negative reactions whereas arginine dihydrolase, catalase and gelatin
liquifaction are positive. A variety of extracellular enzymes are also produced by
P. aeruginosa including proteases, lipases, esterases and elastases.
P. aeruginosa can grow readily on minimal medium and use a wide range of organic
substances as carbon and nitrogen sources. The use of selective medium
incorporating selective agents, including Dettol, cetrimide or acetamide, may assist
in the isolation and identification ofP. aeruginosa. P. aeruginosa can be recovered
from a variety of sources ranging from soil, vegetation, surface water, plants and
animals; it is also a commensal in the intestinal and respiratory tracts of a small
proportion of healthy humans. P. aeruginosa is a classic opportunistic pathogen with
innate resistance to many antibiotics and disinfectants and has the ability to cause a
wide range of infections in patients compromised by underlying disease or treatment.
It grows as a saprophyte in warm, moist situations and is commonly found in hospital
environments, including sinks, drains, humidifiers, respirators and disinfectant
solutions. Swimming pools and jaccuzis may also act as reservoirs ofP. aeruginosa,
particularly if disinfection is impaired. Two main characteristics ofP. aeruginosa
contribute to this ubiquity; first, the ability to use more than 50 organic compounds
as energy and/or carbon sources (Stanier et al, 1966), second, a capacity to survive
lengthy periods of time in moist environments. P. aeruginosa does not only survive
but utilises diesel fuels and kerosene as carbon sources for growth (Bushnell & Hass,
1941) and has been shown to grow in distilled water (Favero et al, 1971). Like many
Gram-negative bacteria, P. aeruginosa is relatively sensitive to drying.
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The four distinct pigments produced by P. aeruginosa are pyocyanin, pyoverdin,
pyorubrin and pyomelanin. The characteristic blue phenazine pigment, pyocyanin,
which is soluble in both chloroform and water, is only found in P. aeruginosa and is
produced by approximately 80% of strains. Production of pyocyanin can be
enhanced with the addition of glycerol, magnesium, potassium or iron to the culture
media. Pyocyanin acts as a potential antibacterial agent and has a bactericidal affect
on a number of bacterial species, notably Escherichia coli, Staph, aureus and
Mycobacterium smegmatis (Schoental, 1941). Pyoverdin is a yellow/green pigment
(fluorescein) produced by most strains ofP. aeruginosa and other fluorescent
pseudomonads. This pigment, which is an important iron-chelating siderophore, is
formed in the presence ofphosphate and low iron and is soluble in water but not
chloroform. Colonies producing pyoverdin will fluoresce under UV light. Pyorubrin
and pyomelanin are less commonly found pigments. Pyorubrin produces a reddish
pigmentation, which is enhanced by the addition of 1% DL-glutamate to the culture
medium, and pyomelanin produces a brownish-black pigmentation and may require
the addition of 1% tyrosine to culture medium.
In some in vitro and in vivo environments, P. aeruginosa grows as microcolonies
forming an adherent matrix or biofilm which can be observed by light and electron
microscopy (Lam et al, 1980). This biofilm mode may be an important factor in the
organism's universal distribution in natural environments. Biofilms offer a survival
advantage to a bacterium as the inner cells are protected by an outer layer of exterior
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cells and exopolysaccharide which also protects the organisms from host immunity
and antimicrobial treatment.
7.3 PATHOGENICITY
P. aeruginosa seldom causes infection in healthy individuals but is one of the most
common pathogens involved in nosocomial infections; individuals particularly
susceptible are immunocompromised patients and intubated patients in intensive care
units, or patients predisposed to infections as a result of destruction of physical
barriers such as in burns, eye damage and surgery (Dart & Seal, 1988). Infections
include septicaemia, urinary tract, ear infections (including 'occupational' infections
in deep sea divers), corneal ulceration due to contamination of contact lens fluid and
respiratory tract infections in patients with CF, COPD, AIDs and cancer (Alcock,
1976; Speert, 1994; Zloty & Belin, 1994; Spencer, 1996). Although P. aeruginosa is
a serious cause ofhospital infection, the highest morbidity and mortality occurs in
individuals with underlying diseases such as CF and cancer. The pathogenesis of
infections caused by P. aeruginosa is multifactorial and complex with different
virulence factors exhibiting different levels of importance. P. aeruginosa produces a
considerable armoury of virulence factors which include fimbriae, flagella,
lipopolysaccharide (LPS), slime, alginate, exotoxin A, exoenzyme S, haemolysins,
proteases, elastase, cytotoxin, siderophores and pyocyanin.
Most strains ofP. aeruginosa produce polar fimbriae or pili, which are associated
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with adherence of the organism to various cell surfaces. P. aeruginosa pilin adheres
to cell surfaces via the receptor site, GalNAcpi-4Gal, which is present in certain
asialylated glycoproteins, including asialoganglioside GM1 (aGMl) (Krivan et al,
1988). However, these binding sites are not specific to P. aeruginosa as other
bacterial pathogens including Staph, aureus also adhere readily to aGMl (Imundo et
al, 1995).
The single polar flagellum ofP. aeruginosa is an important taxonomic characteristic
of this organism. Flagella are proteinaceous, filamentous cell surface appendages
responsible formotility and chemotaxis of the organism. They are associated with
virulence as non-flagellate strains are less likely to cause systemic infections in the
burned mouse model than their flagellate counterparts (Drake & Montie, 1988).
The LPS of P. aeruginosa comprises lipid A, which is integrated into the bacterial
outer membrane, and a core region which extends from lipid A. In smooth strains, a
carbohydrate side chain, known as the O-specific side chain, is attached to the core
region. The composition and structure of the side chains are variable, forming the
basis of serotyping, whereas the lipid A and core region are relatively conserved.
LPS plays a major role in the virulence ofP. aeruginosa and other Gram-negative
organisms conferring a resistant barrier to the bactericidal action of complement in
human serum and protection of the bacterial cell against opsonisation and
phagocytosis (Engels et al, 1985). Most clinical isolates ofP. aeruginosa are
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smooth, indicating the possession of O-antigen and are resistant to normal human
serum. In contrast, isolates from chronic infections, including those involving the
respiratory and urinary tracts are deficient in O-side chains and are serum sensitive
(Hancock et al, 1983). However, there is no absolute relationship between serum
resistance and possession of O antigenic side chains. The LPS ofP. aeruginosa is
similar in general structure to that ofEnterobacteriacae but has a lower intrinsic
toxicity (Pitt, 1988; Liu, 1974). Unlike enterobacteria, serologically rough strains of
P. aeruginosa are seldom 'rough' in colonial appearance (Pitt, 1988). There is little
doubt that LPS plays a significant role in P. aeruginosa infections as antibody
towards LPS is highly protective in human infections and in animal models (Pollack
& Young, 1979).
All strains ofP. aeruginosa produce extracellular slime which is distinct from the
alginate-like exopolysaccharide associated with the mucoid colonial morphotype.
The composition of pseudomonas slime varies depending on the strain, cultural
conditions and method of analysis (Govan, 1990). More than 50% of the slime is
composed of polysaccharide, mainly glucose and mannose with around 20% nucleic
acid and a small protein fraction (Brown et al, 1969).
The most toxic virulence factor ofP.aeruginosa is exotoxin A, an exoenzyme
produced by more than 90% of strains (Vasil, 1986). Exotoxin S is more heat
resistant than exotoxin A and is partially destroyed by the reducing agents urea and
dithiothreitol which interestingly increase the activity of exotoxin A. Exotoxin S
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may act as an adhesion factor and play an important role in the initial adherence of
P.aeruginosa to epithelial cells (Baker et al, 1991).
Most P.aeruginosa produce phospholipase C and rhamnolipid (Vasil, 1986).
Phospholipase C is a heat-labile haemolysin; rhamnolipid is heat-stable and inhibits
mucociliary clearance.
Most P. aeruginosa produce a range ofproteases which are active against a variety of
substrates, including gelatin, casein, elastin and fibrin (Liu, 1974). Elastase is
produced by 85-90% of strains and is active against human lung elastin,
immunoglobulins, complement factors, human collagens and human mucins.
Clinical isolates ofP. aeruginosa produce significant levels of haemolysin,
proteases, gelatinase, fibrinolysin, lipase, coagulase, lecithinase and DNase in
contrast to environmental isolates which are relatively inert enzymatically. However,
Mansi et al (1995) reported variability in expression of virulence factors in both
clinical and environmental strains ofP. aeruginosa.
Leucocidin is produced by most strains ofP.aeruginosa and is an inactive or weakly
active toxin capable of conversion to an active toxin by the action of various
proteases, including elastase. Thus, leucocidin may contribute to inflammation and
human tissue necrosis indirectly following release ofproteolytic enzymes from
bacterial and host cells.
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7.4 P. AERUGINOSA IN CF PATIENTS
P. aeruginosa is the most common and life-threatening pathogen in CF with a
prevalence reaching 80% or higher in CF adults (Pier, 1985; Gilligan, 1991; Govan
& Deretic, 1996). Characteristically, pulmonary colonisation with P. aeruginosa
increases with age (Govan et al, 1987; Gilligan, 1991) and tends to appear in early
adolescence following previous infections with Staph, aureus and H. influenzae. The
association ofP. aeruginosa with the CF lung is complex and involves a range of
host/pathogen interactions (Hutchison & Govan, 1999) which will be described in the
following sections and summarised diagramatically in Fig.7.1a.
7.4.1 Aquisition ofP. aeruginosa
Several theories have been proposed over the years to identify possible P. aeruginosa
reservoirs and explain the mechanism ofP. aeruginosa colonisation in CF patients.
Apart from natural sources such as soil and surface water, the gastrointestinal tract
has also been investigated as a possible source of non-mucoid P. aeruginosa',
however the organism was only isolated from the faeces in CF patients who already
had P. aeruginosa present in their sputum (Agnarsson et al, 1989). It was therefore
difficult to determine whether gut colonisation preceded or resulted from
colonisation of the respiratory tract. Finally, contamination of the gut from the
respiratory tract was confirmed by Speert et al (1993) who demonstrated that






























































FIG. 7.1a. Effects of CFTR dysfunction on pulmonary immunity and the
implications for P. aeruginosa colonisation. Stage 1: Attracted by positive
chemotaxis to host mucin, P. aeruginosa binds to the aGMl receptor on the apical
surface of the lung epithelium. CFTR dysfunction causes epithelial upregulation of
IL-8, a potent neutrophil attractant, and a larger than appropriate neutrophil response.
Neutrophil elastase and reactive species, as well as virulence factors exported by
P. aeruginosa contribute to damage of the pulmonary epithelium raising further
levels ofpro-inflammatory cytokines and recruiting more neutrophils to the CF lung.
Damaged epithelial cells regenerate with increased apical expression of aGMl which
allows more P. aeruginosa to bind to the epithelial cell surface. Thus an upwardly
spiralling cycle of host damage and enhanced pathogen binding is initiated. Binding
ofP. aeruginosa LPS to aGMl results in upregulation of human muc genes thereby
increasing the burden of an already viscid mucosal blanket. A higher than normal
concentration of salt in the airway surface fluid (ASF) ofCF patients is believed to
cause diminished activity of antimicrobial defensins. As a consequence, the natural
antimicrobial activity of the ASF is compromised and fails to control the ever-
increasing numbers ofP. aeruginosa. Furthermore, aberrant control mechanisms fail
to react to increased levels ofpro-inflammatory cytokines and hence do not
upregulate levels of the inducible nitric oxide (NO) synthetase enzyme in the
pulmonary epithelia. Thus, the levels of the highly reactive antimicrobal NO
molecule are lower than would be otherwise expected and the antimicrobial
properties of the ASF are further diminished, promoting P. aeruginosa proliferation.
Other proposed mechanisms that contribute to the lowered lung defences include the
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CFTR desquamation hypothesis. The majority of CF patients lack apical CFTR,
whose properties include specific P. aeruginosa binding. Since binding of
P. aeruginosa to CFTR is thought to result in uptake of the pathogen into the
epithelium, followed by clearance by desquamation, the lack of apical CFTR in CF
compromises another pulmonary defence mechanism. Stage 2: As numbers of
P. aeruginosa rise, a combination of spontaneous mutation, quorum sensing and
environmental stress causes upregulation of bacterial alginate and formation of a
bacterial biofilm. Key properties of the biofilm are decreased susceptibility to
antibiotic and frustrated phagocytosis leading to neutrophil degranulation and
inflammatory damage (Hutchison & Govan, 1999).
7.4.2 Adherence
Following flagella-mediated chemotaxis to the mucociliary blanket, adherence of
P. aeruginosa to respiratory epithelium and respiratory mucus is thought to play a
crucial role in the initial colonisation of the CF airways (Woods et al, 1980).
Interestingly, it has also been suggested that flagella are important in the colonisation
since they may act as a tether in initial interaction with epithelial membranes. This
function, however, is offset by the contribution of flagella to phagocytic clearance
(Feldman et al, 1998). It has been suggested that P. aeruginosa adhere more avidly
to buccal epithelial cells of CF patients compared with normal individuals. This
attachment is thought to be due to the action of dietary pancreatic supplements which
strip fibronectin from the buccal cell surface allowing attachment ofP. aeruginosa
(Woods et al, 1980). P. aeruginosa is believed to adhere to epithelia primarily by
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means ofpili (Fick et al, 1992; Prince, 1992) but exoenzyme S (Baker et al, 1991),
mucin and alginate (Pedersen, 1992) also have adhesin properties. Mucin is a major
component of respiratory mucus together with other defensins lactoferrin,
immunoglobulins, lipids, lysozyme and serum glycoproteins, some ofwhich may
have antimicrobial functions (Vishwanath & Ramphal, 1984). Mucus and cilia are
the key components involved in mucociliary clearance. However, in CF patients
clearance is impaired by the dehydration of the mucosal blanket and as a
consequence P. aeruginosa adherence to mucin probably plays an important step in
the early colonisation of the respiratory tract. Subinhibitory concentrations of
ceftazidime inhibit the binding ofmucoid P. aeruginosa strains to tracheobronchial
mucins whereas tobramycin has no effect (Vishwanath et al, 1987).
Non-mucoid strains ofP. aeruginosa do not adhere well to normal ciliated epithelial
cells indicating that prior damage of the epithelia by viral or bacterial infections may
be necessary for colonisation to occur (Ramphal & Pyle, 1983). As mentioned
previously, P. aeruginosa pilin adheres to epithelial cells via the receptor site,
GalNAc(31-4Gal. Since these sites are not generally exposed, a number of factors
have been considered to explain the increased availability of aGMl receptor sites in
the CF lung (Krivan et al, 1988). It has been suggested that the P. aeruginosa
exoproduct, neuraminidase, increases the availability of aGMl receptors by cleaving
terminal sialic acid residues from cell surface gangliosides which may contribute to
the initial bacterial colonisation process in the respiratory tract (Cacalano et al,
1992).
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Defective CFTR may also play a role in the colonisation of CF airways with
P. aeruginosa. Several studies have shown that CFTR dysfunction leads to an
increase in aGMl on the apical surface of airway epithelial cells (Saiman & Prince,
1993; Immundo et al, 1995; Davies et al, 1997). Furthermore, De Bentzmann and
colleagues have demonstrated enhanced aGMl receptors on regenerating epithelial
cells, causing increased adhesion ofP. aeruginosa (De Bentzmann et al, 1996).
This is an interesting result since increased a GM1 would explain why P. aeruginosa
tends to follow Staph, aureus in childhood (Gilligan, 1991) and the association of
P. aeruginosa with previous infection by RSV (Petersen et al, 1981).
7.4.3 Mucoid conversion
P. aeruginosa isolates cultured from initial pulmonary infection in CF patients are
typically pigmented and non-mucoid and indistinguishable from P. aeruginosa
isolated from non-CF infections. However, once P. aeruginosa becomes established
in CF airways the organism undergoes a number ofhighly characteristic phenotypic
changes associated with adaptation to the lung environment and evasion of host
immunity. The most striking change is the production of alginate resulting in a
mucoid colonial morphotype which is rarely seen in non-CF patients with the
exception of patients with COPD (Doggett et al, 1966; Hoiby, 1975; Govan &
Deretic, 1996).
Mucoid variants ofP. aeruginosa, belonging to Phillips colonial morphotype 5,
produce large amounts of the unusual non-capsular exopolysaccharide, alginate,
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which is chemically distinct from pseudomonas slime. The association ofmucoid
P. aeruginosa with CF was first made by Doggett and colleagues in the 1960's
(Doggett et al, 1964; Doggett et al, 1966; Doggett, 1969) and the exopolysaccharide
identified as alginate by Linker & Jones (1964). Alginate produced by mucoid
P. aeruginosa is a strongly anionic polysaccharide composed of acetylated
D-mannuronic acid and L-guluronic acid (Evans & Linker, 1973). Govan & Harris
(1986) have shown that mucins, released from respiratory epithelium following the
action ofpseudomonas proteases, combine with alginate, in the presence of divalent
cations, particularly Ca++, to form highly viscous gels. Gel formation enhances
microcolony formation which may result in poorer mucociliary clearance of the
organism and 'frustrated' phagocytosis leading to release of tissue damaging
neutrophil elastase. Alginate production is not restricted to the mucoid colonial
phenotype as non-mucoid revertants ofmucoid P. aeruginosa have been found to
produce alginate albeit at very much lower levels than in mucoid forms (Pier et al,
1986). Mucoid P. aeruginosa are so characteristic ofCF lung infections that their
culture from sputum is almost diagnosis of CF per se. However, mucoid variants are
also responsible for approximately 40% ofP. aeruginosa cultured from cases of
COPD and 10% from urinary tract infections (McAvoy et al, 1989). Examination of
post mortem lung material from CF patients infected with P. aeruginosa shows the
bacteria in the form of distinct fibre-enclosed microcolonies in the infected airways
(Lam et al, 1980). These authors speculated that growth ofmucoid P. aeruginosa in
microcolonies and biofilms in the CF lung plays an important role in pathogenesis by
protecting the bacteria from surrounding environmental factors such as complement
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and antibiotics. Alginate production is not exclusive to P. aeruginosa as it is also
produced by strains ofAzotobacter vinelandii (Gorin & Spencer, 1966) and other
pseudomonads including P. fluorescens, P. putida and P. mendocina (Govan et al,
1981).
In CF patients, the time interval for conversion from the classic non-mucoid to the
mucoid phenotype ofP. aeruginosa varies but may be as short as three months
(Govan, 1990). As infection becomes chronic, many CF patients harbour both
mucoid and non-mucoid strains ofP. aeruginosa concurrently; however, some CF
patients reach adulthood without becoming chronically colonised or infected with
mucoid P. aeruginosa. Long term colonisation with mucoid P. aeruginosa may
damage the lung in two ways, firstly, tissue damage due to the in situ production of
virulence factors such as elastase, exoenzyme S and exotoxin A and secondly, the
constant aggrevation of the inflammatory response leading to neutrophil
degranulation and immune-mediated damage. The alginate exopolysaccharide
produced by mucoid P. aeruginosa also associates with host mucin and DNA
forming bronchial plugs (Fig. 7.1b) which impair ciliary clearance and assist
P. aeruginosa to avoid phagocytosis and other antimicrobial agents (Govan &
Nelson, 1992).
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FIG. 7.1b Plugged bronchial airway during chronic colonisation with mucoid
P. aeruginosa (Govan, 1989).
The conversion of non-mucoid P. aeruginosa to the mucoid morphotype is
controlled by a number of bacterial genes. In non-mucoid P. aeruginosa, the protein
AlgU (product of the algU gene) which plays an important role in transcription of
alginate biosynthetic genes is repressed by Muc A and possibly MucB (products of
mucA and mucB genes, respectively). In mucoid strains, mutations that inactivate
the mucA gene relieve AlgU from inhibition which in turn activates algD, a key
132
alginate biosynthetic gene, and thus alginate production is achieved (Deretic et al,
1993; Govan & Dereetic, 1996). It is thought that P. aeruginosa mutants with
inactivated mucA are selected in the CF lung and that these alginate producers
establish a biofilm in which there is effective protection against opsonisation,
phagocytosis and antibiotic treatment.
The protective properties of alginate for P. aeruginosa include defence against the
action of complement (Pedersen et al, 1990) and damaging free radicals.
Environmental conditions which influence P. aeruginosa alginate production and
selection in vitro include nutrient limitation (Speert et al, 1990), increased osmolality
(Govan, 1990), response to stress (Deretic & Govan, 1996), selection by phage
(Govan, 1975) and antimicrobial pressure (Govan, 1976).
7.4.4 LPS deficiency
Many isolates ofP. aeruginosa from CF patients have altered LPS with loss of all or
part of the polysaccharide O-antigenic side chain (Hancock et al, 1983). This smooth
to rough transition results in only a small percentage of strains from CF patients
being serotypeable, the majority of strains being untypeable, polyagglutinable or
autoagglutinable with O antisera. LPS O-antigen deficient or rough forms are
invariably serum sensitive, i.e. killed by human serum while smooth or LPS
complete strains are serum resistant, i.e. protected against complement-mediated
killing by normal human serum. There is, however, no absolute relationship between
serum susceptibility and possession ofO-antigenic side chains. There is also no
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correlation between mucoidy and serum sensitivity, typeability, LPS phenotype or
OMP patterns ofCF isolates. The property of serum sensitivity which seems to be
associated with the LPS phenotype may explain why patients with CF rarely suffer
from bacteraemia due to P. aeruginosa (Hancock et al, 1983).
7.4.5 Serum antibody response
Antibodies are produced in response to initial colonisation with P. aeruginosa in CF
patients and an increased humoral host response in some patients is associated with
poor prognosis (Hoiby, 1993). IgA and IgG antibodies are significantly elevated in
CF compared to normal individuals but IgM is not (Schwartz, 1966). These findings
were confirmed by Turner et al (1978) although the increase in IgA and IgG was
only observed during exacerbations. Precipitating antibodies against P. aeruginosa
are commonly detected in CF patients and are always detectable when the strains are
mucoid (Burns & May, 1968). Antibodies against P. aeruginosa may prevent
septicaemia but are unable to eliminate the bacteria from the lungs ofCF patients
(Pedersen et al, 1989); paradoxically, patients with high titres of antibodies are those
who are commonly chronically colonised by this organism.
7.4.6 Antibiotics
It is often said that antibiotic treatment ofP. aeruginosa infection in CF patients
seldom if ever eradiates the organism. This is not strictly true. Treatment of non-
mucoid P. aeruginosa in the early stages can result in eradication (Govan et al, 1987)
and during the last decade two important studies have shown that aggressive early
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treatment can eradicate P. aeruginosa. However, this is usually only a temporary
phenomena as the organisms return at a later date with the interval of time for re-
colonisation varying with each patient. In most patients, it becomes increasingly
difficult to eradicate the organisms on subsequent infection and eventually a stage is
reached when the organisms remain (regardless ofwhether they are sensitive to the
antibiotic used) and the patients become chronically colonised. Littlewood and
colleagues (1985) showed that treatment, of young CF patients with nebulised
colomycin as soon as P. aeruginosa was isolated from throat swab or sputum delayed
chronic colonisation. This aggressive early treatment reduced the number of
organisms present in CF secretions and also the frequency of isolation of
P. aeruginosa. A controlled study ofDanish CF patients treated with ciprofloxacin
and colomycin and untreated patients showed that 58% of the untreated patients
became chronically colonised with P. aeruginosa while only 14% of treated patients
became chronically colonised (Valerius et al, 1991). These Danish results confirm
the findings of Littlewood and colleagues (1985) that early treatment with antibiotics
helps to prevent or delay colonisation with P. aeruginosa.
The present Danish approach is to administer intensive therapy, with a combination
of intravenous and nebulised antibiotics, at regular three month intervals regardless
ofwhether the patient has an exacerbation or not. This is claimed to increase
survival rates even after colonisation has occured (Hoiby, 1993). The Danish
strategy is not universally accepted and has problems of cost, side-effects of
antibiotics and development of resistance.
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CF patients are generally treated with two antibiotics to reduce the risk of the
emergence of resistant strains; this is usually a combination of an aminoglycoside
and a P-lactam, third generation cephalosporin or a carbapenem (Pitt, 1986;
Livermore, 1989). A particular problem in the use of antibiotics for infections in CF
patients is the difficulty of achieving an adequate therapeutic dose of antibiotic at the
target site in the congested airways. Alginate produced by the mucoid strains of
P. aeruginosa poses an additional problem as it can act as a physical and ionic barrier
preventing the antibiotic from reaching the bacteria. Most anti-pseudomonal
antibiotics are administered intravenously but a major advance in therapy was the
introduction of the first oral antibiotic, the quinolone, ciprofloxacin. Tobramycin is
generally the aminoglycoside of choice and is frequently administered in a nebulised
form, although it can be given intravenously. Recently, a large multicentred trial of
highly pure nebulised tobramycin (TOBI) has shown particular success in reducing
the normally progressive deterioration in lung function (Ramsay et al, 1999)
Ironically, 20% of isolates ofP. aeruginosa from chronically colonised CF patients
may exhibit antibiotic hypersusceptibility to P-lactams. These hypersusceptible
P. aeruginosa are morphologically indistinguishable from resistant strains and both
strains can be present in the same sputum (Irvin et al, 1981). Hypersusceptibility
results from two chromosomal mutations known as bis and tps (Fyfe and Govan,
1984). An explanation for such bacteria is that hypersusceptibility represents a state
ofhigh permeability to cope with nutrient depletion with the bacterial biofilm.
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7.4.7 Early diagnosis ofP. aeruginosa in CF patients
It has been reported that antibodies specific to P. aeruginosa can be detected in
serum prior to isolation of the organism from sputum, suggesting that only small
numbers of organisms may be necessary for initial infection (Brett et al, 1988).
Rapid detection ofP. aeruginosa may be achieved by monoclonal antibody based
immunoassay (Nelson et al, 1992) and by amplification of nucleic acid sequences
specific to the algD gene using PCR (Mcintosh et al, 1992). These techniques can
be applied directly to sputum or saliva and can detect small numbers of organisms
which may not be detected by cultural methods. However, a disadvantage of the
immunological and PCR-based methods is that there is no organism on which to
carry out other tests such as antimicrobial sensitivities or epidemiological
investigations. Another PCR technique using a species specific oligonucleotide
probe derived from the variable regions of the nucleotide sequence of 16S rRNA
from P. aeruginosa was developed (O'Callaghan et al, 1994). The probe itself is not
particularly sensitive, however, sensitivity can be increased by amplification of the
DNA using PCR followed by hybridisation of the PCR product with labelled
oligonucleotide. Results showed full concordance between culture and the PCR and
DNA hybridisation technique with a 100% sensitivity. A similar technique used by
Karpati & Jonasson (1996) involved a primer based on the 16S rRNA sequences and
confirmed the previous findings. P. aeruginosa was isolated by culture in three cases
which were undetected by PCR; in contrast, PCR was positive in five cases in which
the organism was not isolated by culture.
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7.5 EPIDEMIOLOGY
Systems which allow reproducible and discriminating typing ('fingerprinting') of
pathogens are essential tools in the epidemiology ofmicrobial infection. Typing is
particularly important in the case of ubiquitous opportunistic pathogens such as
P. aeruginosa to determine whether infection is endogenous, exogenous and to
investigate spread of an epidemic clone in an outbreak. In CF, bacterial typing has
been used to determine whether individual strains ofP. aeruginosa persist
throughout the many years of colonisation despite characteristic phenotype changes
in motility, mucoidy, LPS structure and serum susceptibility (Gilligan, 1991;
Mahenthiralingam et al, 1996; Govan & Deretic, 1996). When a CF patient becomes
reinfected with P. aeruginosa, following eradication due to antimicrobial therapy or
transient colonisation, fingerprinting can establish whether the recent infection is due
to the original strain or acquisition of a new strain.
The environmental sources from which CF patients acquire P. aeruginosa remain
unclear. Environmental aquatic habitats have been shown to be a possible source of
P. aeruginosa which subsequently colonise susceptible CF hosts (Romling et al,
1994; Leitao et al, 1996). Although, Romling et al (1994) found similarities between
strains of P. aeruginosa recovered from aquatic habitats, in several geographical
areas, and those recovered from CF patients, the aquatic sources were at least 200Km
from the CF centre. Tredgett et al (1990) found that the incidence of the most
common bacteriocin (pyocin) types namely 1, 3, 5 and 10 in non-CF isolates, which
accounted for 58-85% of strains of P. aeruginosa, differed significantly from CF
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isolates which showed a higher incidence of rare types. These findings suggested the
existence of a subpopulation ofP. aeruginosa which have a predilection for
pulmonary colonisation in CF. The properties of this subpopulation can only be
speculated. However, it is interesting to note that the strain responsible for
colonising two CF patients during a jacuzzi session was highly motile and
mucinophilic (Govan & Nelson, 1992).
With the exception of siblings, CF patients are generally not thought to acquire
P. aeruginosa by cross infection. However, evidence of small clusters ofpatients
with the same strain has been reported from the Danish Centre (Hoiby & Rosendal,
1980). Combined results of serotyping and phage typing showed 13 clusters ranging
from 2-10 patients within each cluster; each with distinct epidemiological types.
One of the problems with this study was that many of these isolates shared
polyagglutinability and rough LPS and thus would be expected to 'appear' similar by
these phenotypic typing systems. However, further studies on some of the isolates
were carried out using the genomic techniques of ribotyping and PFGE and
confirmed the earlier findings and provided evidence of epidemic spread of
P. aeruginosa amongst the Danish CF patients. In contrast, Grothues et al (1988)
showed that, in general, only CF siblings were colonised with the same or closely
related strains ofP. aeruginosa; unrelated CF patients being typically colonised with
different strains. In another study, it was shown that siblings are not always
colonised with the same strain ofP. aeruginosa. Renders et al (1997) studied six
pairs of CF siblings over a 20-126 month period using arbitrarily primed PCR. They
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found that two of the six pairs of siblings were each colonised with the same strains,
which persisted over a ten year period. However, these authors also reported that the
other pairs of siblings showed only transient cross-infection, probably from an
environmental source in the home. In the mid 1980's, evidence of potential epidemic
spread of an antibiotic-resistant strain ofP. aeruginosa within CF patients was again
observed in the Danish Centre (Pedersen et al, 1986). However, the study was based
on phage and serotyping hence the hypothesis of a single strain being responsible for
cross-infection was criticised. The incidence ofP. aeruginosa cross infection among
CF patients attending summer camps is minimal and the 'risk' considered to be trivial
compared to the social and psychological benefits of these camps (Hoogkamp-
Korstanje et al, 1995). There is no evidence of cross-infection due to P. aeruginosa
in CF patients sharing hospital rooms (Speert & Campbell, 1987) or attending CF
clinics on a regular basis (Govan & Nelson, 1992). Finally, in 1993 a working party
comprising clinicians and scientists from Europe and North America reached the
consensus that "Although cross-infection with P. aeruginosa does not seem to be a
major problem in some hospitals, cross-colonization and epidemic spread of
multidrug-resistant P. aeruginosa between CF patients has been observed in some
studies" (Bingen et al, 1993).
7.5.1 Phenotypic typing systems for P. aeruginosa
Until recently, typing ofP. aeruginosa for epidemiological purposes relied on
phenotypic systems such as serotyping, phage susceptibility and bacteriocin
production. Despite the advantages and fashionability of genomic fingerprinting
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these three classical phenotypic systems are still widely used and can play an
important role as screening techniques especially when epidemiological
investigations involve large numbers of isolates.
7.5.2 Serotyping
Serotyping is based on the identification of the heat-stable O-specific LPS antigen of
the outer membrane. Antisera to O antigens are obtained from rabbits and the O
antigen type is determined either by slide agglutination or microtitre plate (Fisher et
al, 1969; Pitt,1988). In 1983, an International Antigenic Typing System (IATS) was
developed (Liu et al, 1983), establishing the existence of at least 17 major heat-stable
somatic antigens and 3 new antigens have been recently added to the existing group
(Liu & Wang, 1990). This typing system characterises most P. aeruginosa isolates
possessing smooth LPS but shows poor discrimination against isolates with rough
LPS which are common in CF patients. The majority ofCF isolates, especially
mucoid strains, are polyagglutinating or non-typeable due to the loss ofO antigenic
moiety ofLPS (Hancock et al, 1983). Approximately 90% of isolates of
P. aeruginosa from non-CF sources are typeable by serotyping and show fairly good
discrimination.
7.5.3 Phage typing
Phage typing is based on lysis of bacteria by bacteriophage in which lytic patterns
obtained by a set of phages against the 'test' isolate provide a lytic 'fingerprint'
(Asheshov, 1974; Pitt, 1988). Approximately, 85% of clinical strains of
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P. aeruginosa can be phage typed but the reproducibility is poor and phage typing is
particularly unsuitable for CF isolates due to the loss of LPS receptors from the
bacterial surface and the gelatinous growth ofmucoid isolates.
7.5.4 Bacteriocin typing ofP. aeruginosa
Bacteriocins are antibacterial proteins that are inactive against the producing strain
but kill other strains of the same species and occasionally closely related species.
The three categories ofbacteriocin (pyocin) produced by P. aeruginosa are
designated R, F and S. R-type pyocins resemble the tails of contractile phages and
their bacterial receptor is LPS (Govan, 1974a; Govan, 1974b). F-type pyocins are
rod-shaped, flexuous and resemble the tail of non-contractile Pseudomonas phages.
S-type pyocins are of low molecular weight and are generally trypsin sensitive
although a trypsin resistant category resembling the enterobacterial microcins has
also been described (Darrell & Wahba, 1964; Govan, 1978). The nature of receptor
for both F and S-type pyocins remains unknown although the F receptor is thought to
lie within LPS. S-type pyocins diffuse readily through agar resulting in the
production of a wide zone of inhibition on solid media in contrast to R- and F-types
which produce a narrow zone of growth inhibition around the producer strain
(Govan, 1978). R and F pyocins are produced by over 90% of clinical isolates with
the S-type found in about 70% of strains (Govan, 1986). The inhibition patterns
produced by pyocins from a 'test' isolate against the eight indicator strains form the
basis of the 'cross-streak' pyocin typing technique described by Gillies and Govan
(1966). This typing method identifies 105 pyocin types which can be further
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subdivided by the use of 5 subtype indicator strains (Govan, 1978). The original
method was later revised by Fyfe et al (1984) who introduced an overlay technique
resulting in a more rapid procedure. Pyocin typing is readily applicable to isolates of
P. aeruginosa including those from CF patients; approximately 90% of all clinical
and environmental isolates are typeable by this method.
7.5.5 Genomic typing ofP. aeruginosa
Genomic typing systems applicable to P. aeruginosa include use of gene probes,
restriction fragment length polymorphism (RFLP) and PCR. Use of a DNA probe
based on the exotoxin A (ETA) gene was probably one of the first genomic typing
systems applied to P. aeruginosa. Most P. aeruginosa possess the ETA structural
gene which consists of a conserved region which is common to most strains of
P. aeruginosa and a variable region. The typing probe is a 741 base pair Pstl-Nrul
fragment from the variable region upstream of ETA. As a typing tool, the probe has
been shown to be more discriminatory than serotyping, biotyping, antibiograms and
colonial morphology; isolates indistinguishable by these systems were subdivided
using the probe and isolates found to have different antibiograms were shown to be
the same using the probe (Olgle et al, 1987). Interestingly, pyocin typing and the
ETA gene probe were used together to produce the first documented evidence for
clonal transition from the non-mucoid to the mucoid form within three months
(Govan, 1990).
143
7.5.6 Random arbitrarily primed DNA (RAPD) PCR
Random arbitrarily primed DNA PCR has been applied to numerous epidemiological
investigations ofP. aeruginosa. In the majority of cases this fingerprinting system
has been compared to PFGE with RAPD demonstrating equal discrimination (Bingen
et al, 1996; Mahenthiralingam et al, 1996). In contrast, RAPD was shown to be less
discriminating than PFGE when examining closely related isolates ofP. aeruginosa
from CF patients (Kersulyte et al, 1995). When RAPD, serotyping, phage and
pyocin typing were used to investigate the incidence of cross infection of
P. aeruginosa among CF patients attending summer camp, RAPD was found to be
more discriminating than any of the other typing techniques investigated
(Hoogkamp-Korstanje et al, 1995). The primers used for RAPD are important as
some primers show reduced resolution compared to PFGE. An advantage ofRAPD
over PFGE is that the template DNA need not be high molecular weight, double
stranded or high purity and only nanogram amounts are required.
7.5.7 Flagellin gene polymorphisms
The flagellin gene is a widely applicable and useful genetic marker for studying
genetic variation within populations of closely related bacteria. Two distinct
flagellin protein antigenic types, a and b, are found in P. aeruginosa (Allison et al,
1985). Flagellin gene sequence analysis has shown that variation is most apparent in
the central region of the flagellin protein. Oligonucleotide primers were developed,
specific to the N and C-terminals of this conserved region, and used to amplify by
PCR the central region of the flagellin protein (Winstanley et al, 1996). The
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resultant PCR product was digested using seven different restriction enzymes prior to
electrophoresis. Isolates ofP. aeruginosa were differentiated according to the RFLP
pattern produced. This technique requires relatively simple equipment, is
reproducible and rapid to perform as results are available within five to six hours.
However, flagellin gene polymorphisms have been reported to be less discriminating
than other DNA-based methods (Grundmann et al, 1994).
7.5.8 Field-inversion gel electrophoresis (FIGE)
The technique field-inversion gel electrophoresis has been applied in a number of
epidemiological studies ofP. aeruginosa (Grothues and Tummler, 1987; Tummler et
al, 1991). Grothues et al (1988) found FIGE to be more discriminating than
serotyping, phage and pyocin typing. The number ofDNA fragments observed after
electrophoresis was dependant on the restriction enzyme used with Spel producing
the fewest bands. Spel digestion makes interpretation easier; however, the cost of
this enzyme limits its use. This study also stated that strains were classified as being
clonally related even with up to a six band difference. Ojeniyi et al (1991) used a
number of typing systems, including FIGE, to fingerprint polyagglutinating strains of
P. aeruginosa from CF patients and found that the discriminating power ofFIGE
was even higher than that for the ETA probe and both systems showed poor
correlation with all the phenotypic techniques used.
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7.5.9 Pulsed-field gel electrophoresis (PFGE)
Pulsed-field gel electrophoresis has been shown to be the most discriminating
method of genomic typing for P. aeruginosa. Grundmann et al (1995) confirmed
that PFGE showed the highest discriminatory power than either the exotoxin A probe
or ribotyping. Grundmann et al also suggested that up to a four band difference in
banding patterns, using restriction enzyme SpeI, indicates that isolates are related.
7.5.10 Ribotyping
Ribotyping has been used in a number of epidemiological studies ofP. aeruginosa.
The discriminatory ability of this technique is dependant on the restriction enzyme
used with PvuW showing the highest discrimination and BamHl and EcoRl having
the lowest (Gruner et al, 1993; Bennekov et al, 1996; Nociari et al, 1996). The
profiles produced by ribotyping are composed of strong and weak bands. The weak
bands produced by Pvull, Hindlll and BamHl are reproducible in contrast to those
produced by EcoRl. Use of additional genomic typing systems suggests that a single
band difference within a ribotyping profile indicates that an isolate is a different
genotype. Bingen et al (1992) used ribotyping and esterase electrophoresis (ETT) to
investigate the relatedness ofCF isolates before and after antimicrobial therapy and
observed that a CF patient remained colonised with a single strain ofP. aeruginosa
even after several courses of antibiotics. Both systems showed a good degree of
discrimination but ETT was sightly more discriminating than ribotyping. Although
several studies have stated that ribotyping is highly discrminatory, Bingen et al
(1996) demonstrated that multiresistant strains ofP. aeruginosa serotype 0:12 were
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indistinguishable by ribotyping, in comparison to the discriminatory ability ofboth
RAPD and PFGE.
A fully automated ribotyping system has recently been developed, RiboPrinter (TM)
Microbial Characterization System (DuPont) and allows the typing of 32 isolates in 8
hours (Pfaller et al, 1996). In comparison with PFGE, this system is less sensitive in
discriminating different strains ofP. aeruginosa than when used for typing
Escherichia coli.
A number of other typing systems have been used to fingerprint P. aeruginosa; these
include plasmid profiles, multilocus enzyme electrophoresis and pyrolysis mass
spectrometry.
7.5.11 Comparison of typing systems for P. aeruginosa
In the early 1990's, a multicentre study examined 11 techniques then available for
typing strains ofP. aeruginosa. Typeability, reproducibility and discriminatory
power was determined for each of the methods. The typing systems included several
serotyping methods, phage susceptibility, bacteriocin production, pilin gene typing,
and analysis by RFLP using exotoxin A probe. The study involved typing 200
strains comprising 150 CF isolates and 50 isolates from non-CF infections,
vegetables and river water. RFLP analysis with the exotoxin A probe was
determined to be the method of choice for strains from CF patients having rough LPS
although LPS-based serotyping methods were effective for typing non-CF strains.
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RFLP analysis also showed the highest degree of discrimination, good
reproducibility and was the only technique able to type all 200 strains (Speert et al,
1994). It must be noted that PFGE was not included in this comparison of typing
systems. A key feature of this study was that each of the 200 isolates was examined
'blindly' on three occcasions.
7.6 AIMS
The overall aim of this section of the thesis is to apply PFGE to investigate, and
hopefully resolve, two important features ofP. aeruginosa epidemiology.
1. Although mucoid P. aeruginosa have long been considered to be variants arising
from colonisation by classic non-mucoid P. aeruginosa, there is surprisingly little
documented evidence of a clonal relationship based on the use of reliable genomic
typing techniques. The first aim of this section of the thesis was to apply, develop
and test the use ofPFGE to investigate isolates ofP. aeruginosa cultured during the
initial stages of colonisation and continuing longitudinally to the emergence and
chronic colonisation by mucoid P. aeruginosa.
2. In contrast to B. cepacia epidemiology, there has been little scientific evidence
that cross-infection plays a significant role in the prevalence ofP. aeruginosa
amongst CF patients, with the important exception ofCF siblings. During the early
stages of this thesis, an apparent outbreak of cross-infection in Liverpool involving a
P-lactam resistant P. aeruginosa provided an important opportunity for investigation.
The second aim of this section was to use PFGE to investigate the epidemiology of
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the Liverpool isolates in conjunction with a Liverpool-based typing study based on
flagellin gene polmorphisms.
7.7 RESULTS
7.7.1 The application of PFGE to isolates ofP. aeruginosa
Prior to the application ofPFGE for epidemiological studies ofP. aeruginosa the
discriminatory power of the technique and various procedural parameters were
investigated using a collection of clinical and environmental isolates. Initially, three
different restriction enzymes, Xbal, Dral and Sspl (AATATT), were used to digest
chromosomal DNA prior to the separation ofDNA fragments by PFGE. A portion
of the same plug, from an isolate ofP. aeruginosa, was digested by each restriction
enzyme. All three enzymes produced 25 or more DNA fragments, ranging from
< 48.5kb to 436.5kb. Restriction enzyme Sspl produced numerous low molecular
weight bands which were close together on the gel and were difficult to distinguish.
Although Dral produced the smallest number ofDNA fragments, the bands appeared
considerably fainter than those produced by Xbal. After considerable 'preliminary'
studies, Xbal was selected as the enzyme of choice for genotyping isolates of
P. aeruginosa in this thesis based on the quality of the PFGE profiles. Fig. 7.1
illustrates representative PFGE profiles and demonstrates the discriminatory power
of this technique for isolates ofP. aeruginosa.
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FIG. 7.1 Xbal digestion ofDNA from nine epidemiological^ unrelated isolates of P.
aeruginosa, from CF patients. Lanes 1 to 9, H133, C1001, C2270, C1224, C763,
C1334, C518, C1864, C907; lane 10, lambda concatemers (size range 48.5kb to 582
kb, in increments of 48.5kb)
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7.7.2 Investigation of isolates ofP. aeruginosa cultured from CF patients during
chronic infection.
This investigation involved the use of pyocin typing and PFGE to type the initial or
early isolate of P. aeruginosa and isolates obtained from the same patient at least two
years and up to 11 years later. Isolates ofP. aeruginosa were obtained from 44 CF
patients, comprising 18 paediatric and 26 adult patients. Typing results are
summarised in Table 7.1.
In only one case did the paired isolates ofP. aeruginosa fail to produce a pyocin
type. According to the pyocin typing results, only 6 (14%) of the 43 CF patients
produced identical pyocin types in both isolates ofP. aeruginosa cultured from the
same patient over a period of time. However, further comparison of the pyocin
types, produced by paired isolates, revealed that in four cases the only difference was
variation in the activity of s-pyocins which are of low molecular weight and produce
large zones of inhibitory activity. The evidence from this study suggests that
production of s-type pyocins is unstable as most paired isolates failed to show the
same pattern of's' activity. If's' activity is ignored a further four paired isolates have
the same pyocin type.
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TABLE 7.1. Bacteriocin typing and PFGE results from paired isolates of
P. aeruginosa from 44 CF patients.
Patient Bacteriocin type Time interval (yrs) PFGE
1st isolate 2nd isolate
AA 10/b (s-3,7) 10/c (s-6,d) 3 same
FB u/c/a (s-2,a,b) 9/u/c (s-a,b) 3 different
VD 9/u/c 9/j 8 ut
SD 9/j (s-5) 9/u/c (s-7) 10 ut
VE 3/g (s-5) 3/g (s-5) 2 same
EG 3/g (s-2) 35/c (s-7) 3 different
CG 3/c 3/g 5 same
MG 3/g 5/u/c 3 different
SG 5/f (s-5) 44/f 4 different
RG 19/u (s-7) u/c/h (s-7,b) 6 same
JH 9/f (s-7) 9/f (s-5) 7 same
CJ 29/x 3/a (s-d) 2 different
LL 3/s 3/c 4 same
CL 3/a 3/a (s-a,b,d) 4 same
SL 3/a 3/n 4 same
RM 1/c 1/c 3 same
FM 35/e 45/e (s-b) 9 same
JW 105/h (s-3,7) 5/u/c 3 different
DB 33/c (s-3,7) 101/c 7 different
TB 92/r (s-5) 5/v 2 same
LB 31/v (s-7) ut 9 different
FC u/c/v ut 4 same
SD 10/a (s-7) 10/a (s-5,a) 5 same
MD 10/d 10/d 9 same
CF 5/u (s-5) 5/u (s-5) 5 same
BF 1/d (s-7) 1/w (s-b) 4 different
Gl 60/v 60/f (s-7) 6 same
SJ u/c/f 6/v (s-5) 11 different
AK 31/v (s-7) 29/e 11 same
DK u/c ut/v 2 same
JMcE 6/v (s-3,4,5) 5/x 7 different
JM 10/a (s-5,a,b,e) u/c/r (s-7) 11 different
BM 3/n 3/n 4 same
NM 10/h 3/b 8 different
JMn 3/e 3/n 10 same
DN ut ut 6 same
DO'N 1/a (s-b) 10/a 4 different
CO 10/a (s-3,7) u/c/x (s-7) 10 different
VS 6/c 1/x 4 same
PS 49/k 50/k 8 same
AS 10/c (s-7,e) 10/c 6 same
RT 1/p 45/b (s-5) 8 different
AW A3/a 37a 4 same
FW 50/v u/c/v 4 same
u/c unclassifiable type; ut untypable
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Pyocin typing results can sometimes prove difficult to read especially when strains
produce faint zones of inhibition. When two isolates only differ by the inhibition
pattern of a single indicator they are generally classified as the same strain.
Consequently, a further 8 patients would be regarded as having the same strain of
P. aeruginosa in the two isolates. In conclusion, 18 (42%) of the 43 CF patients
could be regarded as harbouring the same strain ofP. aeruginosa after at least two
years colonisation.
Surprisingly, two isolates were untypeable by PFGE, producing only a smear in the
lane of the agarose gel. The same result was obtained on repeated investigation
involving digestion with other restriction enzymes using a different procedure for
DNA extraction. Failure to obtain a 'PFGE result' is unusual as very few isolates are
untypeable by PFGE. Interestingly, both isolates were recovered from CF siblings
and although they failed to produce a PFGE profile the isolates produced pyocin type
patterns differing by a single sub-type indicator and's' activity, suggesting that they
are the same strain ofP. aeruginosa.
Comparison of the PFGE profiles produced by the paired isolates from the other 42
CF patients revealed that 26 (59%) of the patients harboured the same strain of
P. aeruginosa for considerable periods of time, in some cases for 11 years. Isolates
ofP. aeruginosa from the remaining 16 patients were found to be different by PFGE,
suggesting that re-infection with a different strain had occured.
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When the data from pyocin typing and PFGE were compared; paired isolates of
P. aeruginosa from 26 patients were shown to have the same strain by PFGE
whereas only 18 patients were found to have the same strain by pyocin typing.
However, the paired isolates ofP. aeruginosa from the 16 patients which were
shown to have different PFGE profiles also produced different pyocin types with the
exception of one patient, D O'N. The pyocin types ofboth isolates from D O'N only
differed by inhibition of a single indicator strain suggesting that both isolates belong
to the same strain.
7.7.3 Are mucoid isolates a variant of the non-mucoid form?
Despite a surprisingly lack of scientific evidence, it has long been assumed that
mucoid colonial morphotypes ofP. aeruginosa isolated from CF patients are derived
from the original classic non-mucoid form, responsible for initial colonisation. In
this study, the initial non-mucoid isolate ofP. aeruginosa, recovered from sputum
culture, was compared to the first isolate of the mucoid phenotype in 12 CF patients.
Results of fingerprinting by PFGE showed that in six patients the mucoid and non-
mucoid forms produced identical PFGE profiles suggesting that they were the same
strain ofP. aeruginosa. However, isolates from the remaining six patients produced
different PFGE profiles. In the interpretation of these results it is important to bear in
mind that the time for conversion from the non-mucoid to the mucoid form varied
from patient-to-patient with a range varying from 3 months to 10 years (Table 7.2).
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TABLE 7.2. Time taken for conversion from the non-mucoid to the mucoid
phenotype in isolates ofP. aeruginosa and PFGE relationship between the isolates.
Patient Conversion time PFGE profile
FC 3 mths same
wc 6 mths same
TG 7 mths different
JH 9 mths same
CJ 2 yrs same
PO 2 yrs different
AG 3 yrs different
DB 4 yrs same
Gl 4 yrs same
JM 4 yrs different
NM 8 yrs different
CO 10 yrs different
In general, the shorter the period of time for conversion from the non-mucoid to the
mucoid phenotype the more likely the strains were to be the same. However, in one
CF patient, only seven months elapsed prior to the emergence of the mucoid form of
P. aeruginosa and these isolates were found to be clonally unrelated by PFGE. In
two other patients, both phenotypes were found to be identical despite a time interval
of four years between first culture ofnon-mucoid P. aeruginosa and conversion to
the mucoid form. As might be expected, in the two CF patients where conversion
occured at eight and 10 years the non-mucoid and mucoid phenotypes were found to
be different.
A further four CF patients were investigated where non-mucoid and mucoid forms of
P. aeruginosa were isolated from sputum culture simultaneously; in all cases, both
colonial morphotypes produced identical PFGE profiles. An interesting case
involved a non-mucoid isolate ofP. aeruginosa (CI 3 85) which was cultured from a
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CF patient who apparently became colonised after using a jacuzzi which contained
the colonising strain. Within three months the patient was found to harbour a mucoid
form (CI532) which when typed by PFGE showed only a two-band difference from
the original non-mucoid isolate (Fig. 7.2).
To test the reliability ofPFGE further, it was decided to make use of the large
collection of isogenic derivatives of the P. aeruginosa genetic type strain PAOl held
in the strain repository of the Edinburgh CF Microbiology Laboratory. The isolates
investigated (Table 7.3) comprised the wild-type parent strain PAOl and a selection
of variants chosen to include auxotrophy, antibiotic resistance, the presence of the
conjugative plasmid FP2 and a series ofmuc mutations known to be responsible for
the mucoid phenotype. These include mucoid mutants ofP. aeruginosa isolated in
vitro and mucoid isolates from CF patients (Fyfe and Govan, 1980; Deretic et al,
1993; Govan and Deretic, 1996; Boucher et al, 1997). PAO 568, PAO 578, PAO 579
and PAO 581 represent the major independent muc loci which act as master switches
for alginate regulation; they also cover the range ofnutritional and environmentally
responsive phenotypes observed in mucoid P. aeruginosa cultured from CF patients
(Govan et al, 1983; Govan and Deretic, 1996). PAO 552 and PAO 553 represent two
classes ofmutation found in non-mucoid revertants following loss of the mucoid
phenotype. In view of the aims of this thesis, it was interesting (and reassuring) to
observe that despite the multiple genetic and phenotypic differences in these PAO
isolates, all of the strains produced the same PFGE profile (Fig. 7.3)
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FIG. 7.2. Xbal digestion ofDNA from isolates of non-mucoid (NM) and mucoid
(Muc) P. aeruginosa from 5 different CF patients. Lanes 1 to 10, patient A (CI367
NM, C1387 Muc), patient B (C1158 NM, C1390 Muc), patient C (C748 NM, C904
Muc), patient D (C742 NM, CI 377 Muc), patient E (J1385 NM, J1532 Muc).
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TABLE 7.3. Type strain PA01 and a selection of derivatives











leu-38, strep-2, FP2, muc-2
leu-38, strep-2, FP2, muc-22
leu-38, strep-2, FP2, muc-23
leu-38, strep-2, FP2, muc-23
Holloway (1969)
Stanisich & Holloway (1969)
Fyfe & Govan (1980)
Deretic et al (1993)
Fyfe & Govan (1980)
Fyfe & Govan (1980)
Fyfe & Govan (1980)
Non-mucoid revertant ofPAO 579
retaining original muc-23
Non-mucoid revertant ofPAO 579





leu, leucine requirement; chl, resistance to chloramphenicol; strep, resistance to
streptomycin; FP2, contasins conjugative plasmid FP2; muc, mutation in alginate
regulation.
158
FIG. 7.3. Xbal digestion ofDNA from P. aeruginosa PAOl and its derivatives.
Lanes 1 to 8, PAOl, PA0568, PA0578, PA0581, PA0579, PA0552, PA0553,
PA0381.
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7.7.4 Evidence of transmission ofP. aeruginosa among CF patients.
As part of a multicentred antibiotic trial of cefpirome, a large number of isolates of
P. aeruginosa were received from Liverpool CF patients. In total, 246 isolates were
obtained from 72 CF patients. Sensitivity testing of these isolates showed that a
large proportion were resistant to cefpirome and to other P-lactams, including
ceftazidime. To investigate the relatedness of the Liverpool isolates, pyocin typing
was used as a primary screen. A large proportion of the P-lactam isolates produced a
pyocin type 45/e pattern and this clonal relationship was confirmed by PFGE.
Isolates which produced pyocin types other than type 45/e were regarded as being
different strains but any isolate which produced doubtful results or pyocin types
similar to 45/e was examined by PFGE.
PFGE showed that isolates ofP. aeruginosa from 53 of the Liverpool patients
produced identical PFGE profiles. This unexpected result suggested that they were
the same strain and providing the first compelling scientific evidence for cross-
infection ofP. aeruginosa in CF patients based on DNA fingerprinting. Isolates
from a further eight patients produced up to a three band difference in their PFGE
profiles and based on the criteria suggested by Tenover et al (1995), were regarded as
being clonally related. The overall typing data indicated that 61 of the 72 Liverpool
CF patients were colonised with the same strain of P. aeruginosa. Figure 7.4 shows
the PFGE profiles of six isolates ofP. aeruginosa recovered from CF patients in
Liverpool including similar profiles produced by three P-lactam resistant isolates and
three other profiles from Liverpool patients not harbouring the 'epidemic' strain. FIG.
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FIG. 7.4. SpeI digestion ofDNA from six isolates ofP. aeruginosa from different
CF patients in Liverpool. Lanes 1 to 3, transmissible strain; lanes 4 to 6, different
strains ofP. aeruginosa; lane 7, lambda concatemers (size range 48.5kb to 582kb, in
increments of 48.5kb).
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Since this outbreak was to have important implications for the future management of
P. aeruginosa infection in CF patients it was reassuring to note that a parallel
investigation by the Liverpool team using flagellin gene polymorphisms produced
concordant results (Cheng et al, 1996).
Rather disturbingly, following the Liverpool outbreak isolates of P. aeruginosa
showing identical or similar PFGE profiles to that of the Liverpool strain have been
observed in CF patients attending CF centres in Manchester, Nottingham and
Edinburgh. There is also epidemiological evidence of transmission of this strain
between two patients in Manchester, one of whom had previously attended the CF
clinic in Liverpool (personal communication, Dr T. Stanbridge). Interestingly, there
is also evidence that the Edinburgh patient has harboured this P. aeruginosa in her
sputum for eight years with no evidence of transmission to any other CF patient. A
distinguishing feature of this strain is its ability to grow on the commercially
available B. cepacia medium.
162
7.8 DISCUSSION
In this study, investigation ofP. aeruginosa cultured longitudinally from the same
CF patient, and extending from initial through to chronic colonisation, showed some
discrepancies between the results ofpyocin typing and PFGE. Results of pyocin
typing could be interpreted to suggest that this technique can distinguish between
paired isolates which were found to be clonally-related by PFGE. However, a more
likely explanation is that the differences in pyocin typing patterns between the paired
isolates reflect lack of reproducibility of this simple phenotypic technique either in
the sensitivity of the indicator strains or loss ofpyocin production; this particular
instability applies to s-type pyocins. Phenotypic changes in P. aeruginosa during
chronic colonisation or by storage at - 70°C has been shown to be responsible for
loss ofpyocin production (Romling et al, 1994). In this study, the initial isolates of
P. aeruginosa were stored at -70°C prior to fingerprinting whereas the later isolates
were generally typed following sub-culture of fresh sputum isolates.
Examination ofpaired isolates ofP. aeruginosa from the same CF patient indicates
that the majority ofpatients (59%) harboured the same strain for extended periods.
However, in some patients the original strain appeared to have been replaced. Other
investigators, have reported that most CF patients are colonised with a predominant
strain ofP. aeruginosa, although some patients may harbour more than one strain
(Romling et al, 1994; Godard et al, 1993; Loutit & Tompkins, 1991). However,
most of these studies involved small numbers ofCF patients. Similar results to the
ones observed in this study were found by Speert and collegues (1989) in a study of
163
23 CF patients over a seven year period. Thirteen of the patients were colonised with
the same strain ofP. aeruginosa while the remaining 10 patients were colonised with
at least two different strains off. aeruginosa.
A possible explanation for the results obtained in this thesis, and those reported by
Speert et al (1989) could be the presence ofmixed infection with different
P. aeruginosa strains being fingerprinted on each occasion. Alternatively, it could be
argued that it would be realistic to expect differences in paired isolates when the
time interval was extensive, for example in some instances, extending to ten-years.
In each of the two sets of siblings SD, VD and FM, JMn the strain of P. aeruginosa
was found to be the same either by pyocin typing in the case of SD and VD or by
PFGE in siblings FM and JMn. The isolates recovered from SD and VD were
untypeable by PFGE, which is probably due to the high content of endogenous
nuclease present, indicated by the presence of a smear in the lane of the PFGE gel.
Although it is unusual for microorganisms to be untypeable by genomic methods,
similar findings have been reported (Romling et al, 1994) and have also been
observed in a small number of isolates ofB. cepacia (personal observation).
Genomic fingerprinting by PFGE also suggested that non-mucoid and mucoid
isolates of P. aeruginosa, from the same CF patient were not always clonally-related.
In the four patients, where mucoid and non-mucoid variants were present on the first
P. aeruginosa culture the PFGE profiles were identical. This provides additional
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evidence to confirm the long-standing speculation that the mucoid phenotype is a
variant of the non-mucoid form. Similar findings have been observed when mucoid
and non-mucoid isolates ofP. aeruginosa, from the same specimen, have been
fingerprinted by serotyping and pyocin typing (Bergen & Hoiby, 1975) and by PFGE
and FIGE (Romling et al, 1994).
The fact that fingerprinting by pyocin typing and PFGE showed non-mucoid and
mucoid isolates to be different in half the patients could be explained by subsequent
colonisation by a second P. aeruginosa prior to conversion to the mucoid phenotype.
The time interval prior to conversion from non-mucoid to the mucoid phenotype is
highly variable. In patient TG, only seven months elapsed between the appearance of
the first non-mucoid isolate ofP. aeruginosa and the emergence of the mucoid
variant. Conversely, two patients DB and GI were colonised with non-mucoid
P. aeruginosa for four years prior to the emergence of the mucoid phenoytpe and
both colonial morphotypes demonstrated identical PFGE profiles.
In contrast to the widely accepted transmissibility of B. cepacia amongst CF patients,
the issue of transmission ofP. aeruginosa has until recently remained highly
controversial. Several prospective studies have found no evidence of cross-infection
either in CF centres or during summer camps. Furthermore, in 1993, a consensus
report drawn up following a workshop on the epidemiology of CF pulmonary
infection contained the statements: "At present, there are more studies suggesting
person-to-person transmission ofB. cepacia than ofP. aeruginosa" and "cross-
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infection with P. aeruginosa does not seem to be a problem" (Bingen et al, 1993).
Thus with the important exception of CF siblings it might be reasonable to conclude
that P. aeruginosa cross-infection does not present a major problem in the
management of CF patients (Grothues et al, 1988). However, generalisations are
always dangerous in CF microbiology and small clusters of patients apparently
harbouring the same strain ofP. aeruginosa have been reported in Denmark (Hoiby
& Rosendal, 1980; Pedersen et al, 1986). It must be noted, however, that these
findings were based on the phenotypic systems of serotyping and bacteriophage
typing, which as previously discussed are particularly inappropriate for typing CF
isolates ofP. aeruginosa.
The evidence for P. aeruginosa cross-infection in CF patients in Liverpool is
compelling both in the large number ofpatients involved, and in the concordance
observed with the two genomic but distinct typing systems, namely PFGE and
flagellin gene polymorphisms. Unfortunately, the identification of the origins and
modes of spread of this epidemic strain were hindered by the retrospective nature of
the investigation and remain unclear. Interestingly, many patients had previously
received monotherapy with ceftazidime which was thought to be responsible for the
emergence of P-lactam resistance. If tme, this explanation demonstrates the
importance of the recommendation of the use of at least two antibiotics for therapy to
minimise the risk of emergence of resistant strains (Livermore, 1989; Pitt, 1986).
However, the mere development of resistance following monotherapy does not
explain the spread of a single strain ofP. aeruginosa amongst the Liverpool patients.
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Had monotherapy been the major reason for (3-lactam resistance, then the typing
results should have indicated a large number of individual strains within the
Liverpool isolates. An intriguing and worrying posibility is that the 'Liverpool' strain
resembles an unusual highly transmissible lineage ofP. aeruginosa resembling the
highly transmissible and notorious lineage ofB. cepacia referred to as ET12. Further
studies on the 'Liverpool' P. aeruginosa might prove fruitful. One possibility is that
this interesting and clinically-relevant P. aeruginosa be put forward as a candidate





8.1 TAXONOMY AND NOMENCLATURE
Burkholderia cepacia (synonyms Pseudomonas cepacia, Pseudomonas multivorans,
Pseudomonas kingii, and eugonic-oxidizer group I) was first recognised as a
phytopathogen, causing soft rot of onion bulbs (Burkholder, 1950). In 1960, a
taxonomic study of aerobic pseudomonads revealed a distinctive cluster of isolates
within the Pseudomonas rRNA homology group III which were capable of utilising a
wide range of organic compounds. The name P. multivorans was designated to this
group of isolates (Stanier et al, 1966). Subsequently, it was realised that similar
isolates, causing soft rot in onions, had already been described and the designation P.
cepacia (Latin: cepa = onion) was given precedence (Palleroni & Holmes, 1981).
On the basis of cellular lipid and fatty acid composition, 16S rRNA sequences,
DNA-DNA homology values and phenotypic characteristics,Yabuuchi et al (1992)
proposed that P. cepacia and six other members of the rRNA homology group II
(Pseudomonas mallei, Pseudomonas pseudomallei, Pseudomonas caryophylli,
Pseudomonas gladioli, Pseudomonas pickettii, Pseudomonas solanacearum) be
transferred to the new genus Burkholderia with B. cepacia as the type-species. This
proposal was subsequently validated in 1993 (List No. 45). Two species, B. pickettii
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and B. solanacearum have since been transferred to the genus Ralstonia (Yabuuchi et
al, 1995). Further possible changes to the genus Burkholderia are currently under
investigation.
B. cepacia isolates presumptively identified by conventional techniques have
recently been further divided by polyphasic taxonomy, comprising DNA-DNA
hybridisation and whole cell protein analysis, into five genotypic subgroups refered
to as genomovars I -V (Vandamme, 1995). All five genomovars form a group of
closely related organisms known as the B. cepacia complex. The term genomovar
was introduced to denote phenotypically similar but genotypically different groups of
bacteria; according to taxonomic conventions, new species names cannot be given to
bacteria that cannot be identified by phenotypic characteristics (Ursing et al, 1995).
Genomovar V has been designated B. vietnamiensis, based on its nitrogen-fixing
properties.
There is also sufficient biochemical information to propose a species name for
genomovar II isolates; namely B. multivorans (sp. nov. mul. ti' io.rans L. ajd. multus,
much; L. part. ajd. vorans, devouring, digesting; M. L. part ajd. multivorans,
digesting many compounds). B. multivorans has been cultured from sputum samples
from CF patients but can also cause infection in non-CF patients; the organism is
also present in the hospital environment and in soil (Vandamme et al, 1997).
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Genomovar III has been divided into two subgroups or biovars with a third biovar
consisting ofnon-saccharolytic strains. Although isolates from CF patients can be
found in each of the genomovar groups, a high proportion belong to genomovar III
and this includes most strains associated with epidemics and those responsible for
'cepacia syndrome'. Until recently, no environmental isolates ofB. cepacia had been
found in genomovar III. However, a striking piece of new taxonomic evidence
indicates that a major group of soil isolates thought to represent a new species of
Burkholderia are in fact in the genomovar III group within the B. cepacia complex.
This observation provides the first compelling scientific evidence of the close
relationship between soil isolates of the Burkholderia complex and genomovar III,
arguably the most virulent and transmissible members of the complex (personal
communication, P. Vandamme).
8.2 GENERAL CHARACTERISTICS
For the purpose of this thesis, and unless stated otherwise, the term B. cepacia will be
used to represent all five members of the B. cepacia complex including
B. multivorans and B. vietnamiensis. B. cepacia is non-sporing, strict aerobic Gram-
negative bacillus and is motile with a tuft of polar flagella. Most strains are catalase
and oxidase positive and produce various non-fluorescent, diffusible pigments.
Pigmentation ranges from greyish white or yellow to reddish purple or brown and is
often dependent on the carbon source. The transcontinental 'epidemic' strain of
B. cepacia is sometimes refered to as the ET12 lineage, and belongs to genomovar
III, produces a characteristic dry, rough colonial appearance and a dark-brown
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melanin-like pigment; this pigment is rarely found in other strains ofB. cepacia.
Production of this pigment is enhanced with the use of a tyrosine-containing
medium, including Furunculosis agar (Ogunnariwo & Hamilton-Miller, 1975). The
optimum temperature for growth ofB. cepacia is 30° - 35°C although some strains
can grow at 42°C; none grow at 4°C although they can survive at this temperature.
Characteristically, B. cepacia only survive for 3 - 5 days on nutrient agar although
they survive longer on minimal media or on charcoal slopes or plates.
In general, B. cepacia are relatively uniform in the following biochemical
characteristics; gelatin liquifaction, hydrolysis of o-nitrophenyl (3-D-
galactopyranoside and aesculin, nitrate reduction to nitrite, lysine decarboxylase,
production ofpoly-(3-hydroxybutyrate and arginine dihydrolase is not produced.
Additional biochemical characteristics, frequently present in isolates ofB. cepacia
from CF patients, include production of ornithine decarboxylase, C14 lipase,
alginase, trypsin, hydrolysis of urea and xanthine (Govan & Deretic, 1996).
Interestingly, the 'epidemic' ET12 strain ofB. cepacia does not produce C14 lipase
(Govan et al, 1993).
A small proportion of isolates ofB. cepacia, from CF patients, are non-saccharolytic
and such organisms may be misidentified as Alcaligenes or Comomonas.
Saccharolytic and non-saccharolytic strains may possess the same ribotype (Pitt et al,
1996).
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B. cepacia is an incredibly versatile organism, capable of utilising a wide range of
nutrients for growth; these range from simple salts such as ammonium acetate (Geftic
et al, 1979) to complex organic compounds such as 2,4,5-trichlorophenoxyacetic
acid, the principal herbicide in 'agent orange' (Kilbane et al, 1983). Aromatic and
polyhalogen compounds can be catabolised by B. cepacia and poly-P-
hyroxyalkanoates accumulated as reserve materials. B. cepacia is intrinsically
resistant to antimicrobial agents, including potent anti-pseudomonal antibiotics
(Gilardi, 1971) and can even utilise penicillin G as the sole carbon, nitrogen and
energy source (Beckmen & Lessie, 1979). B. cepacia can survive in distilled water,
saline and disinfectants for many years (Holmes, 1986; author, unpublished results).
Without the use of selective medium, B. cepacia may be difficult to culture from
human respiratory secretions, particularly in CF patients colonised with
P. aeruginosa. Several media have been developed (Gilligan et al, 1985; Welch et
al, 1987; Henry et al, 1997): including a commercially produced B. cepacia selective
medium (Mast Diagnostics). Selective agents are generally antibiotics; such as
ticarcillin and polymyxin in Mast B. cepacia medium. Unfortunately, other
organisms such as Alcaligenes xylosoxidans, Comomonas acidovorans, and some
strains ofP. aeruginosa may also grow on the Mast selective medium. It is therefore
important that presumptive identification ofB. cepacia be confirmed by the use of
multitest identification systems such as API 20NE. If large numbers of isolates are
to be investigated these can be screened for characteristic biochemical reactions on
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arginine-glucose medium (Govan, 1989) to avoid excessive use of the expensive
commercial kits such as API 20NE.
In some cases, identification of isolates ofB. cepacia can prove difficult, even with
the use of commercially available identification kits, and it has been speculated that
as many as 10 - 20% ofB. cepacia isolates fall into this category. Mis-identification
of an isolate of S. maltophilia as B. cepacia has been reported (Burdge et al, 1995).
Such a mistake may have serious consequences in CF patients. A policy of
segregation ofCF patients following the initial isolation ofB. cepacia from sputum
culture is generally undertaken to prevent the spread ofB. cepacia to non-colonised
patients. If an isolate is wrongly identified as B. cepacia the patient will probably be
exposed to B. cepacia colonised patients and is likely to acquire a genuine strain of
B. cepacia.
B. cepacia is often described as ubiquitous, the natural habitats being soil, water and
vegetation, in particular the plant rhizosphere. Interestingly, B. cepacia can be
surprisingly difficult to culture from environmental samples. In a study, involving
the use of selective media and 619 samples from environmental sources from homes,
soil, water, sink drains, vegetables, food store counters and salad bars B. cepacia was
cultured from only 4.5% of the samples, and these were confined to salad bars
(Fisher et al, 1993). Another study involved 55 environmental samples from soil,
pond water and vegetation from tropical and temperate greenhouses; despite the use
of enrichment and selective media only 12 (17%) isolates ofB. cepacia were cultured
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(Butler et al, 1995). These findings indicate that B. cepacia is not readily isolated
from all environmental sources and is not as ubiquitous as other pseudomonads.
8.3 BIOLOGICAL CONTROL AGENT
Because ofnutritional adaptability and its ability to antagonise and suppress soil-
borne plant pathogens, there has been growing interest in the use ofB. cepacia as a
biological control agent and bioremediation agent for herbicide-contaminated soils
(Homma et al, 1989; Hebbar et al, 1992; Folson et al, 1990). In their natural habitat,
B. cepacia probably play a useful role in the control ofphytopathogenic fungi
resulting in enhanced crop yields. Antifungal products produced by B. cepacia
include pyrrolnitrin and related phenylpyrroles (Bevivino et al, 1994). At present,
there is great concern that bulk spraying ofB. cepacia into the environment as a
biological control agent may present a serious human hazard for agricultural workers
and for immunocompromised individuals, in particular CF patients. Several studies
have investigated the properties of clinical and environmental isolates ofB. cepacia
and claimed that the two groups are distinguishable. However, both clinical and
environmental isolates have the ability to macerate onions (Butler et al, 1995). A
report of macerated hyperkeratotic foot lesions or 'foot rot' amongst troops training in
swamps in northern Florida demonstrates that an environmental isolate ofB. cepacia
has the ability to cause infection in humans (Taplin et al, 1971). A key issue in
B. cepacia epidemiology and the controversial debate on the human risk of
Burkholderia biopesticides has been the origins of the genomovar III isolates and the
link between environmental and clinical isolates of the B. cepacia complex. As
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already mentioned, there is now evidence of environmental and clinical isolates of
B. cepacia belonging to the genomovar III group. Many of these issues were
addressed at a specially convened meeting of the United States Environmental
Protection Agency (US EPA) on July 20th 1999 (www.epa.gov/pesticides).
8.4 PATHOGENICITY
B. cepacia is virtually non-pathogenic in healthy individuals, however in recent
years, pneumonia and septicaemia caused by B. cepacia have resulted in fatalities in
otherwise healthy individuals (Pujol et al, 1992). Generally, B. cepacia tends to
colonise patients rather than infect them although fatalies can occur, particularly in
severely compromised patients.
Prior to the 1980's, infections caused by B. cepacia were primarily restricted to
hospitalised patients exposed to contaminated disinfectants and anaesthetic solutions
and included infections of soft tissue, respiratory, urinary tract and bacteraemia
ocassionally associated with endocarditis and septic shock (Phillips & Eijken, 1971;
Cabrera & Drake, 1975). Immuno-deficient patients may succumb to B. cepacia
infections which include endocarditis (particularly in intravenous drug users),
peritonitis, meningitis, pneumonia, bacteraemia and infections of the urinary tract,
surgical and burn wounds (Goldman & Klinger, 1986). B. cepacia can cause serious
problems following contamination ofhealthcare products such as medical devices
and solutions used in medical practice (Craven et al, 1981; Gilardi, 1983). Use of
B. cepacia contaminated ear drops were also thought to lead to multiple brain
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abscesses secondary to suppurative otitis media in an offshore oil worker (Hobson et
al, 1995).
The first evidence of transmission ofB. cepacia from CF patients to a non-CF patient
was demonstrated in a previously healthy mother who acquired the 'epidemic' strain
from her two CF children who were colonised with the strain. The mother became
chronically colonised resulting in bronchiectasis (Ledson et al, 1998a).
Nebuliser devices are possible sources of infection in non-CF patients (Takigawa et
al, 1993). Nebulised albuterol therapy was responsible for an outbreak ofB. cepacia,
involving 42 patients, in an intensive care unit; in the same unit, a medication
preservative, benzalkonium chloride, was also found to be contaminated with
B. cepacia (Hamill et al, 1995). B. cepacia is also an important pathogen in patients
with chronic granulomatous disease (CGD); causing pneumonia, bacteraemia, skin
abscesses, cervical adenitis, and disseminated fatal infection (Sanford, 1995; O'Neil
et al, 1986; Lacy et al, 1993). B. gladioli can also be a cause of pneumonia, in these
patients, and it is important to distinguish this organism from B. cepacia. This may
prove difficult especially as many of the commercially available identification kits do
not differentiate between the two organisms. The role ofB. cepacia in CF infections
will be discussed later in this chapter.
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8.5 VIRULENCE FACTORS
In contrast to the extensive armoury exhibited by P. aeruginosa, B. cepacia appears
to produce few known virulence factors. Studies on putative virulence determinants
produced by clinical isolates ofB. cepacia suggest that production may be strain
dependant. Several studies have shown that the majority of isolates ofB. cepacia
from CF patients demonstrate production of protease, gelatinase and lipase but no
production of elastase or haemolysin (McKevitt & Woods, 1984; Nakazawa et al,
1987; Gilligan, 1991; Gessner & Mortensen, 1990). In contrast, Govan & Deretic
(1996) indicate that many CF isolates do not produce lipase or protease activity.
Unlike P. aeruginosa, isolates ofB. cepacia produce phosopholipase C and a
relatively few produce extracellular haemolysins (McKevitt & Woods, 1984;
Nakazawa et al, 1987) which may be heat-labile or heat-stable (Abe & Nakazawa,
1994). In contrast Vasil et al (1990), demonstrated that 40% of strains showed
haemolysis with at least one form of erythrocyte when tested against a panel of
erythrocytes from various species. This suggests that the detection ofhaemolysins is
dependant upon the source of erythrocytes used. All haemolytic strains produce
lecithinase activity but the converse is not the case (Nakazawa et al, 1987). The
'epidemic' or ET12 lineage of B. cepacia, J2315, produces a haemolysin, when
grown in a glucose rich medium with rapid aeration, capable of lysing horse and
human erythrocytes (Hutchison et al, 1998). Isolates ofB. cepacia from plants and
rhizospheres were found to have greater biochemical activity than clinical isolates
(Gonzalez & Vidaver, 1979) although Bevivino et al (1994) found isolates from
rhizospheres to be defective in proteases.
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Other extracellular products considered as virulence factors, which may enhance the
pathogenic potential ofB. cepacia, are siderophores such as pyochelin (Sokol, 1986),
its biosynthetic precursor salicylic acid or azurechelin (Visca et al, 1993), cyclic
hydroxamic acid, cepabactin (Meyer et al, 1989) and tetrapeptide derivatives,
ornibactins (Stephan et al, 1993). Pyochelin production has been associated with
morbidity and mortality in CF patients colonised with B. cepacia.
The fact that not all strains ofB. cepacia produce recognised virulence determinants
and that studies on purified lipase indicate that this enzyme is not cytotoxic to HeLa
cells nor is it toxic when injected into mice (Lonon et al, 1988) suggests that these
extracellular factors do not play an important role in B. cepacia infection. However,
protease purified from a clinical isolate, instilled into a rat lung, resulted in
bronchopneumonia (McKevitt et al, 1989). This pathogenicity in the animal model
was confirmed when transgenic CF mice were exposed to B. cepacia-, 70% of the CF
mice succumbed to a more severe broncho-pulmonary infection than the control mice
(Davidson et al, 1995).
Approximately 60% ofB. cepacia isolates express peritrichous fimbriae or pili while
others possess polar fimbriae or are non-fimbriate. Outer membrane protein (OMP)
preparations from fimbriated strains ofB. cepacia demonstrate the presence of three
proteins which are not found in non-fimbriated strains. Some OMPs and fimbriae, in
particular a 22 kDa protein, present only in peritrichous fimbriae, mediate adhesion
to various surfaces such as buccal, tracheal, urinary epithelial cells, pneumocytes and
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mucin (Sajjan & Forstner, 1993). Isolates ofB. cepacia from CF patients have
demonstrated binding to both CF and non-CF respiratory mucin as well as buccal
epithelial cells but this binding ability is considerably less than with P. aeruginosa.
However, another study has reported a low incidence of B. cepacia binding (Butler et
al, 1992). The conflicting reports may be explained by the strains ofB. cepacia
used. Butler et al (1992) used strains from different geographical locations, which
had been phenotyped and genotyped to verify their clonal independence. In contrast,
Sajjan et al (1992) used isolates from a single clinic which may have been clonally
related. Isolates with the highest binding values tended to correlate with patients
with severe illness; the 'epidemic' strain demonstrated binding six-fold greater than
any of the other strains tested (Butler et al, 1992). This difference in binding ability
may explain why some strains ofB. cepacia are only transient colonisers while
others persist.
Respiratory mucin in CF patients is highly sulphated which protects the mucin from
bacterial degradation unless the bacteria have mucin-sulphatase activity (Tsai et al,
1991). A recent study by Jansen et al (1999) demonstrated for the first time that
B. cepacia and P. aeruginosa can desulphate mucin, although, it is likely that
adhesion to the mucin molecules is a prerequisite for desulphation. Mucin-
sulphatase activity was shown to be associated with whole cells ofB. cepacia and
P. aeruginosa, both in clinical and environmental isolates and there was no
difference between 'epidemic' and non-epidemic strains ofB. cepacia. However, the
levels ofmucin-sulphatase may vary considerably between isolates.
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Adhesion to respiratory mucin is thought to be associated with intertwined fibres
refered to as cable pili (Sajjan et al, 1992; Sajjan & Forstner, 1992). The gene
responsible for cable pili, cblA has been detected in the ET12 strain ofB. cepacia
(Sun et al, 1995) and was originally thought to be associated with transmission of all
'epidemic' strains. However, further studies revealed cable pili were not present in all
'epidemic' strains, suggesting that other factors are involved (Sun et al, 1995). A
study of clinical and environmental isolates confirmed at least five different
structural classes ofpilin fibres (Goldstein et al, 1995) which correlate with the
source from which the strains, expressing the pili, were isolated. Another property
associated with fimbriae is haemagglutination which occurs in some strains of
B. cepacia (Kuehn et al, 1992).
Lipopolysaccharide (LPS) preparations from environmental and clinical isolates of
B. cepacia and the closely related phytopathogen B. gladioli exhibit a higher
endotoxic activity and cytokine stimulation, in vitro, than LPS from the major CF
pathogen P. aeruginosa (Shaw et al, 1995). This surprising observation confirms the
pathogenic potential ofB. cepacia. Hughes et al (1997) described the potent priming
activity ofB. cepacia LPS for neutrophils; increased neutrophil recruitment and
respiratory burst reponses in the lung may contribute to inflammation, by release of
tissue-damaging proteolytic enzymes. B. cepacia LPS was also found to be a
powerful priming agent for the respiratory burst in monocytes (Zughaier et al, 1999).
This response was significantly greater than that produced by P. aeruginosa or
S. maltophilia, although this priming was CD14 dependent. A purified form of the
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characteristic melanin-like pigment produced by the 'epidemic' strain ofB. cepacia
was found to be an efficient scavenger of superoxide radicals produced in the
respiratory burst (Zughaier et al, 1999). This response may allow melanin-producing
strains ofB. cepacia to survive phagocytosis and thus assist in the colonisation of the
CF lung. The levels of inflammatory markers such as C-reactive protein, neutrophil
elastase-a-l-antiproteinase complex are significantly higher in patients colonised
with B. cepacia compared to those colonised with P. aeruginosa. In addition, the
levels of these markers are reduced following aggressive antimicrobial therapy, even
although B. cepacia is not eliminated (Elborn et al, 1994).
The majority of clinical and environmental isolates ofB. cepacia demonstrate
smooth LPS (McKevitt & Woods, 1984) whereas isolates from CF patients may be
smooth or rough, with the latter type more commonly found (Nelson et al, 1994).
All isolates expressing rough LPS were serum sensitive, while isolates expressing
smooth LPS exhibited a range of responses (Butler et al, 1994). There is no evidence
that B. cepacia changes from smooth to rough in the CF lung, as is observed with
P. aeruginosa. In CF patients, the presence of LPS-specific antibodies in the serum
(IgG) and sputum (IgA) does not prevent colonisation by B. cepacia. Some patients
even succumb to septicaemia in the presence of high concentrations of circulating
antibodies (Nelson et al, 1993). Unlike P. aeruginosa, B. cepacia rarely produce
mucoid colonial forms nor synthesise alginate. There has been one reported case of a
mucoid colonial variant in a CF patient (Straus et al, 1989) as well as an isolated case
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in our laboratory; also from a CF patient. In neither case was the polysaccharide
responsible for mucoidy identified as alginate.
8.6 B. CEPACIA IN CF PATIENTS
The emergence ofB. cepacia as a major threat to the CF community has led to
anxiety in patients, families, carers and clinicians. The first reported case of
pulmonary colonisation with B. cepacia in CF was in the early 1970s (Ederer &
Matsen, 1972); subsequent reports followed in 1977 from Philadelphia (Lourdes et
al, 1977) and in 1979 from the west coast of the USA (Blessing et al, 1979). It has
been suggested that B. cepacia is not a pathogen in CF but merely a marker of
deteriorating lung disease. However, B. cepacia was reported as the cause of
pneumonia and septicaemia in a 17 year old CF patient (Rosenstein & Hall, 1980).
The incidence of B. cepacia colonisation in CF patients in North America, increased
considerably in the early 1980's to as high as 45% in one Canadian centre (Nolan et
al, 1982; Isles et al, 1984; Thomassen et al, 1985) and with approximately one third
of these patients succumbing to a rapidly fatal outcome (Gold et al, 1983).
The clinical course ofB. cepacia colonisation is unpredictable and can follow three
courses: first, no change in clinical status; second, a gradual decline in lung function,
or third, a rapid fatal deterioration (Thomassen et al, 1985). Approximately 30% of
CF patients succumb to the third course called 'cepacia syndrome', a necrotising
pneumonia with fever, bacteraemia, elevation of erythrocyte sedimentation rate and
leucocytosis resulting in rapid and fatal clinical deterioration (Isles et al, 1984).
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Colonisation with B. cepacia may accelerate decline in pulmonary function and
result in poor prognosis (Tablan et al, 1985). Most recently, longitudinal analysis
based on the Canadian national database and statistical models has shown that
B. cepacia (at least the ET12 lineage) increases mortality risk over periods of one to
several years (Corey, 1999).
It has been speculated that pulmonary decline may be associated with production of
anti-B. cepacia antibodies by the host resulting in subsequent immune complex
mediated damage to the lung (Nelson et al, 1994). The major impact ofB. cepacia in
children with CF is on respiratory function. In a disturbing outbreak ofB. cepacia
infection (later identified as genomovar II; i.e. B. multivorans) in a large paediatric
CF clinic; children with the highest lung function deteriorated faster than children
whose lung function was already poor (Whiteford et al, 1995). A number of risk
factors are thought to be associated with the acquisition ofB. cepacia. These include
increasing age, underlying severe lung disease, use of aminoglycosides in particular
tobramycin, CF siblings colonised with B. cepacia and hospitalisation (Tablan et al,
1985). Interactions between B. cepacia and other infecting organisms, in particular
P. aeruginosa, may also affect the outcome of CF lung disease (Hughes et al, 1997).
P. aeruginosa colonisation alone has also been considered as a predisposing factor.
However, not all patients are colonised with this organism prior to colonisation with
B. cepacia as was demonstrated in a large outbreak in the Edinburgh area in the early
1990's where almost 40% of CF patients colonised with B. cepacia were not
colonised with P. aeruginosa (Govan et al, 1993).
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Although B. cepacia did not appear to be a problem in CF patients in the UK until
the early 1990's, the first fatal case of'cepacia syndrome' was reported in 1986 (Glass
& Govan, 1986). During the 1980's the prevalence ofB. cepacia in a CF centre in
Leeds had also increased from 1% in 1984 to 10% in 1988 (Simmonds et al, 1990).
Similar increases in prevalence were reported from other CF centres in London
(Taylor et al, 1992) and Manchester (Gladman et al, 1992). As a consequence of
increased prevalence and growing evidence of cross-infection from patient-to-patient
CF centres in the USA as early as 1986 (Thomassen et al, 1986), and in Birmingham
in 1988, segregated CF patients colonised with B. cepacia from those who were non-
colonised. Subsequently, segregation was extended to include summer camps and
not surprisingly became the subject of considerable controversy amongst some
clinicians and patients (Speert et al, 1989). A strict segregation policy was instituted
at the 3rd National Conference of the Adult CF Association held in Birmingham in
1991 and expanded in 1993 to limit contact between colonised and non-colonised
individuals (Newsletter ofAssoc. CF Adults, 1993). Despite segregation, the
prevalence ofB. cepacia among CF patients in Birmingham remained at 8.3% in
1991; furthermore, genotyping suggested that social contact outwith the hospital was
responsible (Smith et al, 1992). Although segregation ofCF patients in hospital
resulted in a decline in incidence of cross-infection (Govan et al, 1993; Thomassen et
al, 1985), outbreaks ofB. cepacia still occured in several CF centres throughout the
UK, including Edinburgh and Manchester (Govan et al, 1993), Cardiff (Millar-Jones
et al, 1992), and Liverpool (Smyth et al, 1993). Accumulated evidence indicated
that a single highly transmissible strain ofB. cepacia was responsible for inter-
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regional spread amongst CF centres in the UK. In 1996, this 'epidemic' strain was
found to be present in 50% of the CF centres throughout the UK and accounted for
38% of all B. cepacia isolates from patients in the UK (Pitt et al, 1996). Meanwhile,
molecular epidemiological evidence had shown a clonal relationship between this
strain and an epidemic strain responsible for an outbreak in North America (Sun et
al, 1995). Currently, this highly transmissible strain is referred to as the
Edinburgh/Toronto or ET12 lineage (Govan et al, 1996). ET12 based on its
association with the Edinburgh and Toronto outbreak and its identification by
multilocus enzyme electrophoresis as electrophoretic type 12 (Johnson et al, 1994).
Colonisation with more than one strain ofB. cepacia is unusual, occuring in less than
10% patients (Pitt et al, 1996). Elowever, several centres have reported episodes
when patients initially colonised with non-epidemic strains have later acquired the
'epidemic' strain (Ledson et al, 1998b; Webb & Govan, 1998). This super-infection
poses a difficult problem in patient management, namely whether patients colonised
with the 'epidemic' strain ofB. cepacia should be further segregated from those
colonised with non-epidemic strains.
8.7 EPIDEMIOLOGY
Prior to 1980, epidemiological investigations into infections caused by B. cepacia
were hampered by the lack of typing systems. During the 1980s, however, a number
of phenotypic fingerprinting techniques included biotyping, bacteriocin susceptibility
and production, antimicrobial susceptibility and serotyping were developed.
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The first typing system reported for 'fingerprinting' isolates ofB. cepacia was
serotyping. A study carried out using 139 isolates of eugonic-oxidizer group 1
described five serotypes I, la, lb, II and III. A sixth serotype IV was later described
by Klinger et al in 1984. A large proportion of CF isolates were type I, compared
with only 8% of isolates from other sources, however, many isolates, particularly
those from environmental sources, were polyagglutinable or nontypeable.
Monteil's group differentiated seven somatic 'O' and five flagellar 'FT antigens in a
collection of 285 B. cepacia isolates (Heidt et al, 1983); with two new serotypes, in
each category, added at a later stage (Werneburg & Monteil, 1989). Typeability was
98% and 43% for 'O' and 'H' antigens, respectively. A Japanese system described 10
serotypes but only 12% of the 105 isolates were typeable by this method (Nakamura
et al, 1986) . Another method used antisera raised against unheated whole bacteria
but only 39% of isolates were typeable (McKevitt et al, 1987).
Three biotyping schemes were investigated with the first system classifying
B. cepacia into four biotypes on the basis of growth at 41°C and gelatin liquifaction
at 37°C (Esanu & Schubert, 1973). Another system divided B. cepacia into eight
biovars on the basis of biochemical characteristics including aesculin hydrolysis,
nitrate reduction, o-nitrophenyl-(3-D-galactopyranoside (ONPG) hydrolysis and
pigment production (Richard et al, 1981). The third scheme involved the use of the
commercially available identification kit, API 20NE, but results were too variable for
it to be of any use as an epidemiological typing system.
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Bacteriocin typing was first demonstrated by Gonzalez & Vidaver (1979) and
divided 30 strains into two groups on the basis ofbacteriocin production. As only
30% ofB. cepacia produce bacteriocins; bacteriocin production alone is not a
suitable method of typing isolates ofB. cepacia. Govan & Harris (1985) developed a
more discriminating method which was based on susceptibility to and production of
bacteriocins. This system differentiated 373 isolates ofB. cepacia into 44
cepaciacins with 95.2% typeability.
In the mid 1990s, a multi-centred comparative study assessed the discriminatory
powers of various phenotypic systems including biotyping, bacteriocin susceptibility
and production, antimicrobial susceptibility and serotyping was compared with
ribotyping (Rabkin et al, 1989). The authors concluded that ribotyping, serotyping
and biotyping were useful methods for epidemiological fingerprinting isolates of
B. cepacia. Antimicrobial susceptibility by disk diffusion was extremely variable
and not considered to be a useful typing method and although bacteriocin typing was
the most sensitive phenotypic system for detecting differences between groups of
isolates or unrelated isolates, results varied substantially among outbreak-related
strains.
SDS-PAGE and pyrolysis mass spectroscopy (PMS) were applied to 15 isolates of
B. cepacia, from CF patients, and 11 were indistinguishable by PMS and found to be
the 'epidemic' strain, whereas the remaining four isolates were different (Corkill et al,
1994). SDS-PAGE was found to be less discriminatory than PMS.
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Development ofDNA-based genomic fingerprinting systems in the early 1990's
provided a greater understanding of the epidemiology ofB. cepacia and confirmed
the existence of'epidemic' strains (Dasen et al, 1994; Kostman et al, 1992; Stull et
al, 1988). Numerous studies were then undertaken in the hope of determining how
B. cepacia was transfered among CF patients.
Johnson et al (1994) used multilocus enzyme electrophoresis (MLEE) and ribotyping
to examine 83 isolates ofB. cepacia cultured from CF patients and from nosocomial
and environmental site isolates. MLEE was found to be more discriminating than
ribotyping and demonstrated that environmental isolates ofB. cepacia were
genomically different from pulmonary and nosocomial isolates. MLEE also
provided evidence that two CF patients from the UK were colonised with the
'epidemic' ET12 lineage ofB. cepacia at an Ontario summer camp (Johnson et al,
1994). MLEE has the disadvantage of being labour intensive and technically too
complex for use in most clinical laboratories. This technique has also been applied
to isolates ofB. cepacia from decayed onions, soils, and clinical sources but
considerable diversity was demonstrated among the isolates with no evidence of
shared clonality in the case of clinical and environmental isolates (Yohalem &
Lorbeer, 1994).
Ribotyping ofB. cepacia has been shown to to have good specificity and sensitivity
(Stull et al, 1988) and numerous epidemiological studies have been undertaken.
Early studies provided evidence of clusters of isolates with the same ribotype within
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individual CF centres suggesting cross-infection or a common source (LiPuma et al,
1988). Wilkinson & Pitt (1995a) found that 35% of isolates ofB. cepacia from CF
patients in the UK produced the same ribotypes, confirming evidence of spread of the
ET12 lineage. Transatlantic spread of the ET12 lineage was demonstrated with the
use of ribotyping (Johnson et al, 1994; Sun et al, 1995). In one study, considerable
variation in colonial morphology in 14 isolates ofB. cepacia, recovered from a CF
patient over a two and a half year period, were reported. However, ribotyping
showed them to be all clonally-related (Larsen et al, 1993).
Four PCR techniques have been applied in epidemiological studies ofB. cepacia-,
these include arbitrarily primed PCR (AP-PCR), PCR-ribotyping, enterobacterial
repetitive intergenic consensus sequence PCR (ERIC-PCR), and random amplified
polymorphic DNA (RAPD).
AP-PCR provided evidence ofpatient-to-patient transmission ofB. cepacia in CF
patients or alternatively the presence of a common hospital source (Bingen et al,
1993). Isolates ofB. cepacia from patients colonised for periods of 3-14 months
were shown to be similar by AP-PCR. This is in contrast to observations of changes
occuring in ribotypes and PFGE profiles but not in MLEE types in B. cepacia
cultured from CF patients over a period of several years (Johnson et al, 1994). It was
speculated that these alterations might be due to selective pressures in vivo and minor
genomic base changes.
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When compared to ribotyping, AP-PCR was shown to be as discriminating but not as
discriminatory as PFGE (Bingen et al, 1993). However, Johnson et al (1994) argued
that AP-PCR lacks reproducibility and is not sufficiently reliable to evaluate clonal
diversity ofB. cepacia. Ellsworth et al (1993) found AP-PCR vulnerable to subtle
changes in annealing temperature, template and primer concentrations and
magnesium concentration, resulting in loss ofmajor bands. When this technique was
compared to PCR-ribotyping and ERIC-PCR, greater day-to-day variation in
fingerprints was obtained by AP-PCR (Liu et al, 1995).
PCR-ribotyping was shown to be as discriminatory as conventional ribotyping, with
the advantage ofbeing more rapid to perform and avoiding the use of radioactive
material (Kostman et al, 1992). Discriminatory powers ofPCR-ribotyping could be
improved by restriction digestion of the PCR product, however, Mahenthiralingham
et al (1996) were unable to demonstrate any improvement in discrimination with the
use ofHaeIII, in their study. In an earlier study using 23 distinct unrelated isolates of
B. cepacia, PCR-ribotyping could only identify 12 types, even after digestion of the
PCR product using Alul (Liu et al, 1995). PCR-ribotyping is reproducible but is less
discriminating than PGFE, ERIC-PCR or AP-PCR. PCR-ribotyping has an
advantage that only small amounts, as little as 1 Opg, of template DNA are required to
amplify polymorphisms, but this can also be a disadvantage in that trace amounts of
contaminating DNA may interfere with banding patterns (Mahenthiralingham et al,
1996).
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RAPD was able to group epidemiologically related B. cepacia which had previously
been shown to be related by PFGE and ribotyping (Mahenthiralingham et al, 1996).
Two conditions which affect reproducibility in RAPD typing are the concentration of
DNA template and the concentration of the primer. RAPD is relatively simple to
perform and this enables genomic comparison even when large number of isolates
are involved. However, RAPD was demonstrated to be less discriminating than
PFGE when fingerprinting isolates ofB. cepacia (Steinbach et al, 1994).
A study ofB. cepacia cultured from 60 CF patients in a CF centre in Verona, Italy
and examined by FIGE revealed that 32 (53%) patients were colonised with different
strains while the remaining 28 (47%) patients were colonised with isolates belonging
to one of 10 distinct genotypes (Cazzola et al, 1996). Evidence of direct patient-to-
patient transmission was only found in 10 cases including two classmates.
Examination of eight pairs of siblings revealed that only three pairs were colonised
with the same strain ofB. cepacia; only one sibling was infected out of a further
three pairs and transient infection was observed in the remaining two pairs of
siblings.
Genotyping by PFGE showed that most of the isolates ofB. cepacia, from CF
patients in a French centre, were clonally related, suggesting either cross infection or
a common source (VuThien et al, 1996). The prevalence of 14%, in this centre, was
high compared to the French national average of 2%.
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8.8 TRANSMISSION OF B. CEPACIA IN CF PATIENTS
The first evidence of patient-to patient transmission ofB. cepacia was demonstrated
at a CF educational camp using ribotyping (LiPuma et al, 1990). Further compelling
evidence for direct transmission between patients included close contact in hospital
(Smith et al, 1993), and social contact at a fitness class (Govan et al, 1996).
Numerous studies, using ribotyping, PFGE, MLEE and other genomic fingerprinting
systems have confirmed these observations ofperson-to-person transmission by
certain strains ofB. cepacia, in particular the ET12 lineage (Bingen et al, 1993;
Smith et al, 1993; Govan et al, 1993; Corkill et al, 1994; Pegues et al, 1994;
Whiteford et al, 1995). Transfer of respiratory secretions, from colonised patients, is
considered to be the principal source ofB. cepacia acquisition among CF patients
(Pitt & Govan, 1993; Govan et al, 1996). B. cepacia has been cultured from the air
in a room occupied by a B. cepacia positive CF patient and viable organisms found
to persist for up to 45 minutes (Humphreys et al, 1994). However, other studies have
been unable to detect airborne contamination even when sampling the air beside a
B. cepacia colonised patient undergoing physiotherapy (Govan et al, 1993).
No evidence ofpatient-to patient transmission was found in a study of the UK's
largest adult CF centre at the Royal Brompton hospital although nosocomial
infection may have occured (Stableforth & Smith, 1994). This may be explained by
the fact that patients attending this hospital come from a wide geographical base
including overseas, and did not have the same opportunity for social interactions
outwith the hospital as may occur in other CF centres. Another study on 65 isolates
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from 17 CF patients plus five patients who had undergone transplantation also found
no evidence of person-to-person spread (Steinbach et al, 1994). This study showed
that each patient harboured a different strain ofB. cepacia. There is also convincing
evidence that B. cepacia is not invariably transmitted even between CF siblings.
Glass & Govan (1986) reported a lack of transfer between a CF sibling, who
succumbed to 'cepacia syndrome' following colonisation with a genomovar III
B. cepacia, and her CF sibling. Similar findings were observed in the Verona study
refered to previously. In this study of eight pairs of siblings; only three pairs were
chronically infected with the same strain ofB. cepacia and only one sibling was
infected in each of the other five pairs (Cazzola et al, 1996). In the early 1990's, a
growing suspicion that transmissibility is strain dependant was confirmed in a patient
who harboured two strains ofB. cepacia', one being the 'epidemic' strain. Following
a close relationship only the 'epidemic' strain was transmitted to the patient's
girlfriend (Govan et al, 1993).
Indirect transmission ofB. cepacia may occur since patients contaminate
environmental fomites such as drinking vessels, respiratory equipment and
disinfectants which can then act as a source of infection for other patients (Burdge et
al, 1993; Nelson et al, 1991). Nebulisers are a potential but apparently not a major
source of acquisition of B. cepacia as B. cepacia was recovered from only three of
the 35 home-use nebulisers investigated (Hutchinson et al, 1996). PFGE
demonstrated that one of the two strains recovered from a nebuliser was the same as
the isolate obtained from the patient's sputum. In the other two cases, B. cepacia was
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recovered from nebulisers but no B. cepacia was detected in sputum culture from the
patients, suggesting that the isolates from the nebulisers were probably obtained from
an environmental source.
A final intriguing question remains. Proponents of the use ofB. cepacia
biopesticides have claimed that there is no scientific evidence that environmental
strains are responsible for colonising CF patients. In a study of environmental
samples, only four isolates ofB. cepacia were recovered from 58 samples and when
these isolates were compared to those isolated from CF patients, ribotyping
demonstrated that the environmental isolates were distinct from any of the clinical
isolates (Honicky et al, 1993).
8.9 AIMS
B. cepacia is a cause of great concern within the CF community. Anxiety arises, in
particular, because of evidence of patient-to-patient spread of transmissible strains,
and the association of certain strains and genomovars with the lethal outcome known
as 'cepacia' syndrome. A reliable discriminatory typing system for B. cepacia is
essential for ongoing surveillance studies and for prospective studies to identify
reservoirs and modes of spread. As PFGE is regarded as the 'gold standard' in
molecular typing techniques, the aim of this section of the thesis was to assess the
use ofPFGE for fingerprinting B. cepacia using the recognised criteria for an ideal
typing system. According to Hawkey (1989), an ideal typing system should:
1. Possess the ability to type the majority of strains encountered: 2. Demonstrate
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good discriminatory powers and reproducibility: 3. Be readily applicable to
environmental and clinical isolates as well as laboratory collections of strains: 4. Be
easy to perform and inexpensive. Another aim was to compare PFGE with another
genomic typing system, PCR-ribotyping, and with a simpler and faster phenotypic
method, bacteriocin typing.
The first UK isolate of the 'epidemic' strain ofB. cepacia, later known as ET12, was
obtained from an Edinburgh CF patient in August 1989. For this thesis, a
longitudinal study was made of the isolates ofB. cepacia recovered from this patient
over the nine year period to determine whether PFGE could detect any variation in
the isolates as the organism adapted to the lung environment. A parallel study
investigated whether alterations in PFGE patterns occured as the strain spread
amongst the Edinburgh CF population.
Following application to North America regulatory authorities for bulk
environmental release ofB. cepacia as a commercial prospect and soil remediator, a
further aim of the thesis was to use PFGE to investigate the relationship between
environmental B. cepacia and those colonising CF patients.
8.10 RESULTS
8.10.1 Genomic fingerprinting of B. cepacia by PFGE
Chromosomal DNA was extracted frrom isolates of B. cepacia using the method
described by Vasil et al (1990) except that the concentration of low melt agarose,
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used for making the agarose plugs, was reduced from 2% to 1 % to provide clearer
banding patterns.
Digested chromosomal DNA was separated by PFGE using inital and final pulse
times of 2.9 s and 35.4 s, respectively for 20 h at 14°C. These conditions were
provided by Bio-Rad from information given to them regarding the estimated range
in size of the DNA fragments produced following digestion with restriction enzymes
Xbal and Spel. This technique worked well for about two years and then failed to
produce banding patterns clear enough to allow comparison of isolates ofB. cepacia.
As the technique had not altered in any way, it was decided to investigate the
chemicals involved. The outcome was that EDTA, used in the making ofbuffers,
gave variable results depending on the manufacturer; EDTA supplied by Bio-Rad
producing clearer PFGE profiles than that ofEDTA obtained from Sigma. Further
investigation into the technique used for lysing B. cepacia revealed that superior
results were achieved by substituting proteinase K with 0.5% Triton X-100 in the
lysis buffer. Unfortunately, this procedure failed to work for the ET12 lineage of
B. cepacia. The 'ET12' problem was overcome by incorporating an additional
incubation step using lysis buffer containing proteinase K (50 pg/ml) at 55°C
overnight following the initial lysis in lysis buffer containing 0.5% Triton X-100.
Initially, it was thought that the failure of the ET12 isolates ofB. cepacia to lyse
might be due to the fact that the lineage exhibits rough lipopolysaccharide (LPS).
Flowever, no problems were encountered using the 0.5% TritonX-100 lysis
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procedure for the extraction of chromosomal DNA from other strains ofB. cepacia
(CI394, CI632, ATCC 17762) also known to have rough LPS (Simpson et al, 1994).
To reduce the time taken for PFGE ofB. cepacia, the initial overnight bacterial
culture was shortened by growing the bacteria in 5 ml NBYE for 3 h at 37°C in
shaking incubator. One millilitre of the culture was centrifuged at 13,000 rpm for
2 min, washed in 1 ml SE buffer, centrifuged at 13,000 rpm for 2 min and the pellet
resuspended in 0.5 ml SE buffer. The plugs were made by adding an equal volume
of 1% low melt agarose and pipetting the mixture into the plug mold. The plugs
were then lysed by the procedure mentioned above.
8.10.2 Is PFGE a suitable typing system for B. cepacia ?
Isolates ofB. cepacia were used to investigate the major criteria necessary for a good
typing system; discriminatory power, reproducibility and stability. With the
exception of closely related isolates, considerable diversity in DNA banding profiles
was observed when clinical or environmental isolates ofB. cepacia were examined
by PFGE. Fig 8.1 illustrates the degree of discrimination of this technique for nine
isolates ofB. cepacia following digestion with Xbal.
Reproducibility of PFGE ofB. cepacia was demonstrated by making agarose plugs
from nine different cultures ofB. cepacia isolate A599. The plugs were lysed
individually, prior to digestion with restriction enzyme Xbal. Identical PFGE
profiles were illustrated in Fig 8.2.
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FIG. 8.1. Xbal digestion ofDNA from nine different isolates ofB. cepacia showing a
range of PFGE profiles. Lanes 1 to 9, J2315, J2553, A552, C1504, A548, C1372,
A599, J2543, C1513; lane 10, lambda concatemers (size range 48.5kb to 582 kb, in
increments of 48.5kb).
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FIG. 8.2. PFGE ofXbal digested genomic DNA from nine different preparations of
B. cepacia isolate A599 (lanes 1 to 9), demonstrating the reproducibility ofthis technique.
Lane 10, lambda concatemers (size range 48.5kb to 582kb, in increments of 48.5kb).
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A considerable advantage of PFGE over other typing systems is that a banding
pattern, produced by an isolate, can be compared to the patterns produced by other
isolates within the same gel or in different gels.
Several isolates ofB. cepacia were used to investigate the stability of PFGE. Results
using the 'ET12' strain of B. cepacia (J2315) are illustrated in Fig 8.3. Stability of
PFGE for B. cepacia was demonstrated both in vivo and in vitro. J2315, the original
UK index isolate stored at -70°C for nine years produced the same pattern as a fresh
isolate from the same patient (results not shown).
Passaging of J2315 through numerous subcultures (six passages) on nutrient agar did
not alter the PFGE banding profiles nor did culture on the following media; NBYE,
Mueller Hinton broth, LB broth, Brain heart infusion broth and Malka medium, prior
to DNA preparation have any affect on the PFGE profiles produced. Comparison of
DNA preparations made from cultures grown overnight with log phase cultures also
showed no difference in the banding patterns produced by PFGE (results not shown).
When J2315 and other strains ofB. cepacia were inoculated into distilled water or
saline, and kept at room temperature, they remained viable for the four year period of
this study. During this time, the PFGE profiles remained identical to that of the
original isolate J2315. In conclusion, PFGE profiles ofB. cepacia remain unaltered
following storage at different temperatures, starvation in distilled water and saline
and culturing in different media prior to extraction of chromosomal DNA.
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FIG. 8.3. PFGE ofXbal digested genomic DNA from B. cepacia isolate J2315, under
varying conditions. Lane 1, recent fresh isolate (recovered 9 years after original isolate);
lane 2, storage at -70°C; lane 3, passaged on 6 occasions; lane 4, grown in NBYE; lane
5, grown in Mueller Hinton broth; lane 6, grown in LB broth; lane 7, grown in Brain
Heart Infusion broth; lane 8, grown in Malka medium; lane 9 and 10, starvation in
distilled water and saline, respectively.
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Longitudinal studies of the first Edinburgh CF patient to acquire the 'epidemic' strain
ofB. cepacia were undertaken over the nine years in which this patient has remained
colonised. The PFGE profile of the original isolate J2315, recovered from sputum
culture in 1989, was compared to subsequent isolates from this patient; in all cases,
the restriction enzyme Xbal was used to digest chromosomal DNA. No difference in
the PFGE profiles was detected until 1995 when five isolates from this patient were
obtained during the gene therapy trials. At this time, two different profiles were
observed. Three isolates revealed a three band difference from the original; this
change involved the appearance of two new bands and a band missing. The other
two isolates produced patterns identical to the original 1989 isolate ofB. cepacia. In
1996, the PFGE profile of a recent isolate only showed a single band difference
involving the appearance of an extra band.
An isolate ofB. cepacia recovered in 1997 showed an identical PFGE profile to that
of the original isolate while the most recent isolate, recovered in 1998 produced a
three band difference in PFGE pattern; this change involved the appearance of two
new bands and a band missing. A comparison of the PFGE profiles of the most
recent isolate taken in 1998 and the original can be seen in lanes 1 and 2 in Fig.8.3.
All differences in the PFGE profiles occured in the top region of the agarose gel,
suggesting variation in the larger fragments ofDNA.
202
Interestingly, isolates ofB. cepacia, which demonstrated a difference in PFGE
profile using restriction enzyme Xbal, showed no change in their PFGE profiles
following digestion with restriction enzyme SpeI (results not shown).
The results of this study indicate that genomic fingerprinting ofB. cepacia by PFGE
provides good discrimination, reproducibility and stability. One of the disadvantages
of this system, however, is that it is time-consuming and typically takes 3-4 days
before a result can be obtained. With this in mind, it was decided to investigate a
more rapid molecular typing system, namely PCR-ribotyping. Another PCR-based
random amplified polymorphic DNA (RAPD) typing system was also considered.
However, after numerous failures to apply this system satisfactorily to B. cepacia, it
was abandoned in favour ofPCR-ribotyping.
8.10.3 PCR-ribotyping
The reproducibility ofPCR-ribotyping for B. cepacia was investigated as follows:
DNA was extracted from cultures from two different CF patients on six occasions
and amplified using PCR-ribotyping. The PCR product was then analysed by
electrophoresis and the results, illustrated in Fig 8.4, confirm the reproducibility of
the technique. However, variations in banding patterns were observed. These
variations occured when DNA extracted from the same strain ofB. cepacia on
different occasions, was amplified by PCR-ribotyping at different times and the PCR
products analysed by electrophoresis on different gels (results not shown).
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The discriminatory power ofPCR-ribotyping was investigated using the same nine
strains ofB. cepacia which were used to demonstrate genomic diversity by PFGE.
Comparison of the profiles produced by PCR-ribotyping showed each isolate to be
different with the exception of isolates A548 and A599 (lanes 5 and 7, Fig.8.5) which
showed very little, if any, differences in their profiles. Since all of the isolates had
been shown to be clearly different by PFGE, it seemed that PCR-ribotyping was
reasonably discriminatory but not as discriminatory as PFGE.
8.10.4 Comparison of bacteriocin typing, PFGE and PCR-ribotyping
Bacteriocin typing is a reasonably reliable method for typing B. cepacia-, for
example, the ET12 strain invariably produces a bacteriocin type, S3/P0 or S13/P0
pattern. There is only a single indicator difference between the two typing patterns
and in general, variation only occurs following storage at -70°C. Another 'epidemic'
strain ofB. cepacia, responsible for a major outbreak in Manchester, produces a
bacteriocin type S3/P6. This fingerprint is also very reproducible. Unfortunately,
bacteriocin typing failed the discriminating test as a large proportion of isolates of
B. cepacia produce a bacteriocin type S22/P0 pattern. When these isolates are typed
by PFGE, the majority produce unique profiles indicating that they are clonally
unrelated.
Interestingly, initial studies using bacteriocin typing suggested that a large group of
CF patients attending a Glasgow CF centre were colonised with the same strain of
B. cepacia (Whiteford et al, 1995).
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FIG. 8.4. PCR amplification patterns ofsix differentDNA extractions from two different
isolates of B. cepacia J2315 (lanes 1 to 6) and CI355 (lanes 7 to 12), demonstrating
reproducibilty; lane 13 lambda DNA marker (125 to 21,226bp).
FIG.8.5. PCR amplification of nine different isolates of B. cepacia. Lanes 1 to 9,
J2315, J2553, A552, C1504, A548, C1372, A599, J2543, and C1513; lane 10 lambda
DNA marker (125 to 21,266 bp).
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All isolates produced a bacteriocin type S22/P0 pattern and this 'phenotypic' clonality
was confirmed when the same isolates were analysed by PFGE.
Eight epidemiologically unrelated isolates ofB. cepacia, all bacteriocin type S22/P0,
were typed by PFGE and PCR-ribotyping to compare the three systems (Figs. 8.6 &
8.7). PFGE analysis revealed that two isolates, C1503 and C1462, showed identical
PFGE profiles; isolates CI572 and C2080 showed a two band difference, indicating
that they are closely related, and the remaining isolates produced unique profiles
suggesting that they are different strains ofB. cepacia. PCR-ribotyping showed that
isolates C1571 and C1596 were obviously different while isolates C1462, C1572 and
C2080 produced identical profiles.
Although CI503 produced an identical PFGE profile to that of C1462, the profile
produced by PCR-ribotyping revealed a difference in thickness of the dense band and
also the absence of a faint band. These minor differences in isolate CI 503 suggest
that this isolate is different from CI462. The two isolates of B. cepacia (CI447 and
C1552) show varying degrees of similarity to the three isolates (C1462, C1572 and
C2080) with identical patterns by PCR-ribotyping; thus it was difficult to determine
whether the strains were the same or different by this technique.
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FIG. 8.6. Xbal digestion ofDNA from eight isolates ofB. cepacia, all bacteriocin type
S22/P0. Lanes 1 to 8, C1447, C1503, C1552, C1571, C1596, C1462, C1572, C2080;
lane 9, lambda concatemers (size range 48.5kb to 582kb, in increments of 48.5kb).
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FIG.8.7. PCR-ribotyping of the same eight isolates of B. cepacia. Lanes 1 to 8, as
above; lane 9, lambda DNA marker (125 to 21,226 bp).
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8.10.5 Comparison of PFGE and PCR-ribotyping
Thirteen CF isolates ofB. cepacia C2701 - C2713, from Verona, Italy were
fingerprinted by PFGE and PCR-ribotyping (Figs. 8.8 & 8.9). PCR-ribotyping
revealed three groups ofpatients, each with their own strain ofB. cepacia. Group 1
comprised of isolates C2701 and C2702, group 2 - C2703 and C2704, and group 3 -
C2705, C2707, C2710, C2711, and C2712. The banding patterns produced by the
remaining seven patients were each unique, suggesting that these patients were
colonised with different strains ofB. cepacia. These results were confirmed by
PFGE although minor differences in PFGE profiles, within the groups, were
observed. The PFGE profile produced by isolate C2707 showed a six band
difference compared to the banding patterns produced by the other isolates in this
group. However, according to the criteria proposed by Tenover et al (1995) for
interpretation ofPFGE profiles, isolate C2707 would be regarded as being related to
the other isolates ofB. cepacia in group 3.
8.10.6 ET12 lineage of B. cepacia in Edinburgh CF patients.
The major 'epidemic' strain ofB. cepacia known as ET12 colonised 15 CF patients in
Edinburgh following its emergence as the index isolate, J2315, in August 1989.
Figures 8.10 & 8.11 show the slight variations in the PFGE profiles of this strain as it
transferred from patient-to-patient. Investigations into the mode of transmission of
ET12 among the Edinburgh CF patients provided compelling evidence that social
contact was responsible for spread in all cases except one; this patient did not appear
to have had contact with any of the other B. cepacia colonised patients.
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FIG.8.8. Xbal digestion of 13 isolates ofB. cepacia from Verona followed by PFGE.
Lanes 1 to 13, C2701 - C2713, respectively.
FIG. 8.9. PCR-ribotyping of the same 13 isolates of B. cepacia. Lanes 1 to 13, as
above; lane 14, lambda DNA marker (125 to 21,226 bp).
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FIG. 8.10 (top) & 8.11 (bottom). Xba I digestion of the 15 isolates of the 'epidemic'
strain ofB. cepacia from the Edinburgh CF patients. Fig. 8.10. Lanes 1 to 8, C1355,
C1358, C1359, C1382, C1392, C1512, C1525, C1895; lane 9, lambda concatemers
(size range 48.5kb to 582kb, in increments of48.5kb). FIG. 8.11. Lanes 1 to 7, J2315,
C1385, C1430, C1372, C1500, C2374, C2606; lane 8, lambda concatemers.
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Social contacts included attending the same gym class, drinking partners, boyfriend-
girlfriend relationship, a car journey with a colonised patient, and a single visit of a
previously non-colonised patient to his B. cepacia colonised friend in hospital. The
same fifteen isolates of ET12 were typed by PCR-ribotyping (Fig. 8.12) and provided
identical banding patterns apart from isolate CI525 in lane 12, which demonstrated
an extra band. It would appear, from previous analysis ofPCR-ribotyping profiles,
that a single band difference, when comparing two PCR-ribotyping profiles, is
sufficient to indicate that isolates are different. Thus, the PCR-ribotyping results
suggested that isolate CI 525 could be different to that of the ET12 lineage of
B. cepacia. However, the PFGE profile ofCI 525 was found to be identical to the
PFGE profile of J2315. The other PRC-ribotyping results were in agreement with
the results of PFGE profiles which demonstrated only minor band differences in the
profiles of 5 of the 15 CF patients.
This study provided little evidence to suggest that the Edinburgh version of the
B. cepacia ET12 lineage has changed to any extent over the eight year period in
which this strain has spread amongst the Edinburgh CF community. A comparison
of two PFGE profiles produced from the index isolate J2315 and the most recently
colonised CF patient (C2606), showed a four band difference, using restriction
enzyme Xbal (Fig. 8.10). The differences observed included an additional band in
isolate C2606, while the other three bands showed only an alteration in density or
thickness in comparison to that produced by J2315.
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FIG. 8.12. PCR-ribotyping of the 15 isolates of the ET12 strain ofB. cepacia, from the
CFpatientsinEdinburgh. Lanes 1 to 15, J2315, C1355,C1358,C1359,C1372,C1382,
C1385, C1392, C1430, C1500, C1512, C1525, C1895, C2606, C2374.
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When the restriction enzyme Spel was used to cut chromosomal DNA from
B. cepacia ET12 isolates from seven of the CF patients, minor differences were again
observed in the PFGE profiles (Fig. 8.13). Comparison ofPFGE profiles of the
index isolate J2315 and isolate C2606, using restriction enzyme Spel, revealed only a
slight difference; namely, the appearance of an additional band and difference in
intensity of another band.
8.10.7 Genomovars
Recently, organisms presumptively identified as B. cepacia have been shown to
comprise of five distinct genomic species or genomovar groups, I - V. These are
identified as genomovars I - V, with genomovar II and IV renamed as B. multivorans
and B. vietnamiensis, respectively. The group as a whole are refered to as the
B. cepacia complex.
Although isolates ofB. cepacia from CF patients have been found in each of the
genomovar groups, a large proportion ofCF isolates, including the ET12 strain,
belong to group III. Nine CF isolates ofB. cepacia, belonging to genomovar group
III were examined by PFGE to determine the relationship, if any, between isolates of
B. cepacia within this closely-related taxonomic group. PFGE showed genomic
heterogeneity even within genomovar group III (Fig 8.14), and similar heterogeneity
in PFGE pattern was found in each of the other genomovars (results not shown). The
genomovar III isolates investigated consist of an interesting group of strains.
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FIG. 8.13. Spel digestion of the same seven isolates of the ET12 strain ofB. cepacia as
in Fig. 8 11. Lanes 1 to 7, J2315, CI385, C1430, CI372, CI500, C2374, C2602; lane
8, lambda concatemers (size range 48.5kb to 582kb, in increments of 48.5kb).
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FIG. 8.14. Xbal digestion of nine isolates ofB. cepacia belonging to genomovar III.
Lanes 1 to 9, J415, C1335, J2315, C1394, C1773, C1632, J2660, A548, and A552.
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The isolate from patient KD (J419), in lane 1, was the first reported case of a CF
patient succumbing to 'cepacia' syndrome in the UK in 1986. Surprisingly,
B. cepacia was not detected in her sister's sputum (C1335) until 4 years after KD's
death and interestingly, both isolates showed similar PFGE profiles (lanes 1 & 2).
Representives ofET12 and other 'epidemic' strains ofB. cepacia are shown in lane 3
(ET12 strain), and lane 4 (Manchester 'epidemic' strain). Lanes 5 and 6 show a
clonal relationship in isolates from CF patients in Papworth and Newcastle,
respectively. Lane 7 is a CF isolate from Cardiff and lanes 8 & 9 are isolates from
paediatric CF patients in Edinburgh not associated with the Edinburgh ET12 lineage.
Interestingly, the majority ofpaediatric CF patients in Edinburgh are colonised with
their own unique strain ofB. cepacia.
8.10.8 Evidence of clonality between an environmental and a clinical isolate of
B. cepacia
Twelve environmental isolates ofB. cepacia and 12 ATCC type strains were
examined by PFGE and the resulting profiles compared to profiles produced by a
large number of clinical isolates. Interestingly, an isolate ofB. cepacia (C2808)
recovered from a CF patient produced a striking bright yellow pigmentation when
grown on NA medium (Fig. 8.15a). This characteristic is unusual in clinical isolates
and is generally confined to environmental isolates ofB. cepacia. Further
investigations revealed that both the clinical isolate and the yellow-pigmented type
strain ATCC 25416, isolated from an onion, shared identical biochemical profiles
when identification as B. cepacia was confirmed by the API 20NE system. In terms
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of antibiotic susceptibility, both isolates also produced similar MIC's of ceftazidime
(1 mg/1), ciprofloxacin (0.5 mg/1), colomycin (>64 mg/1), trimethoprim (1 mg/1),
meropenem (0.25 mg/1), imipenem (4 mg/1), and trobramycin (8 mg/1).
Although different types of rot in onions, including wet and dry rot, have been
produced by clinical and environmental isolates ofB. cepacia both of the isolates
C2808 and ATCC 25416 demonstrated the same wet, slimy type of rot after 6 days
incubation at 30°C. Further evidence to suggest that these isolates were clonally
related was obtained by PFGE, using two different restriction enzymes Xbal and
SpeI, where both isolates produced identical PFGE profiles with each enzyme (Fig.
8.15). Analyses ofwhole-cell protein electrophoresis patterns also showed that both
isolates belonged to genomovar I (results provided by P. Vandamme, Belgium).
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FIG. 8.15a. Clinical isolate C2808 and environmental type strain ATCC 25416 of
B. cepacia demonstrating the striking bright yellow pigmentation.
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FIG. 8.15. PFGE profiles of environmental and clincal isolates of B. cepacia, using
restriction enzymes Xba\ and Spe\, respectively. Lanes 1 and 3 C2808; lanes 2 and 4




8.11.1 Improvements in DNA extraction methods prior to separation by PFGE
As with all molecular procedures, PFGE can produce variable results with respect to
the clarity of the banding patterns produced by isolates ofB. cepacia. Initially, the
DNA extraction method using lysis buffer containing proteinase K appeared to work
as clear PFGE profiles were seen in the majority of the agarose gels. However, after
a period of time and for no apparent reason the banding patterns produced by PFGE
showed faint, ill-defmed bands, making comparison ofprofiles extremely difficult.
Having ruled out all other possibilities, these results necessitated the development of
another procedure for DNA extraction. The use ofTriton X-100 incorporated into
the lysis buffer, as a substitute for proteinase K, resulted in consistently clear, well
defined profiles showing good resolution. This modification made interpretation of
the results and the comparison of PFGE profiles much easier.
Interestingly, the 'epidemic' strain ofB. cepacia known as ET12 appears to be the
only strain which resists lysis by the Triton X-100 method. Initially, the rough LPS
structure ofET12 was thought to be a possible explanation for its failure to lyse by
this method. However, DNA was successfully extracted from other rough strains of
B. cepacia using the Triton X-100 method. This problem was overcome by an
additional lysis step using proteinase K, but at a lower concentration than was used in
the original method.
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The other modification to PFGE was to grow B. cepacia to log phase which requires
incubation for three hours. This resulted in a faster technique with results obtained a
day earlier than with the previous method. However, this advantage is lost when
fingerprinting isolates of the 'epidemic' strain ofB. cepacia as they require an
additional overnight incubation step.
When each of the criteria necessary for a good typing system was considered
independently, PFGE was successful in fulfilling the majority of the requirements set
out by Hawkey (1989). PFGE has the ability to type the majority of strains from
most genera ofmicroorganisms. However, different lysing procedures are required
to enable extraction of chromosomal DNA from different microorganisms and
selection of an appropriate restriction enzyme is necessary to cleave the varying
nucleic acid sequences of chromosomal DNA encountered. Digestion of
chromosomal DNA results in a range ofDNA fragments varying both in the size and
number produced. Initial and final pulse times, the most important factors for
production ofwell-resolved banding patterns in PFGE, are dependant on the size
range of resultant DNA fragments following cleavage with an appropriate restriction
enzyme. Although the majority of isolates can be typed by PFGE, two isolates of
P. aeruginosa and a single isolate ofB. cepacia, in this study, were found to be
untypeable by this technique. However, it should be stressed that several hundred
isolates from each species were typed by PFGE without any problem. Different
DNA extraction methods were used in the hope of resolving these problem isolates
but without success. Similar findings have been reported by Romling et al (1994)
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who found that isolates ofP. aeruginosa from two different patients were untypeable
by PFGE. Romling et al (1994) speculated the problem was due to a high
concentration of endogenous nuclease that could not be inactivated.
PFGE demonstrated good discrimination; indeed it may be argued that it is too
discriminatory. However, if the guidelines suggested by Tenover and colleagues
(1995) for interpreting DNA restriction patterns generated by PFGE are taken into
account, isolates which are closely related can demonstrate up to a three band
difference. Furthermore, isolates showing up to a six band difference may be
considered related when an epidemiological linkage can be shown.
PFGE showed good reproducibility and enabled comparison ofprofiles from isolates
within the same gel and between different gels. Thus PFGE compares favourably
with other genomic typing systems where comparison of isolates between different
gels is not reliable - a disadvantage when large numbers of isolates are being
investigated.
The only criteria on which PFGE fails to meet the requirements for an ideal typing
system for B. cepacia is that the technique is technically demanding, time consuming
and uses specialised, expensive equipment. However, the majority of the other
genomic typing systems also fall into the same category, although some methods are
less time consuming to perform and results can be obtained faster than is possible
with PFGE.
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8.11.2 Comparison of two genomic typing systems
Comparison of the two genomic typing systems PFGE and PCR-ribotyping showed
that PFGE is more discriminating and produces more reproducible results. Although
PCR-ribotyping demonstrated good reproducibilty of isolates within the same gel, as
was observed by repeated isolates of the same strain ofB. cepacia, there were
considerable variations from gel-to-gel. One of the main disadvantages ofPCR-
ribotyping is that only a few bands are produced; making it difficult, in some cases,
to make judgements on the relationship between isolates. Comparing profiles
produced by PFGE and PCR-ribotyping, it appeared that any slight variation in
banding patterns from PCR-ribotyping such as the intensity or thickness was
sufficient to indicate that an isolate was different. However, PCR-ribotyping has the
advantage that it is a quicker procedure to perform and results from the PCR
amplification and subsequent separation by electrophoresis were achieved within a
few hours. The DNA extraction procedure is, however, more time consuming taking
a day to complete. Results from PCR-ribotyping can be achieved within 48 hours
compared to 3 - 4 days by PFGE.
Although somewhat discredited as a 'phenotypic system', bacteriocin typing was
found to be reliable as a step in the identification ofB. cepacia ET12 and other
'epidemic' strains ofB. cepacia. Bacteriocin typing can also distinguish other
B. cepacia strains. However, it was necessary to use the genomic systems to divide
isolates ofB. cepacia within the common S22/P0 group. Nevertheless, in large
epidemiological studies, bacteriocin typing is a useful screening procedure.
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8.11.3 'Epidemic' strain of B. cepacia
The 'epidemic' strain ofB. cepacia, known as the intercontinental or ET lineage, has
been responsible for colonising 15 CF patients in Edinburgh since 1989. All patients
attended the adult CF clinic with the exception of a 21-year-old female who
continued to attend the paediatric clinic. As previously indicated, there was
compelling epidemiological evidence that social contact outwith the hospital was
responsible for transmission of this strain in all but one patient. For example, the
patient, who attended the paediatric clinic appeared to have acquired the 'epidemic'
strain from her CF boyfriend who had acquired the strain some months earlier.
Surveillance ofET12 isolates by PFGE showed that there was very little detectable
change in ET12 isolates as it transferred from patient-to-patient. The most recent
patient to acquire B. cepacia ET12 was colonised in 1997; comparison of the PFGE
profile of this isolate with that of the index isolate showed only a four band
difference in the banding patterns using restriction enzyme Xbal and only a two band
difference with restriction enzyme SpeI.
Longitudinal studies of the Edinburgh index case who acquired ET12 in August 1989
showed only a few minor variations occuring in the PFGE profiles in subsequent
years. Using restriction enzyme Xbal, variations were observed in the most recent
isolate ofB. cepacia from this patient, taken nine years after the initial isolate;
however, the use of another restriction enzyme SpeI showed no difference in this
isolate when compared to the original.
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8.11.4 Genomovars
It appears that the majority of CF isolates ofB. cepacia of clinical importance belong
to genomovar III; these include isolates associated with epidemic spread (Govan et
al, 1996; LiPuma, 1998) and those responsible for 'cepacia syndrome' within the CF
community. However, as demonstrated by the Glasgow 'epidemic' strain which
belongs to genomovar II (Vandamme et al, 1997), strains ofB. cepacia
demonstrating transmissibility between CF patients are not exclusively found in
genomovar III. Although isolates of B. cepacia belonging to other genomovar
groups have not been associated with patient-to patient transmission it cannot be
assumed that these strains are not transmissible. It may be that these strains have not
had the opportunity to spread among CF or non-CF patients.
It was initially thought that the cable-like pili encoded by the cblA gene (Sun et al,
1995) and/or a novel DNA marker, the B. cepacia epidemic strain marker (BCESM)
(Mathenthiralingam et al, 1997) were associated with transmissiblity as is the case in
the ET12 lineage (Govan et al, 1996). Further research has shown that not all
transmissible strains carry these markers; the 'epidemic' strain ofB. cepacia appears
to be unique in possessing both the cblA and the BCESM markers. Further research
work is necessary to identify other transmission factors within the B. cepacia
complex and to identify the key host/pathogen relationship responsible for virulence.
Meanwhile, all members ofB. cepacia complex must be regarded as having the
potential to spread from patient-to-patient and all B. cepacia-positive patients
segregated from those not colonised with B. cepacia.
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8.11.5 How far should segregation be practised?
Recent evidence has shown that a number ofB. cepacia-positive patients colonised
with non-epidemic strains ofB. cepacia have required the ET12 lineage. This
worrying development most likely occured through contact at CF clinics. As a
result, CF centres are now faced with the logistical and social problem of
segregating B. cepacia-postive patients colonised with the ET12 lineage of
B. cepacia from those colonised with other strains ofB. cepacia.
8.11.6 Are environmental and clinical isolates of B. cepacia different?
B. cepacia has attracted considerable interest from the agricultural industry as a
bacterial biopesticide and bioremediator to replace the present rather toxic agents.
Not unexpectedly, this development is a cause of considerable concern for CF
patients and their carers. Phenotypic and genomic studies on clinical and
environmental isolates ofB. cepacia showed that isolates from each source belong to
a closely-related taxonomic cluster comprising of five genomovars. Isolates of
B. cepacia cultured from both clinical and environmental samples are found in all
genomovars, although few environmental isolates appear to belong to genomovar III.
This study provided the first unequivocal evidence of an isolate ofB. cepacia
recovered from the sputum culture of a CF patient showing similar properties, both
phenotypic and genomic, to that of a phytopathogenic type strain ofB. cepacia
ATCC 25416, which was isolated from an onion. Although this clinical isolate was
only detected on a single occasion from the patient's sputum, it nevertheless suggests
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9.1 TAXONOMY AND NOMENCLATURE
Stenotrophomonas maltophilia, first identified in 1943 following culture from human
pleural fluid, was initially called Bacterium bookerii. This organism was then
classified as Pseudomonas maltophilia in 1961 by Hugh & Ryschenkow but was not
included in the Approved List ofBacterial Names (Skerman et al, 1980) until the
name was revived by Hugh in 1981.
In the early 1980's, the genus Pseudomonas consisted of five rRNA homology
groups ofwhich P. maltophilia designated to groupV. However, genotypic and
phenotypic data suggested that this organism was more closely related to the genus
Xanthomonas than to the Pseudomonas group; hence it was proposed to transfer the
species P. maltophilia to Xanthomonas maltophilia (Swings et al, 1983). This
transfer was not universally accepted as subsequent examination of the properties of
the two genera showed clear differences between P. maltophilia and the genus
Xanthomonas. Palleroni & Bradbury (1993) proposed a new genus,
Stenotrophomonas (Gr. adj. stenus, narrow; Gr. n. trophus, one who feeds; Gr. n.
monas, a unit, monad; M.L. fern. n. Stenotrophomonas, a unit feeding on few
substances) which includes the single species S. maltophilia.
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9.2 GENERAL CHARACTERISTICS
S. maltophilia is an aerobic, non-fermentative Gram-negative bacillus and is motile
with varying numbers of flagella attached at one or both poles of the cell. It
possesses distinct biochemical characteristics, including a positive reaction for lysine
decarboxylase, aesculin hydrolysis, gelatin hydrolysis, DNase, acidity with maltose
and glucose oxidatively, and a weak or negative cytochrome oxidase result.
S. maltophilia normally produces a range of extracellular enzymes including elastase,
esterase, protease, hyaluronidase, lipase and mucinase. Protease and elastase are
produced by strains of S. maltophilia isolated from leukaemic patients with ecthyma
gangrenosum (Bottone et al, 1986); the importance of these virulence factors in CF
isolates has not been analysed. S. maltophilia is unable to use ammonia as a nitrogen
source when grown in chemically defined medium (Gilardi, 1969) and methionine is
a necessary growth factor (Iizuka & Komagata, 1964). Like many of the
pseudomonas species, S. maltophilia has the ability to grow at 42° C (Gilardi, 1969).
Natural reservoirs of S. maltophilia include raw food, rabbit faeces, plants and fresh
water (Hugh & Ryschenkow, 1961); S. maltophilia is also found in sinks, drains,
respirators, and disinfectant solutions in the hospital environment (Moody & Young,
1975).
S. maltophilia exhibits considerable inherent resistance to most antibiotics, including
aminoglycosides, (3-lactams, carbapenems in particular imipenem,and most
fluoroquinolones (Sader et al, 1994). Antimicrobial therapy is generally ineffective
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for the treatment of S. maltophilia. As is the case for B. cepacia, there is growing
concern to prevent colonisation with such inherently resistant opportunistic
pathogens.
9.3 PATHOGENICITY
S. maltophilia was originally considered to be of low pathogenicity. Recently,
however, it has emerged as an important nosocomial pathogen, particularly in
immuno-compromised patients in critical care units (Maningo & Watanakunakorn,
1995), or patients with haematological malignancies or solid tumours (Fujita el al,
1996; Khardori et al, 1990), debilitating illness, indwelling catheters or undergoing
surgical procedures (Bingen et al, 1991; Marshall et al, 1989). In these patients,
S. maltophilia is capable of causing a wide range of infections including respiratory,
urinary and eye infections, bacteraemic and postoperative wound infections.
Clinically significant infection with S. maltophilia is uncommon among healthy
individuals but a case of pneumonia has been reported in a non immuno¬
compromised patient undergoing treatment for bronchiectasis. Interestingly, this is
the first reported case of infection due to a mucoid phenotype of S. maltophilia
(Irifine et al, 1994). No mucoid strains of S. maltophilia have been reported in CF
patients which is surprising considering mucoid strains ofB. cepacia have been
observed occasionally in these patients and that the mucoid phenotype of
P. aeruginosa is so characteristic of CF pulmonary infection.
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Risk factors thought to be associated with contributing to S. maltophilia infection
include prolonged hospitalisation and mechanical ventilation, prior antimicrobial
therapy with broad-spectrum antibiotics, in particular imipenem (Elting et al, 1990),
haematological malignancies (Fujita et al, 1996) and serious underlying illnesses,
especially of the respiratory tract (Laing et al, 1995). Possible reservoirs for
S. maltophilia, associated with infection may be the respiratory tract (Khardori et al,
1990; Morrison et al, 1986), gastrointestinal tract (Elting et al, 1990) or natural
environments (Talon et al, 1994).
9.4 5. MALTOPHILIA IN CF PATIENTS
The first reported isolate of S. maltophilia, from the sputum of a CF patient was in
1975 in Denmark (Frederiksen et al, 1995). From the early 1980s, an increased
incidence in the isolation of S. maltophilia from sputum culture ofCF patients has
been reported leading to a prevalence ranging from 1.9% in USA, 11-15% in UK to
30.7% in Spain (Gladman et al, 1992; Ballestero et al, 1995; Denton, 1997). This
increase in prevalence may be partly explained by an increased awareness of the
organism, the use of selective medium and more aggresive use of antibiotics
(Denton, 1997). As evidence, introduction of selective medium in one UK CF centre
resulted in an increase in the isolation rate from 13% to 19% (Denton et al, 1996).
The use of potent anti-pseudomonal antibiotics, in particular tobramycin, and a more
aggresive antimicrobial therapy, is thought to be a contributing factor in the
acquisition of S. maltophilia in CF patients (Bauernfeind et al, 1992). However, the
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emergence of S. maltophilia during a double-blind, placebo-controlled trial of
inhaled tobramycin in 520 CF patients in USA was higher in the placebo group than
in the tobramycin group (Ramsey et al, 1999). In Leeds, a large number of CF
patients, culture positive for S. maltophilia, were treated with ciprofloxacin in the
year prior to initial isolation (Denton et al, 1996). Although many strains of
S. maltophilia are sensitive to ciprofloxacin, they rapidly develop resistance during
therapy (Lesco-Bornet et al, 1992). Eradicating P. aeruginosa from the respiratory
tract also appears to increase the risk of S. maltophilia colonisation. Imipenem has
been shown to be a risk factor for S. maltophilia in immuno-compromised patients
but there is no evidence ofCF patients, treated with imipenem, acquiring
S. maltophilia (Spencer, 1995).
The clinical significance of S. maltophilia cultured from CF respiratory secretions is
unclear and until recently, colonisation has not been associated with poor prognosis.
However, there is a degree of controversy as to whether S. maltophilia plays a
pathogenic role in CF patients. The Danish CF centre has demonstrated a host
immune response to this organism suggesting, that in some patients, it may be
invasive and may cause harm (Frederiksen, 1994). Specific antibodies against
S. maltophila have not been demonstrated (Karpati et al, 1994). Colonisation of the
lower airways with S. maltophilia shows a similar pattern to P. aeruginosa with
initially intermittent isolation followed by chronic colonisation. Similarily,
S. maltophilia is rarely eliminated and when this occurs it is generally only for short
periods of time (Karpati et al, 1994).
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Extensive studies by Karpati et al (1994) showed that no clinical deterioration was
observed in CF patients colonised with S. maltophilia for up to two years. However,
elevated WBC count and/or ESR values were observed when compared to matched
patients colonised with P. aeruginosa alone. Patients colonised with S. maltophilia
for a period greater than two years showed a gradual deterioration in lung function
and it was concluded that S. maltophilia played a pathogenic role in these CF
patients. The investigation did not identify any predisposing factors contributing to
colonisation in CF patients such as previous colonisation with other bacteria,
antimicrobial therapy or pulmonary function. Gladman et al (1992), concluded that
S. maltophilia was not directly responsible for mortality.
9.5 EPIDEMIOLOGY
The epidemiology of S. maltophilia is unclear; in particular, whether acquisition
occurs through person-to-person transmission or from environmental sources.
However, a number of typing techniques for S. maltophilia have been developed
which should facilitate epidemiological investigations. Various phenotypic
characteristics have been used to compare isolates of S. maltophilia, such as
biochemical tests and antibiograms, but no method has been used extensively and
those available are of little use for epidemiological studies. Serological typing has
been applied to S. maltophilia and is based on heat stable somatic O antigens
detected by agglutination; serotyping , however, shows poor discrimination and the
antisera are not widely available (Schable et al, 1989). Other phenotypic typing
techniques which have been applied to investigation of nosocomial outbreaks of
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S. maltophilia include multilocus enzyme electrophoresis (Schable et al, 1991) and
pyrolysis mass spectrometry (Orr et al, 1991); both systems require specific and
rather expensive, specialised equipment. In general, phenotypic typing has proved
inadequate in determining the route of transmission of S. maltophilia and it would
appear that the more discriminating genomic typing systems are necessary.
Recently, several genomic typing systems have been developed for the fingerprinting
of S. maltophilia; these include ribotyping, PFGE, enterobacterial repetitive
intergenic consensus ERIC-PCR and two PCR typing methods, arbitrarily primed
(AP-PCR) or random amplified polymorphic DNA (RAPD).
In a Danish CF centre, Frederiksen et al (1995) used ribotyping to show two small
clusters of CF patients with the same strain of S. maltophilia, one group of five
patients and the other group with only two patients. All five patients had attended
the CF clinic on the same day but otherwise had no other contact with each other;
whereas there was no evidence of cross-infection between the two patients in the
other smaller cluster. Small incidents of cross-infection due to S. maltophilia in non-
CF patients have also been detected using ribotyping and restriction fragment length
polymorphism, with both systems demonstrating excellent correlation. (Bingen et al,
1991). A later study, in Copenhagen, on nosocomial isolates of S. maltophilia
revealed a small group of four patients harbouring the same ribotype; however, no
epidemiological relationship was determined (Gemer-Smidt et al, 1995).
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A number of investigators have used PFGE for typing strains of S. maltophilia and
no evidence of cross-infection among CF patients has been reported (Talon et al,
1994, VanCouwenberghe et al, 1995). However, Marty (1997) has shown
environmental isolates with the same genotype as those responsible for causing
nosocomial infections. PFGE also demonstrated the presence of the same strain of
S. maltophilia over a 15 month period, in a CF patient, with no change in bacterial
characteristics apart from an increase in resistance to antibiotics (Wust et al, 1995).
AP-PCR has been shown to be marginally less discriminating than PFGE for typing
nosocomial isolates of S. maltophilia (VanCouwenberghe et al, 1995).
Investigations using two PCR techniques, RAPD and ERIC, have demonstrated that
strains of S. maltophilia from some CF patients have closely related profiles
(Chatelut et al, 1995); in contrast, Denton et al (1996) found no evidence of cross-
infection among CF patients using ERIC-PCR.
9.6 AIMS
Since the incidence of S. maltophilia recovered from sputum cultures of CF patients
has greatly increased in recent years, the aim of this study was to determine the
prevalence of S. maltophilia among CF patients in Edinburgh and to investigate




At the time of this study, there were 155 CF patients in Edinburgh, comprising of 79
paediatric and 76 adult patients. At regularly three monthly visits all sputum and
throat swabs were cultured for S. maltophilia using selective medium; 121 isolates
were obtained from 37 different CF patients. The rate of incidence of S. maltophilia
in the 37 patients, comprising of 22 children and 15 adults, was 28% and 20%,
respectively.
Multiple isolates of S. maltophilia were typed by PFGE, using restriction enzyme
Xbal, to determine the diversity of the PFGE profiles prior to any subsequent
epidemiological studies of this organism. Xbal digestion ofDNA extracted from
S. maltophilia produced 18 -25 fragments with a size range of <48.5 - 582kb. The
range ofPFGE profiles obtained from nine different CF isolates of S. maltophilia are
shown in Fig 9.1 and demonstrate the genetic diversity of this organism.
To determine the clonal relationship, if any, among the Edinburgh isolates of
S. maltophilia each isolate was genomically fingerprinted by PFGE, using restriction
enzme Xbal. The results demonstrated that the majority of patients were colonised
with their own unique strain(s) of S. maltophilia, with the exception of three small
clusters ofpaediatric patients. These clusters consisted of four patients in group I
and two patients in each of the groups II and III. Within group I, there are two sets of
two patients with isolates of S. maltophilia which produced identical PFGE profiles.
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FIG. 9.1. Xbal digestion of DNA from nine different CF isolates of S. maltophilia
showing a range of PFGE profiles. Lanes 1 to 9, C1954, C1950, C1936, C1932, C
1953, C 1970, C1972, C1969, C1914; lane 10, lambda concatemers (size range 48.5kb
to 582kb, in increments of 48.5kb).
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However, comparison of the profiles produced by each set ofpatients revealed a six
band difference, indicating that the four isolates within group I may be related. The
PFGE profiles produced by the two isolates in groups II and III were found to be
identical in each case (Fig 9.2).
Interestingly, two patients in group III, isolates CI932 and CI955, acquired
S. maltophilia within a month of each other and in both cases the isolates produced a
melanin-like pigment, which is an unusual characteristic for S. maltophilia. Sharing
of this unusual phenotype suggests that patient-to-patient transmission had ocurred.
To date, both patients continued to harbour the same strain but there has been no
evidence of transfer to any other CF patient. S. maltophilia was isolated from only
one pair of siblings and surprisingly, their isolates appeared to be unrelated.
Interestingly, all isolates from the adult CF patients produced unique genotypic
profiles indicating that the patients are colonised with unrelated strains of
S. maltophilia.
Multiple isolates of S. maltophilia were obtained from 13 of the 37 CF patients, who
were colonised for more than six months, to investigate whether the patients
remained colonised with the same strain of S. maltophilia. PFGE demonstrated that
ten of the 13 patients harboured the same strain for a period of time ranging from six
months to three years. The remaining three patients were found to be colonised by
different strains over the same period with one patient having three different strains
within a year.
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FIG. 9.2. Xba\ digestion of isolates of S. maltophilia demonstrating three clusters of
CF patients colonised with similar strains. Lanes 1 to 4, group I - C1912, C1933,
C1981, C1980; lanes 5 & 6, group II - C1934, C1936; lanes 7 & 8, group III - C1932 &
C1955.
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Further investigations were carried out on eight isolates of S. maltophilia from one
patient cultured over a period of three years. The PFGE profiles using restriction
enzyme Xbal (Fig 9.3), showed that six of the isolates were related although when
compared to the original isolate, CI925, up to a four band difference was observed.
Similar differences, up to a four band difference, were observed when a second
restriction enzyme Spel was used to digest the DNA from the same six isolates (Fig
9.4). According to the criteria set out by Tenover et al (1996), isolates with up to a
three band difference in PFGE profile are closely related and regarded as the same
strain while isolates showing up to a six band difference are considered as possibly
related. In this patient, the most recent isolates, CI971 and CI981, produce identical
profiles indicating that they are the same strain but differ from the original.
The six isolates (C1925, C1915, C1939, C1931, C1941, C1973) were further
examined by biochemical tests and antimicrobial susceptibility tests to determine
whether the differing PFGE banding patterns were associated with any distinguishing
phenotypical markers. Further investigations included colonial morphology and
assay for DNase, lysine and ornithine decarboxylase, protease, and elastase.
Results showed that there was no difference between the isolates in colonial
morphology, elastase was not produced by any isolate and all isolates gave positive
reactions for DNase, LDC, ODC, and protease.
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FIG. 9.3. Xbal digestion of eight isolates of S. maltophilia from the same CF patient.
Lanes 1 to 8, C1925, C1915, C1939, C1931, C1941, C1973, C1971, and C1981.
1 2 3 4 5 6 7 8
FIG. 9.4. SpeI digestion of the same eight isolates of S. maltophilia. Lanes 1 to 8, as
above.
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Examination of the API 20NE profiles also showed identical patterns, with the
exception ofCI 931 which was ONPG negative. These results suggest that the PFGE
banding differences were not associated with any difference in biochemical or sugar
assimulation tests.
It was then decided to investigate the antibiogram patterns of the six isolates to the
following antibiotics: ceftazidime, ciprofloxacin, gentamicin, tobramycin, imipenem,
azlocillin, colomycin, cotrimoxazole and aztreonam. The only difference in
antimicrobial susceptibility patterns were found with imipenem, which revealed that
strains CI931, CI941 and CI973, which gave identical PFGE patterns, were all
sensitive to imipenem whereas the other isolates were resistant.
The minimum inhibitory concentration (MIC) of imipenem to isolates CI 931, CI 941
and CI973 was 2 pg/ml compared to the other isolates which had an MIC
>32 pg/ml. Could this account for a change in the banding pattern? To answer this
question, an imipenem resistant mutant of isolate CI 941 was made (MIC of 35
pg/ml) and then fingerprinted by PFGE to determine whether there was a difference
in the profile pattern compared to the original strain. The results showed that both
the sensitive and the resistant strains produced identical PFGE profiles indicating that




In recent years, a number of epidemiological studies have been carried out to
determine the relatedness of strains of S. maltophilia causing nosocomial infections
in immuno-compromised patients and patients with CF. To date, patients tend to be
infected or colonised with their own unique strain of S. maltophilia and there is little
or no evidence of cross-infection among patients. However, Laing et al (1995)
observed a cluster of six patients in an intensive care unit, over a seven month period,
with isolates producing identical DNA profiles. These findings suggest that either
cross-infection had occurred between the patients or that the patients had been
infected from a common source which was not determined.
The results from this present study on isolates of S. maltophilia, from CF patients,
revealed that the majority ofpatients are generally colonised with their own strain of
S. maltophilia. These findings are similar to those encountered with other CF
pathogens, including P. aeruginosa and B. cepacia (apart from patients colonised
with 'epidemic' strains ofB. cepacia), namely that patients tend to be colonised with
their own strain of the particular organism. However, the presence of the three small
clusters of paediatric CF patients with each patient within the group being colonised
with S. maltophilia producing the same PFGE pattern provides evidence of possible
patient-to-patient transmission. Similar findings were observed in Denmark using
ribotyping. Again, only small clusters of patients with the same strain were observed
(Frederiksen, 1994). In contrast, other studies have found no evidence of cross-
infection in CF patients, using ERIC-PCR and PFGE respectively (Denton et al,
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1996 and VuThien et al, 1996). As cross-infection appears to account for only a
small number ofCF patients acquiring S. maltophilia, other contributing factors must
also be responsible for the increased incidence of S. maltophilia in CF patients.
The risks factors associated with nosocomial infections caused by S. maltophilia
have been reported as long term hospitalisation, prior antimicrobial treatment, and
debilitating illnesses. In recent years, however, management ofCF pulmonary
disease has changed with CF patients spending less time in hospital due to the
increased administration of intravenous antibiotics at home. Thus, long term
hospitalisation does not appear to be a likely cause for the increased incidence in
isolation of S. maltophilia from sputum cultures from CF patients.
Further analysis of the 37 CF patients in this study colonised with S. maltophilia
revealed that 18 (49%) were colonised with P. aeruginosa prior to acquisition of
S. maltophilia. Interestingly, no patients were previously colonised with B. cepacia.
Bauernfeind et al (1992) suggested that tobramycin may act as a contributing factor
in the acquisition of S. maltophilia. This explanation appears feasible as patients
colonised with P. aeruginosa will almost certainly have been treated with widely-
used anti-pseudomonal agents. However, some patients who are colonised with
S. maltophilia have never had P. aeruginosa cultured from their sputum and
subsequently have not been exposed to anti-pseudomonal antibiotics. In such cases,
antimicrobial therapy is not a predisposing factor for the acquisition of S. maltophilia
and there are obviously other factors involved. However, there must be large
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numbers of CF patients colonised with P. aeruginosa who have received treatment
with tobramycin and have not acquired S. maltophilia, even transiently.
The observation, in this study, that sensitive and resistant strains of S. maltophilia
produced identical banding patterns by PFGE has also been confirmed by Wust et al
(1995) who also found that strains with different antibiograms showed no difference
in PFGE profile. It is concluded that variation in phenotypic properties, at least in






At present, genomic fingerprinting by PFGE is considered by many microbiologists
to be the 'gold standard' for molecular typing systems. In most bacterial species,
PFGE provides good discrimination, reproducibility and stability i.e. the criteria
required for a reliable typing system. The only disadvantages encountered with
PFGE during the preliminary studies for this thesis was that it was time-consuming
and required considerable technical expertise and expensive equipment. Flowever, as
discriminatory power and reproducibility are the most important aspects of a typing
system, PFGE can almost be regarded as ideal. Thus for the purpose of this thesis,
PFGE was chosen as the typing system for epidemiological investigation of the four
main CF pathogens, Staph, aureus, H. influenzae, P. aeruginosa, B. cepacia, and the
potential pathogen S. maltophilia.
During the thesis, development of a new procedure for extraction of chromosomal
DNA from isolates ofboth B. cepacia and P. aeruginosa, and subsequent separation
of the digested DNA by PFGE, resulted in improved PFGE banding patterns. Not
only are the banding patterns more clearly defined and more easily interpreted but the
new extraction technique produces consistently good results.
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PFGE banding patterns for different isolates can be compared by visual observation.
However, difficulties can arise when attempts are made to compare the patterns of
new isolates with a large number of previous isolates on different gels. Various
computer-assisted systems for analysing DNA fingerprinting gels have been
developed in an attempt to overcome this problem. One of the disadvantages of
these systems is that at least three molecular size markers have to be run on each gel
to allow comparison ofbanding patterns within and between different gels. As there
are only ten lanes in the majority ofPFGE gels, the inclusion ofmarkers restricts the
number of samples that can be run on a gel at the same time. This is a particular
disadvantage if there is a need to investigate a large number of strains.
Some of the computerised systems do not produce a high correlation value even
when banding patterns are visually identical. A study of two systems, GelCompar
and DENDRON, revealed that they were good for identifying closely related strains
but showed considerable variation in less closely related strains (Seward et al, 1997).
These authors also showed a lack of confidence in these two systems by suggesting
that results from the computerised systems should always be checked visually as
discrepancies can occur.
Comparison of two PCR-based genomic typing systems, PCR-ribotyping and RAPD,
with PFGE showed the PCR systems to be less discriminating for isolates of
B. cepacia examined in this thesis. In the initial studies, considerable difficulty was
encountered with the RAPD technique and even after some of the problems were
247
overcome the technique lacked reproducibility. Consequently, RAPD was not
considered for any of the epidemiological investigations in this thesis. PCR-
ribotyping was easy to perform and reproducible but only a few bands are produced
and interpretation of results can be difficult following electrophoresis of the PCR
product. Differences in PFGE profiles, often involving up to 30 bands, provided
convincing evidence to distinguish individual strains whereas the banding patterns
produced by PCR-ribotyping did not provide good evidence to judge clonal
relationships between isolates. However, PCR-based typing techniques have the
advantage that they are quicker and easier to perform and require less expensive
equipment than PFGE.
10.2 STAPHYLOCOCCUS AUREUS
Staph, aureus is commonly found in the anterior nares ofmany healthy individuals
without causing adverse affects. However, considerable differences have been
observed in the nasal carriage rates of Staph, aureus, even in healthy individuals,
ranging from 25% in this study to 37.2% in a study by Kluytmans and colleagues in
1997.
In this study, the nasal carriage of Staph, aureus was found to be unexpectedly high
in the adult CF patients. This contrasted with carriage in the paediatric group which
was virtually the same as in the normal population. There is no obvious explanation
to account for this variation in nasal carriage rates of Staph, aureus between the
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paediatric and adult CF patients or to explain why the incidence is so high in the
adult patients.
Isolates ofStaph, aureus cultured from the anterior nares have been shown to cause
endogenous infections in non-CF patients (Kluytmans et al, 1997); it has always
been assumed that a similar endogenous route applied to CF patients. However, this
thesis provided striking evidence that in 76% of CF patients isolates ofStaph, aureus
recovered from nasal swabs and sputum were clonaly unrelated. Furthermore,
although transient strains were detected the presence of a strain of Staph, aureus in
the sputum appeared to prevent the acquisition of another strain. Data from these
investigations also showed a patient could harbour the same strain of Staph, aureus
in their nose for at least two years (the duration of the investigation).
Studies on the nasal flora of the 16 CF patients who participated in the gene therapy
trials revealed that the invasive treatment, involving the application of a
liposome/gene complex to the anterior nares, did not appear to have any affect on the
nasal flora. Although more than one isolate ofStaph, aureus was recovered from
nasal swabs from a few patients there was no evidence that the treatment was
responsible.
10.3 HAEMOPHILUS INFLUENZAE
Following the successful development of a method for the extraction of
chromosomal DNA from isolates ofH. influenzae, and digestion with an appropriate
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restriction enzyme, the subsequent DNA fragments were separated by PFGE. This
achievement enabled a comparison between PFGE and the traditional phenotypic
typing system for non-capsulate H. influenzae, namely biotyping. Although as
expected, PFGE was found to be more discriminatory than biotyping, a reasonable
degree of correlation was observed. For example, in no instance did isolates of
H. influenzae producing the same PFGE pattern belong to a different biotype.
Interestingly, a difference in the biotype distribution ofH. influenzae between CF
and non-CF patients was observed with the majority of isolates ofH. influenzae from
the non-CF patients belonging to biotype II. In contrast, isolates ofH. influenzae
recovered from throat swabs and sputum from CF patients did not demonstrate a
predominant biotype. The majority of isolates belonged to biotypes I, II or III, with
similar numbers in each of the biotypes. When CF sputum isolates ofH. influenzae
were analysed separately, a high proportion of the isolates belonged to biotype I.
The significance ofH. influenzae in respiratory secretions in CF patients is a constant
subject of debate, in particular, whether H. influenzae is acting as a pathogen or
merely a respiratory commensal. However, large numbers ofH. influenzae present in
sputum culture have been associated with pulmonary exacerbations and high levels
ofpro-inflammatory cytokines suggesting that the organism is a potential pathogen.
Taking this into account and the fact that the majority of isolates recovered from
sputum samples were biotype I, this may indicate that biotype I organisms may play
a role in producing exacerbations in CF patients. However, the number of isolates of
H. influenzae, recovered from sputum culture and analysed in this study, is probably
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too small to make such an assumption. There was also no evidence to suggest that
particular strains ofH. influenzae are responsible for exacerbations in CF patients.
It is a well known dogma of CF microbiology that Staph, aureus and H. influenzae
tend to cause infection in infants and young patients whereas, with the usual
exceptions, P. aeruginosa generally appears during adolescence. Thus, the recovery
rate ofH. influenzae is significantly lower in adult CF patients compared to the
paediatric group. An interesting observation made during this study was that
P. aeruginosa can inhibit the growth ofH. influenzae providing at least one
explaination as to why the latter organism appears to be less prevalent in CF adults.
10.4 PSEUDOMONASAERUGINOSA
P. aeruginosa is arguably one of the most important pathogens in CF microbiology.
Thus numerous epidemiological studies of this classic bacterial opportunist have
been undertaken employing phenotypic and genomic fingerprinting typing systems.
In this study, PFGE has shown that the phenotypic typing system ofbacteriocin or
pyocin typing (Fyfe et al, 1984) lacks discriminatory powers, reproducibility and
stability. However, pyocin typing has a valuable role to play as a screening
procedure when large numbers ofP. aeruginosa are involved.
Despite surprisingly little scientific evidence another dogma of CF microbiology has
been that the characteristic mucoid colonial form ofP. aeruginosa recovered from
the sputum ofCF patients emerges as a variant of the original non-mucoid form
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responsible for primary colonisation. This speculation was confirmed using PFGE
which demonstrated that both colonial morphotypes produced identical profiles.
However, our evidence also indicates that it cannot be assumed that the mucoid
morphotype is always the same strain ofP. aeruginosa as the original non-mucoid
isolate. This study, of 12 paired isolates of P. aeruginosa (original non-mucoid and
first mucoid isolate) cultured from sputum from different CF patients revealed that
identical PFGE profiles were produced by both the mucoid and non-mucoid isolates
in only half of the patients. The PFGE profiles produced by the paired isolates from
the other six patients were different indicating that the mucoid morphotype was a
different strain ofP. aeruginosa from the original non-mucoid isolate. The time
interval from the recovery of the first isolate of non-mucoid P. aeruginosa until it
converted to the mucoid form did not appear to have any relevance as to whether
both colonial morphotypes were the same strain. A possible explaination is that the
original non-mucoid strain ofP. aeruginosa was replaced by another strain which
subsequently converted to the mucoid morphotype.
Although patients may harbour more than one strain at a particular time several
studies have employed phenotypic typing to indicate that CF patients are colonised
with a predominant strain ofP. aeruginosa over long periods. Longitudinal studies
of the Edinburgh CF patients, extending over two years, revealed that such strain
stability occurred in the majority of patients. However, PFGE and pyocin typing
suggested that a large number of the patients harboured more than one strain of
P. aeruginosa in their sputum and these did not always include the original
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colonising strain. As different strains ofP. aeruginosa may exhibit similar colonial
morphology, it is possible that the original strain may have been present in the
sputum culture and failed to be selected for typing.
P. aeruginosa is generally not associated with episodes of cross-infection in CF
patients with the exception of siblings (Grothues et al, 1988), small clusters of
patients with the same strain in Denmark (Hoiby & Rosendal, 1980), and the spread
of a (3-lactam resistant strain in Denmark(Pedersen et al, 1986). It should be noted
that these investigations were carried out using phenotypic typing systems. In
particular, the study reported by Pedersen et al (1986), and often used as evidence of
cross-infection, employed serotyping and phage typing. In this particular study the
data lacks conviction since the 'epidemic strain' was polyagglutinating and possessed
no clear serotype.
During this thesis, PFGE and flagellin gene polymorphisms (Cheng et al, 1996) were
used to provide unequivocal scientific evidence ofP. aeruginosa cross-infection in
55 of 92 P. aeruginosa colonised CF patients treated in the Liverpool clinic. Further
investigations suggested that the {3-lactam ceftazidime resistant strain of
P. aeruginosa, responsible for this outbreak, emerged as a result ofmonotherapy.
However, this hypothesis does not explain how cross-infection occured amongst so
many CF patients. Recent evidence from genomic and phenotypic analyses suggests
that this strain has spread further and has been acquired by CF patients in Edinburgh,
Manchester and Nottingham. Epidemiological investigation indicates that social
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contact occurred between the patients involved, however, no evidence of
transmission has been observed amongst the Edinburgh patients. Further
investigation of this strain is warranted as it may provide a model of a lineage with
high transmissibility, similar to the ET12 transatlantic lineage ofB. cepacia. This
interesting and clinically-relevant P. aeruginosa may also be a prime candidate for
sequencing following the successful sequencing of the classic PAOl strain.
10.5 BURKHOLDERIA CEPACIA
Longitudinal studies involving the first CF patient in Edinburgh to acquire the
'epidemic' or ET12 transatlantic lineage ofB. cepacia in 1989, showed that the strain
varied little over the nine-year period .in which the patient has remained colonised.
Interestingly, although many environmental and clinical B. cepacia have been
examined only an occasional CF isolate has shown a mucoid colonial morphotype.
No conversion from the non-mucoid was noted and the exopolysaccharide was not
alginate (Govan & Tatnell, unpublished data).
Of the 15 Edinburgh CF patients, who have acquired the 'epidemic' strain of
B. cepacia only slight variation in the PFGE profiles was detected; interestingly,
these differences occurred in the most recent patients to acquire this strain. However,
none of these variations could be linked to phenotypic changes in the organism.
These studies reveal that isolates ofB. cepacia, certainly the 'epidemic' strain, do not
appear to undergo major phenotypic changes even after many years in the lung
environment. This is in striking contrast to P. aeruginosa which undergoes
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considerable phenotypic adaptation (involving colonial morphology and LPS
structure) as it adapts to the CF lung.
B. cepacia also differs from P. aeruginosa in that certain strains ofB. cepacia exhibit
enhanced transmissibility amongst CF patients. Recently, B. cepacia has been
further divided into five subgroups or genomovars I - V based on polyphasic
analyses of total protein profiles and DNA-DNA and DNA-rRNA hybridisation. Of
these genomovars, the first three have fuelled the most interest in research.
Genomovar I generally contains non-transmissible environmental isolates.
Genomovars II (recently renamed B. multivorans) and III contain strains responsible
for major outbreaks in CF clinics. Current evidence suggests that strains associated
with the most severe clinical outcomes (including cepacia syndrome) in CF
populations from various geographic locations belong to genomovar III. The highly
transmissible isolate J2315, which represents the transatlantic ET12 lineage belongs
to genomovar III. Strains from genomovars IV and V (renamed B. vietnamiensis)
have occasionally been isolated from CF patients, but their clinical importance is
unclear. At present, the group of five closely related genomovars is referred to as the
B. cepacia complex.
Transmissible strains ofB. cepacia are not confined to genomovar III as the Glasgow
'epidemic' strain belongs to genomovar II. There is still not sufficient evidence to say
that strains belonging to the other genomovars I, IV, and V are not transmissible.
Furthermore, following recent evidence that the ET12 lineage can super infect
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B. cepacia positive individuals with fatal consequences, there have been calls for
more severe segregation.
Evidence of an environmental/CF link is ofmajor importance in the ongoing debate
ofB. cepacia as a biopesticide and bioremediator. One of the arguments made by
microbiologists advocating the use ofB. cepacia as a biopesticide is that there is no
evidence of humans acquiring B. cepacia from the environment and hence no
'danger' from increasing the environmental population ofB. cepacia by commercial
exploitation. This argument disregards the fact that B. cepacia is not a human or
animal commensal and thus must be acquired from the environment. One of the
most potentially significant findings of this thesis was evidence to support the human
acquisition ofB. cepacia from the environment. The environmental isolate ATCC
25416 is the original B. cepacia type strain isolated from an onion by Burkholder in
1949. During this thesis, ATCC 25416 was found to be similar to a clinical isolate in
a number of aspects including onion rot, antibiogram profiles, colonial morphology,
identical PFGE profiles and amplified fragment length polymorphism (AFLP)
analysis and chromosome size. Although this strain ofB. cepacia was only isolated
from the CF patient on one occasion it nevertheless demonstrates the potential for an
environmental isolate to infect a CF patient, albeit for a short period.
10.6 STENOTROPHOMONAS MALTOPHILIA
Although S. maltophilia is recovered with increased frequency from respiratory
secretions of CF patients the microbiological role of this organism still remains
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unclear. In this study, evidence of cross-infection was limited and observed in only
three small groups ofCF patients. This does not explain the increase in incidence of
S. maltophilia in recent years.
The use of anti-pseudomonal antibiotics, particularly tobramycin and imipenem,
have been associated with the emergence of S. maltophilia in CF patients. However,
in this study only 49% of the Edinburgh patients were colonised with P. aeruginosa
prior to acquisition of S. maltophilia and subsequently 51% ofpatients had not been
exposed to anti-pseudomonal antibiotics. Thus, it would seem that factors other than
the use of anti-pseudomonal antibiotics must be involved.
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Spread of [3-lactam-resistant Pseudomonas aeruginosa in a cystic
fibrosis clinic
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Summary
Background Pseudomonas aeruginosa colonisation of the
airways of patients with cystic fibrosis (CF) is associated
with considerable respiratory morbidity. Although segregation
of colonised patients from non-colonised patients to prevent
cross-infection has been recommended, there is little
evidence that such cross-infection is widespread. We
observed that a high proportion of children attending our CF
clinic were colonised with P aeruginosa that was resistant to
ceftazidime and other p-lactam antibiotics. We used two
genomic fingerprinting techniques to see whether this may
have arisen from epidemic spread of a single strain.
Methods The prevalence of P aeruginosa colonisation and
the antibiotic susceptibility of the organisms was determined
from review of laboratory reports in the case-notes of 120
children with CF. Isolates were cultured from the sputum of
65 children colonised with ceftazidime-resistant P
aeruginosa. Polymorphisms in total bacterial DNA from 92
isolates were analysed with two molecular fingerprinting
techniques—pulsed-field gel electrophoresis after restriction
enzyme digestion and assessment of flagellin gene
polymorphisms by amplification of the whole gene and
restriction enzyme digestion.
Results 92 (76-7%) of 120 children were colonised with
P aeruginosa, and 65 of the 92 harboured isolates that were
resistant to ceftazidime. Only three of the 92 children had
never been treated with ceftazidime. The results of the two
molecular-fingerprinting techniques were concordant and
showed that 55 of 65 children harboured the same epidemic
strain. This strain was resistant to ceftazidime, azlocillin,
and imipenem, and sensitive to tobramycin and
ciprofloxacin.
Interpretation This study provides the first molecular
evidence of a long-term outbreak of P aeruginosa in a CF
centre. We suggest that careful surveillance of the
prevalence of antibiotic resistance in CF centres should be
instituted with measures to prevent cross-infection. We
believe that antipseudomonal monotherapy should be
considered with caution.
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Introduction
Colonisation with Pseudomonas aeruginosa and Burkholderia
cepacia is associated with progressive lung disease and
mortality in patients with cystic fibrosis (CF).1'2 There is also
compelling evidence that epidemic spread of highly
transmissible strains of B cepacia influences the prevalence of
pulmonary colonisation in some centres.3,4 By contrast,
epidemic spread ofP aeruginosa in unrelated patients, either in
CF clinics or through social contacts, is a contentious issue,
and there is a need for scientific evidence to support a policy of
segregation as practised for patients colonised with B cepacia.
Historically, the use of simple phenotypic typing
systems suggested that CF siblings tend to harbour the
same P aeruginosa strain, which indicates the possibility of
cross-infection if personal contacts ajre intimate and
frequent. More recently, this form of person-to-person
spread has been confirmed by reliable DNA-based
genomic typing techniques, including pulsed-field gel
electrophoresis.5'6 Epidemic spread of multidrug-resistant
P aeruginosa in unrelated patients has also been reported;
Pedersen and colleagues7 showed that the incidence of
new cases was reduced by strict isolation of colonised
patients. However, their hypothesis that a single strain of
P aeruginosa was responsible for cross-infection was
criticised8 on the grounds that the study was based on the
use of phage-typing and serotyping—phenotypic
techniques that are unreliable for characterising the
mucoid, polyagglutinable P aeruginosa that is
characteristic of CF.9 Nevertheless, institution of cross-
infection control measures in this unit interrupted spread
of the bacterium. Subsequently, the development and use
of genomic typing methods have indicated that small
groups of patients within a CF clinic may harbour the
same strain, which suggests that cross-infection, or
acquisition from a single source, can happen.6'10
In contrast to the above reports, most epidemiological
studies of patients with CF have not shown spread of
P aeruginosa in association with attendance at summer
camps11-'3, or when sharing hospital rooms,14 or during
regular attendance at a CF clinic over many years.2
However, there is general agreement15 that patients with
CF attending a CF centre usually harbour individual
unrelated strains of P aeruginosa over a period of many
years, and that, although cross-infection can occur, it is
usually restricted to CF siblings or a minority of patients,
the precise mode(s) of spread remaining unclear.
In 1995, we became aware that a large number of
patients were colonised with a ceftazidime-resistant strain
ofP aeruginosa among the 120 patients who received their
CF care in Liverpool but not among the 150 other
patients who were regularly reviewed by our CF team at
their local hospital. Here, we report the use of two
genomic fingerprinting techniques to provide the first
unequivocal evidence of an extensive epidemic in
unrelated CF patients involving a p-lactam-resistant
strain of P aeruginosa.




Case-notes of 120 patients attending the CF clinic at Alder Hey
Children's Hospital in August, 1995, were retrospectively
assessed to identify those colonised with P aeruginosa and to
determine the date of first isolation. Diagnosis of CF was based
on two positive sweat tests and confirmed by genetic testing.
Antibiotic susceptibility for P aeruginosa isolates based on disk-
diffusion tests was available from case-notes. According to the
treatment policy of the unit from 1986 to 1994, all patients with
chronic P aeruginosa colonisation (ie, present on three or more
occasions) and clinical respiratory deterioration were treated
with intravenous ceftazidime for 2 weeks provided that recent
isolates were sensitive. If not, alternatives such as ciprofloxacin,
aminoglycosides, or colistin were used. Before this study,
although patients with B cepacia were routinely segregated from
others in the clinic, we did not specifically isolate patients with
P aeruginosa.
Bacterial isolates
In a prospective study, isolates cultured from sputum collected
in March, 1995, from a cohort of 65 patients, presumptively
identified as having ceftazidime and other |3-lactam-resistant
P aeruginosa, were confirmed as P aeruginosa with standard
biochemical reactions16 and the API 20 NE system (BioMerieux,
Basingstoke, UK). Antibiotic susceptibilities to
antipseudomonal agents were determined initially by the Stokes
diffusion technique; subsequently, minimum inhibitory
concentrations (MICs) of antipseudomonal agents were assessed
with agar dilution methods." Using two independent genomic
fingerprinting techniques, we analysed the clonal relationships
between the P aeruginosa isolates from the 65 patients.
Polymorphisms in total bacterial DNA from 92 isolates were
analysed with pulsed-field gel electrophoresis (CHEF DRII
system, BioRad, Hemel Hempstead, Hertfordshire, UK)
following digestion with the endonucleases Xbal and Spel. We
used the method as previously described for B cepacia18 except
that pulses were 2-28 at 200 V for 20 h at 14°C.
In the flagella of P aeruginosa the two major types of flagellin
(a and b) are differentiated on protein size and antigenicity. We
have designed PCR primers based on the conserved N-termini
and C-termini of the protein that amplify most of the flagellin
gene; this generates amplicons of 1-02 kb and 1-25 kb for type a
and b flagellins, respectively. The central part of the flagellin
gene shows considerable variability. Digestion of the amplicons
separately with seven restriction endonucleases (Cfol, HaeIII,
Mbol, Mspl, Rsal, Sail, ana Taql) followed by agarose gel
electrophoresis, staining with ethidium bromide, and ultraviolet
transillumination permits detection of restriction fragment
length polymorphisms in the flagellin gene." 13 different P
aeruginosa flagellin gene variants have been reported."
Results
Review of the case-notes showed that, in March, 1995,
92 (76-7%) of the 120 children were colonised with
P aeruginosa. Disk susceptibility tests had shown that 65
(70-6%) of these colonised patients harboured isolates
that were resistant to ceftazidime and other (3-lactam
antibiotics but sensitive to tobramycin and ciprofloxacin.
Retrospective analysis of the patients' case-notes
indicated that a ceftazidime-resistant P aeruginosa had
first been detected in 1987. Since then, there has been a
cumulative increase in ceftazidime-resistant P aeruginosa,
with four to 12 newly colonised patients each year (table).
The median age at acquisition was 7-8 years (range
0-3-18-2).
The results of the two genomic fingerprinting methods
were concordant and showed that 55 of the 65 children














Table: Patients infected with ceftazidime-resistant and (3-
lactam-resistant Pseudomonas aeruginosa. 1987-95
epidemic strain (figure). In addition, six of the 5
children harboured other P aeruginosa isolates, whicl
were unique for each patient. The remaining eigh
children each harboured one or more distinct P aeruginos
strains not found in other children. All but one of the 5
children had been colonised with a ceftazidime-sensitiv
P aeruginosa before culture of the epidemic, resistan
strain. A ceftazidime-resistant P aeruginosa that had bee-
isolated from one of them in 1988 had the same genomi
Figure: Genotyping of (3-lactam-resistant P aeruginosa
(a) chromosomal DNA digested with Xba\ and separated by pulsed-field g
electrophoresis. Lanes 1, 2, and 3 show epidemic strain; lanes 5, 6, am
7 show patterns produced by non-epidemic P aeruginosa; lane 8 is a DN.
size marker.
(b) DNA size marker (50-2000 bp) in lane 1; flagellin gene amplification
product from epidemic strain (type b flagellin) in lane 2 and digested witl
Mbo\ in lane 3; flagellin gene amplified from a non-epidemic strain (type
flagellin) in lane 4 and digested by Mbo\ in lane 5; a third type b flagellin
gene in lane 6 and digested with Mbo\ in lane 7; a type a flagellin gene i
lane 8 and digested by Mbol in lane 9.
640 Vol 348 • September 7, 19
1 MC, 1
fingerprint as the epidemic strain. Review of the notes
showed that only three of the 92 children colonised with
P aeruginosa had never received any intravenous
ceftazidime; two of these three children carried the
epidemic strain. The epidemic strain was resistant to
ceftazidime (MIC,,, >32 mg/L), azlocillin (>64 mg/L),
and imipenem (>32 mg/L); it was susceptible to
tobramycin (0-5 mg/L) and ciprofloxacin (0-05 mg/L).
(MIC,0 is the lowest antibiotic concentration that inhibits
the growth of 90% of isolates.)
Discussion
The proportion (76-7%) of our clinic population
colonised with P aeruginosa is typical of many other CF
centres. By contrast, the observation that 70-6% of these
patients harboured ceftazidime-resistant and (3-lactam-
resistant P aeruginosa is higher than the figure of 14%
expected from previous surveillance studies in our
centre20 and of 18-6% from national studies.2' A major
objective of our study was to see whether acquisition of
P-lactam-resistant P aeruginosa reflected antibiotic-
induced or selected resistance in individual patients or
cross-infection of individual patients with a single
resistant strain. The latter proved to be the case for 55
(85%) of the patients harbouring 3-lactam-resistant
P aeruginosa. Our results also raise concern about
antipseudomonal therapy—in particular, therapy with a
single antipseudomonal agent. We speculate that the
introduction of ceftazidime monotherapy in our centre in
1986 as standard antipseudomonal treatment for
respiratory exacerbations might have been a contributory
factor to the development of the high prevalence of p-
lactam resistance.
The importance of our findings is two fold. First,
concordant data based on two highly discriminatory
genomic fingerprinting techniques showed the presence
of identical strains of P aeruginosa from 55 out of a cohort
of 65 patients. This observation provides the first
unequivocal evidence of extensive spread of P aeruginosa
in a CF centre. Second, that most isolates of the epidemic
Strain were resistant to ceftazidime and to other p-lactam
antibiotics is worrying. Retrospective analysis of case-
notes showed that ceftazidime-resistant and p-lactam-
resistant P aeruginosa had first been reported in our centre
in 1987. Unfortunately, isolates from that year were not
available to see whether they were clonally related to the
epidemic strain, although typing of one stored isolate
indicated that the epidemic strain was present in 1988.
Again, because there were no stored isolates, we could
not directly ascertain whether colonisation with a
ceftazidime-resistant P aeruginosa between 1988 and 1995
involved the same epidemic strain.
Previous studies have shown that combination therapy
with ceftazidime and an aminoglycoside has no clinical
advantage over ceftazidime monotherapy22 and that the
prevalence of ceftazidime-resistant P aeruginosa in CF
patients is unrelated to age but associated with prolonged
P aeruginosa colonisation, a low Schwachman score, and
increased use of ceftazidime.20
Why was there such a high prevalence of p-iactam-
resistant P aeruginosa in our centre? The use of
ceftazidime monotherapy might have caused induction
and selection of p-lactamase-producing P aeruginosa. This
possibility is supported by the observation that most
patients initially harboured ceftazidime-sensitive
P aeruginosa. However, the precise mechanism of
P-lactam resistance remains to be determined and, if the
hypothesis were true, each patient would have been
colonised by a distinct strain of P aeruginosa. An
alternative hypothesis is that each patient might have
acquired a sensitive form of the epidemic strain from a
common source, and that resistant forms were
subsequently induced or selected as a result of
antimicrobial therapy. The high number of colonised
patients makes this hypothesis unlikely, though we do not
reject it entirely. Extensive microbiological surveillance of
the ward and clinic environment, including respiratory
function equipment, did not detect the epidemic strain.
Moreover, retrospective identification of the epidemic
strain in the hospital environment could have resulted
from contamination by colonised patients. The most
likely explanation is a combination of induction and
selection of ceftazidime resistance and person-to-person
spread of a highly transmissible strain of P aeruginosa.
Since identifying the epidemic strain, we have
instituted measures to diminish its spread. Intravenous
antibiotic therapy is given at home to most patients
supported by a visiting nurse. Patients harbouring the
P-lactam-resistant P aeruginosa are isolated while in
hospital, and we discourage social mixing of patients. Our
antibiotic policy now is to treat patients who have
ceftazidime-sensitive P aeruginosa with ceftazidime and
tobramycin and those who have the resistant strain with
colistin and tobramycin.
In previous reports of the spread ofmultidrug-resistant
P aeruginosa in Danish CF patients, Hoiby and
colleagues7,23 reported a substantial increase in resistance
to ceftazidime and piperacillin and confirmed induction
of p-lactamase as the major resistance mechanism. The
mechanism of resistance in our epidemic strain is unclear.
We have confirmed the long-term spread of a P-lactam-
resistant strain of P aeruginosa among CF patients
attending the same clinic. It is also possible that the
particular strain responsible represents an unusual highly
transmissible form of P aeruginosa resembling highly
transmissible lineages of B cepacia.* On the basis of
previous studies suggesting that spread of P aeruginosa is
uncommon and usually limited to CF siblings, we do not
recommend that all patients colonised with P aeruginosa
should be segregated. Rather, our results indicate that
careful surveillance of the prevalence of antibiotic
resistance and cross-infection in CF centres should have
an important role in infection control and that
antipseudomonal monotherapy should be considered
with caution.
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